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Abreviations 
 
5-FU - fluorouracil 
ACP - adenocarcinoma do pâncreas 
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Chol- cholesterol 
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1  
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- cyclin-dependent kinase inhibitor 
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PaSCs- pancreatic stellate cells 
PC - Pancreatic cancer 
PDAC - Pancreatic ductal adenocarcinoma 
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PTEN - phosphatase and tensin homolog gene 
qRT-PCR – quantitative real-time polymerase chain reaction 
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Resumo 
O adenocarcinoma ductal do pâncreas (ACP) é uma neoplasia altamente agressiva, 
com um carácter acentuadamente invasivo e um perfil de expressão de microRNAs 
anormal, que tem sido fortemente associado à malignidade do ACP. A gemcitabina é o 
fármaco mais utilizado na terapia deste tipo de cancro, embora sem grande impacto na 
sobrevivência dos pacientes. A falta de tratamentos eficazes para o ACP levou-nos a 
considerar a possibilidade de usar os microRNAs, como potenciais alvos terapêuticos, no 
desenvolvimento de uma estratégia de terapia génica com relevância clinica para esta 
doença. Os microRNAs são uma empolgante e promissora classe de pequenas moléculas 
de RNA capazes de regular pós-transcricionalmente a expressão génica. Cada tipo de 
cancro é caracterizado por uma assinatura genética de microRNAs, apresentando uma 
forte desregulação nos níveis de expressão dos mesmos. Desde modo, acreditamos que 
reequilibrar os níveis de microRNAs em células tumorais pode ser decisivo no tratamento 
do cancro em geral e do ACP em particular. Assim, desenhámos uma estratégia 
terapêutica para abordar o cancro do pâncreas, que consistiu na combinação da 
modulação dos níveis de expressão de microRNAs, utilizando sistemas de transporte e 
entrega de material genético, com pequenas doses de fármacos, de forma a promover um 
forte efeito antitumoral e reduzir possíveis efeitos secundários.   
A primeira parte deste trabalho foi focada no estudo do potencial de um nanosistema, 
composto por albumina–1-palmitoil-2-oleoil-sn-glicero-3-etilfosfocolina: 
colesterol/oligonucleótidos anti-microRNAs (OAMs),na razão de carga (+/-) (4/1), para 
efectuar de forma eficiente a entrega de oligonucleótidos contra microRNAs, como o 
miR-21, miR-221, miR-222 e miR-10, que se encontram sobrexpressos em células 
tumorais de ACP. O nanosistema desenvolvido promoveu uma internalização celular 
eficiente do seu conteúdo, tendo induzido uma redução significativa nos níveis de 
expressão de todos os microRNAs testados e um aumento significativo dos alvos diretos 
do miR-21 e do grupomiR-221/miR-222, os supressores tumorais PTEN e p27
kip1
, 
respectivamente. Adicionalmente, avaliou-se o potencial terapêutico da combinação dos 
OAMs com pequenas quantidades de fármacos. Para tal, procedeu-se à transfeção das 
células de ACP com o nanosistema contendo AMOs e posteriormente ao tratamento com 
fármacos. Os resultados obtidos mostraram que o silenciamento do miR-21 e miR-221 
sensibiliza as células tumorais à acção do sunitinib e que a sua acção conjunta promove 
um efeito sinergístico antitumoral substancial. Estes factos demonstram o grande 
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potencial do nanosistema gerado para mediar a entrega de OAMs e da estratégia 
antitumoral combinada. A segunda parte do trabalho centrou-se no desenvolvimento de 
uma nova estratégia terapêutica visando a supressão da metastização, e no esclarecimento 
dos mecanismos biológicos envolvidos. O microRNA-139-5p, previamente identificado 
encontrar-se silenciado em ACP, foi indicado como potencial regulador da expressão do 
receptor 4 da quimiocina C-X-C (CXCR4), tendo-se verificado constituir um marcador de 
células estaminais tumorais e desempenhar um papel crucial no processo de migração das 
células tumorais. Os nossos resultados mostraram que existe uma correlação inversa entre 
os níveis de miR-139-5p e a expressão do CXCR4 em várias linhas celulares de ACP. 
Após a transdução das células de ACP com um vector lentiviral contendo o gene que 
codifica o miR-139-5p, foi possível obter um aumento substancial dos níveis deste 
microRNA nestas células tumorais. Observou-se uma redução significativa quer dos 
níveis totais da proteína CXCR4, quer dos seus níveis na superfície celular. 
Adicionalmente, verificou-se um efeito inibitório em células com perfil invasivo, 
nomeadamente ao nível das suas características morfológicas. Os resultados obtidos 
mostraram também que o miR-139-5p altera o mecanismo indutor de migração, de forma 
dependente e não dependente do CXCR4, e diminui a capacidade clonogénica das células 
tumorais pancreáticas. Por fim, verificou-se que o miR-139-5p promove um efeito 
sensibilizador à acção de pequenas quantidades dos fármacos docetaxel ou sunitinib, 
tendo a combinação destas estratégias promovido um efeito sinergístico antitumoral 
significativo. 
Em conclusão, os nossos resultados indicam claramente que a modulação da 
expressão de microRNAs em células tumorais de cancro do pâncreas pode promover 
alterações fisiológicas relevantes para a supressão da sua tumorigenicidade e conduzir a 
uma maior susceptibilidade à acção antitumoral de fármacos, mesmo em doses reduzidas, 
resultando num efeito antitumoral sinergístico. Assim, uma estratégia antitumoral 
combinando a modulação de microRNAs com pequenas quantidades de agentes 
quimioterapêuticos apresenta-se promissora no tratamento do cancro pancreático. 
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Abstract 
 
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer, 
characterized by strong invasive features and aberrant microRNA expression which has 
been associated with hallmark malignancy of PDAC. Gemcitabine is the current standard 
treatment for PDAC, although no significant improvement in patient’s survival has been 
achieved. The lack of effective PDAC treatment options prompted us to investigate 
whether microRNAs would constitute promising therapeutic targets toward the generation 
of a gene therapy approach with clinical significance for this disease.  
MicroRNAs are an exciting new class of small RNA molecules that post-
transcriptionally regulate gene expression. Each type of cancer, including PDAC, presents 
a microRNA signature, characterized by abnormal microRNA expression levels. 
Therefore, restoring appropriate microRNA levels in tumoral cells may be a crucial turn 
in PDAC treatments.  
Taking advantage of gene delivery vector technologies such as cationic liposomes 
(non-viral vectors) or viral–based vectors, we designed a therapeutic approach to manage 
pancreatic cancer, consisting of microRNA modulation in combination with small 
amounts of chemotherapeutic drugs, in order to promote a broader antitumoral effect and 
reduce potential side-effects.  The first part of the work was focused on the potential of 
the human serum albumin–1-palmitoyl-2-oleoyl-sn-glycero-3-
ethylphosphocholine:cholesterol/anti-microRNAoligonucleotides (AMOs) (+/-) (4/1) 
nanosystem to efficiently deliver AMOs, targeting the overexpressed microRNAs miR-
21, miR-221, miR-222, and miR-10, into PDCA cells. 
The developed nanosystem promoted an efficient cellular internalization of the 
carried nucleic acids, and all tested microRNAs showed a significant reduction in their 
levels of expression. Moreover, our results clearly demonstrate that abrogation of miR-21 
and miR-221/miR-222 cluster expression levels could induce a significant increase in 
their direct targets, the tumor suppressors PTEN and p27
kip1
, respectively. Additionally, 
experimental studies consisting of a two-step sequential treatment, where PDAC cells 
were firstly transfected with AMOS targeting miR-21, miR-221 and miR 222 and 
subsequently treated with chemotherapeutic drugs, allowed us to evaluate the impact of 
microRNA cell sensitization to chemotherapeutic drugs. The obtained results showed that 
the combination of microRNA silencing, namely miR-21, with low amounts of the 
chemotherapeutic drug sunitinib resulted in a strong and synergistic antitumor effect. 
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Overall, these results are indicative of the great potential of the developed nanosystem, to 
efficiently mediate AMOs delivery, and of the generated combined strategy to mediate a 
significant and synergistic antitumor activity. 
The second part of the work was centered in the development of a new microRNA-
based therapeutic strategy, focused on the suppression of the metastasis processes and in 
the clarification of the underlying biological mechanisms.  
MiR-139-5p was identified as a downregulated microRNA in PDAC and has been 
predicted to target C-X-C Chemokine receptor 4 (CXCR4). Emerging evidence suggests 
that CXCR4 exerts a crucial role in the metastatic process of PDAC, being enrolled in cell 
motility and proliferation, and was identified as a molecular marker in pancreatic cancer 
stem cells (PCSCs) with high metastatic potential. Our studies showed the existence of an 
inverse correlation between miR-139-5p and CXCR4 expression in this type of tumor. 
The use of a lentivirus-based vector able to stably express miR-139-5p in PDAC cells 
allowed the assessment of miR-139-5p relevance in the regulation mechanisms of 
CXCR4 In this regard, the ectopic expression of miR-139-5p in PDAC cells was shown 
to result in a substantial decrease of the CXCR4 protein levels, including the cellular 
surface CXCR4, and in a visible lack of classic motility features. Invasion assays 
indicated that miR-139-5p could affect CXCR4 dependent and non-dependent migration 
in cells overexpressing this microRNA. Furthermore, an inhibitory effect of miR-139-5p 
on the ability of PDAC cells to form spheres, particularly spheres with bigger dimensions, 
was observed, indicating a possible clonogenic suppressor role of miR-139-5p in this type 
of tumor. Importantly, modulation of miR-139-5p expression in PDAC cells was shown 
to enhance cell susceptibility to the action of small amounts of sunitinib or docetaxel, 
resulting in a significant and synergistic antitumor activity. 
Overall, our results clearly demonstrate that restoring expression levels of key 
microRNAs in pancreatic cancer constitutes a promising therapeutic strategy, particularly 
when combined with small doses of chemotherapeutic drugs, since it could result in a 
potent antitumor activity and reduced side effects. 
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Objectives 
 
Cancer is one of the major causes of death, thus molecular mechanisms supporting its 
malignancy require thorough investigation.  The main goal of this work was to evaluate 
the therapeutic potential of microRNAs in PDAC and to generate a novel strategy for the 
treatment of pancreatic cancer. Our approach consisted in combining a gene therapy 
technology focused in microRNA modulation and chemotherapy in order to achieve an 
effective and synergistic antitumor activity, without causing significant side effects.  
In order to accomplish this goal we proposed to use different gene delivery systems 
in two distinct tasks based on the microRNA expression profile, depending on whether 
they display an overexpression, thus acting as oncogenes; or as downregulated 
microRNAs, revealing tumor suppressor features.  
Concerning overexpressed microRNAs, our approach consisted in the use of a lipid-
based system to mediate intracellular delivery of anti-miRNA oligonucleotides (AMOs) 
into tumor cells and combining them with chemotherapeutic agents in order to obtain a 
strong antitumor activity. To accomplish this purpose the following objectives were 
defined: 
 
 Biophysical characterization of a lipid-based system, HSA-EPOPC:Chol/AMOs 
(+/-) (4/1), with the ability to mediate intracellular deliver of anti-miRNA 
oligonucleotides (AMOs) into tumor cells.  
 
 Evaluation of the efficiency of the HSA-EPOPC:Chol/AMOs (+/-) (4/1) 
nanosystem to mediate miR-21, miR-221, miR-222 and miR-10b silencing. 
 
 Characterization of the antitumor activity of microRNA-mediated silencing, 
specifically its impact in apoptosis and proliferation signaling pathways.  
 
 Evaluation of the therapeutic potential of the microRNA silencing in the presence 
or absence of several chemotherapeutic drugs, such as gemcitabine, docetaxel and 
sunitinib, aiming at achieving an antitumor synergistic effect.  
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Regarding the downregulated microRNA, our proposal was to further investigate the 
biological relevance and therapeutic potential of re-establishing its normal expression 
levels. To address this issue, the following objectives were defined: 
 
 Use a lentiviral vector for stable and constitutive expression of a downregulated 
microRNA, miR-139-5p, thus creating a valuable in vitro model, consisting of up-
regulation of this suppressed microRNA.  
 
 Evaluation of the efficiency of the lentiviral vector to mediate miR-139-5p ectopic 
expression in pancreatic cancer cells. 
 
 Assessment of miR-139-5p role in the post-transcriptional regulation of metastasis 
mediators in pancreatic cancer, specifically the C-X-C Chemokine receptor 4 (CXCR4).  
 
 Addressing from multiple perspectives the antitumor activity of miR-139-5p, more 
precisely, its potential to inhibit proliferation and cell motility, arrest metastasis 
formation, and anti-clonogenic features. 
 
 Evaluation of the therapeutic potential of miR-139-5p when integrated into a 
broader strategy that incorporates the use of chemotherapeutic agents, aiming at achieving 
a concerted antitumor effect upon PDAC cells, thus resulting in a synergistic outcome. 
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Chapter 2 
 
 
 
 
 
Managing pancreatic adenocarcinoma: a special focus in 
microRNA gene therapy. 
This chapter was partially based on a review paper – in preparation 
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1. Pancreatic cancer 
Cancer is a worldwide calamitous health problem, with a calculated probability of 
incidence per sex of one in every three women and one in every two men throughout their 
lives in the United States (US), where one in four deaths is also attributed to cancer 
alone.
1
 Pancreatic cancer (PC) is known to be one of the most deadly cancers, with a 
median survival inferior to 6 months and approximately 2% of survival within 5-years 
after diagnosis.
1
 It holds the fourth position in the USA in deaths related to cancer, being 
only surpassed by colorectal, breast and lung and bronchus cancers. PC has an estimated 
incidence of 43,920 new diagnosed cases in both sexes annually in the US, which 
ultimately results in the death of 37,390 patients, reveling the need for an urgent route to 
overcome this drastic numbers.
2,3
 Despite its moderate incidence when compared to other 
carcinomas, PC accounts for the highest mortality rate by far, the survival associated to it 
showing the slightest improvement over the past 30 years.
3
 Pancreatic cancer still remains 
as an unsolved therapeutic challenge for science despite all efforts carried out to improve 
current treatments. Only minor significant advances have been achieved to unravel key 
mechanisms of PC, and always with a modest clinical impact.
4
 Besides, most cases are 
still diagnosed at advanced stages of the disease mainly due to the lack of early symptoms 
or to symptoms resembling other diseases, consequently no improvement in survival 
prognosis being achieved with current diagnostic approaches. Most patients present 
locally advanced or metastatic disease and thus are not eligible for curative surgery.
5
 
 Pancreatic ductal adenocarcinoma (PDAC) is the most predominant type of PC, 
accounting for more than 90% of pancreatic cancers.
6
 PDAC is a very aggressive 
malignancy that is associated to a very low survival rate. Early and belligerent 
metastization to distant organs also characterizes this type of tumor, being one of its most 
hostile features. Surgical resection of the primary tumor still holds the major hope for 
patients, although candidates to this surgery represent a very low percentage of all 
patients, and often allows to remove only a small part of the tumor.
7
 Current 
chemotherapy is often insufficient and controversial in the treatment of inoperable 
PC.
8
Although many studies point towards the use of a cocktail of different 
chemotherapeutic agents in combinations with radiation treatments, gemcitabine is the 
frontline therapy with the better outcome in unresectable tumor cases, representing for 
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now the most prominent strategy in terms of overall survival.
8
 Life span for PC patients is 
largely unsatisfactory, therefore the need for a more efficient and broad therapeutic 
strategy is the primary purpose for PC research.  
 
1.1. Etiology of Pancreatic Cancer 
The causes of pancreatic cancer are still largely unknown. There are several risk 
factors associated to this type of cancer (Table 1), such as the demographic character, 
which is related with the increasing advanced age of the population, the majority of the 
cases are diagnosed at older patients (mainly after 75 years of age), whereas only 
approximately 13% are identified before 60 years of age.
9
 
 
Table 1 - Risk factors for development of pancreatic cancer. 
Group of Risk Factors for PC Risk Factors 
Demographic Increasing advanced age of the 
population 
9
. 
Racial factors 
9
 
Environmental  Smoking 
9
 
Alcohol 
9
 
Diet – obesity related. 9 
Genetic Familiar Inheritance  
Genetic mutations 
Other Pancreatic lesions 
Pancreatitis 
Diabetes 
 
 
Nevertheless, environmental factors have also a major impact in terms of cancer 
development, mainly if are lifestyle related. Several studies point towards smoking habits 
as the most harmful and well-established factors for PC, followed by alcohol 
consumption.
9,10
 A cohort study performed in approximately 34000 women showed that 
current smokers were twice more likely to develop pancreatic cancer than nonsmokers. 
Prolonged smoking habits increase the relative risk of pancreatic cancer, by 1.5-fold to 3-
fold, on a dose-dependent manner correlated with the number of cigarettes smoked. 
Alcoholic beverage intake was also addressed in this study and the results obtained 
suggest a relation between alcohol consumption and PC. Risks tended to be elevated in 
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women who reported to have greater beer, wine and liquor intake, being the liquor the 
beverage with highest relation with pancreatic cancer.
11
 
Dietary unbalance, obesity and/or diabetic problems also have a major contribution to 
pancreatic cancer.
10,12
 Dietary patterns have long been associated with several diseases, 
including cancer. In the case of cancer of exocrine pancreas, a diet composed by a large 
variability of vegetables, fruit, fish, poultry and whole grains, and with low fat dairy was 
associated with an approximate 50% reduction in pancreatic cancer risk both in man and 
in woman. On the opposite side, in the case of a diet characterized by a higher intake of 
red and processed meats, potato chips, sugary beverages, sweets, high fat dairy, eggs and 
refined grains there was a 2-fold elevated risk of pancreatic cancer for men, although no 
significant association was attainable for women.
13
 Disturbed dietary patterns often result 
in obesity, which became an epidemic and an extreme worrying disease mainly in western 
civilization, being frequently related with cancer by causing low-grade chronic 
inflammation. Obesity increases circulating levels of TNF-α and IL-6 and infiltration of 
inflammatory cells in pancreas accelerating the development of  pancreatic lesions, 
specifically pancreatitis, thus ultimately leading to PC.
14
 
Pancreatic cancer exhibits a high complexity underlying carcinogenesis, being 
controlled by a large variety of biological and environmental factors. Therefore, the 
initiation of the disease might be triggered by a multiplicity of molecular events that 
appear long before any tumorigenic feature becomes evident. The aggressive tumorigenic 
phenotype of PC is either supported by a group of well-established mutations, such as in 
the KRAS gene, p53, Smad4, p16 and other tumor-suppressor genes that greatly amplify 
oncogenic signal and lead to the impairment of the main cellular signaling pathways that 
regulate cell proliferation, pro-apoptotic events and cell migration. Additionally, 
heterogeneous assembly of growth factors and/or cytokines can also promote tumor 
growth and spreading from primary site. These factors can derive from cancer cell itself 
(autocrine) or stromal cell (paracrine) and are helper effectors in tumour growth and 
metastization. To better understand the physiology of pancreatic cancer, it is also 
necessary to acknowledge all the events occurring in the tumor microenvironment.  
 
1.2. PDAC microenvironment - pancreatic stroma 
The pancreatic tumour stroma is likely to be one of the central barriers for the 
effective delivery of therapeutic agents and has been reported to have a key role in 
promoting epithelial-to-mesenchymal transition (EMT).
15
 It is characterized by a strong 
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desmoplastic reaction in which the surrounding tissue presents a robust fibrotic texture, as 
one of its most distinctive features, mostly resulting from excessive extracellular matrix 
deposit in the course of chronic inflammation and/or wound healing. The stroma in 
PDAC is a rather multifaceted and dynamic structure as it is composed by a wide range of 
cells that create a rich environment for the tumoral cells, since they produce many growth 
factors that contribute to cell proliferation and migration. The recruitment of 
inflammatory cells to the stroma by these growth factors greatly increases the production 
of cytokines and chemokines, which in turn impair cell adhesion capacities, thus 
promoting cell migration.
16
 Moreover, due to the fact that pancreas produces insulin, 
cancer cells are exposed to high levels of this growth promoting hormone, once more 
thriving a strong tumorigenic niche for pancreatic cancer progression.
17
 On the other 
hand, the mechanisms of chemo-resistance promoted by extra-tumor cell factors are 
related with the fibrotic texture of the stroma that increases the difficulty of drugs to reach 
tumour vasculature, cross the vessel wall and reach the tumour tissue.
18
 Although it is not 
clear the way this chemo-resistance is accomplished, the hedgehog signaling pathways 
seem to have a pivotal role in the microenvironment-related chemotherapy resistance in 
pancreatic cancer, as it has been related with the promotion of the desmoplastic reaction, 
thus decreasing blood vessel net around the tumour.
19
 
 
1.3. Precursor Pancreatic Lesions 
Taking in account the high mortality rate of pancreatic cancer in opposition to other 
types of cancers, where medical advances have permitted to overcome the initial 
malignancy and improve patient’s survival rates, it becomes mandatory to expand our 
knowledge of early indicators or precursors of PC in order to follow this tendency of life 
improvement verified in other types of cancer. It is perceptible that PC does not arise 
from de novo, but rather follows a multistep alteration path involving the disruption of 
many molecular signaling pathways and cellular metabolic balances.  
There are three main precursor lesions of pancreas identified: Pancreatic 
Intraepithelial Neoplasia (PanINs), Mucinous Cystic Neoplasms (MCNs) and Intraductal 
Papillary Mucinous Neoplasms (IPMNs), but many other types and subtypes have also 
been referred.  
PanINs are microscopic non-invasive epithelial lesions found in the smaller 
pancreatic ducts formed by proliferation and metaplasia of ductal epithelium. These type 
of lesions can be classified in three grades:  PanINs 1, PanINs 2 and  PanINs 3 according 
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to the increased degree of  architectural and cytonuclear atypias and represent the most 
frequently observed epithelial precursor lesions in the pancreas.
20
 PanIN3, a high grade 
lesion is usually found simultaneously in the pancreas with invasive PDAC.
21
 
 
 
 
Figure 1- A pancreatic precursor lesion model representing some genetic alterations occurring during 
the multistep progression to invasive PDAC. Molecular abnormalities observed in PanIN progression can 
be broadly classified as “early” (PanIN1), “intermediate” (PanIN2) and “late” PanIN3 (adapted from Maitra 
A et al, 2003).22 
 
Usually, PanINs tend to develop in the head of the pancreas, in resemblance of 
PDAC localization. Pancreatic Intraepithelial Neoplasia is also associated with a chronic 
pancreatitis clinical background, which can elucidate the epidemiological association 
between long standing pancreatitis and an increased risk of subsequent malignancy.
23
 
Some oncogenic traces can be distinguished in PanINs lesions, mainly KRAS gene 
mutations as one of the earliest genetic abnormalities, with increased incidence as higher 
is the grade of PanINs, with 36%, 44%, and 87% of cancer-associated PanIN-1A, PanIN-
1B, and PanIN-2/3 lesions, respectively.
24
 In respect to tumor-suppressor genes 
alterations, p16INK4A/CDKN2A, TP53, and DPC4/SMAD4/MADH4 are the most 
frequently observed, and their function is inactivated in a significant share of PanINs, 
reflecting the relative frequency of loss of their function in invasive adenocarcinomas.
25–
27
 The impaired function of the tumor suppressor gene p16INK4A/CDKN2A in PanINs is 
related with inappropriate progression of cell cycle, thus facilitating cancer development. 
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On the other hand, intraductal papillary mucinous neoplasms (IPMNs) or cystic 
neoplasia of “mucinous” type, are macroscopic cysts, that are easily detectable in 
radiologic exams, in opposition to PanINS. A rich mucin production, which is a 
glycoprotein produced by epithelial cells and usually associated with proliferation of 
tumors,
28
 is a key feature of these types of lesions and is the cause of cystic dilation. Its 
frequency is greater in men than in woman and invasive IPMNs are more prone to happen 
in elderly patients, usually associated with abdominal symptoms before final diagnosis.
20
 
 IPMNs can be divided also in three types according to their morphology, histology 
and depending if the development of these lesions occur with the involvement of the 
branches or main pancreatic duct: MD type, a more aggressive type of IPMNs that 
involves the main pancreatic duct and has a possible malignant outcome; BD type, which 
tend to occur in younger patients, is limited to smaller branches and has a lower 
malignant potential; and mixed-type, which origin is not yet clear, and typically harbors a 
high-grade dysplasia or an associated invasive carcinoma.
29
 Regarding the genetic 
mutation profile, IPMN share a common path with other pancreatic lesions and PDAC 
itself. By instance, KRAS2 gene mutation is often pointed out as the most frequent in 
IPMNs and, although the mutation frequency varies from study to study, it can be found 
approximately in 80% of the cases.
30
 However, there is always a lower prevalence of 
KRAS2 gene mutation in IPMN’s than in PDAC.  TP53 is also a gene that could be 
mutated both in IPMNs (0-50%) and PDCA (75%), and its inactivation seems to be a late 
molecular event before being hit the invasive carcinoma status.
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Mucinous Cystic Neoplasms (MCNs) of the pancreas are mucin-secreting cysts 
epithelial neoplasms and are more often identified in the tail or body of the pancreas, not 
exhibiting a linkage with the pancreatic ductal system. Although MCNs are rare tumors, 
they are mainly detected in women, around  90% of the cases, and in younger patients.
28
 
In contrast with IPMNs, MCNs most probably form de novo cystic tumors. Regarding its 
histology, mucinous cystic neoplasms can be classified according to the grading lining 
epithelium: mucinous cystadenomas, when present noninvasive features; MCNs with 
moderate dysplasia; and MCNs with carcinoma in situ.
32
 Concerning the molecular 
alterations referred above for others pancreatic lesions, MCNs harbourKRAS2 mutations 
even in lower grades of dysplasia, while TP53 and DPC4/SMAD4 mutations usually 
occur at a later invasive stage.
33,34
 
The identification of perceptible precursor lesions for a highly aggressive, often fatal, 
neoplasm like PDAC has created a new hope for the early detection and treatment of this 
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invasive neoplasia.  Although, fruitful therapies for PDAC precursor lesions persist as a 
work in progress and may be of great importance in the future, understanding 
carcinogenesis of pancreatic cancer augments the possibility to translate the acquired 
knowledge into early detection and treatment actions, before the inception of malignancy. 
 
1.4. Current therapeutic strategies for PDAC 
Although cancer remains as a prevailing disease, improved access to universal 
healthcare has permitted to achieve early diagnoses and to develop new and better 
therapies, consequently resulting in an enhancement in the long-term survival for most 
cancer patients. In the case of PDAC, it is clinically classified into three stages regarding 
treatment strategy, namely, resectable, unresectable locally advanced and metastatic, each 
of them with different therapeutic approaches.  
 
1.4.1. Resectable surgery 
Despite the important advances that have been made towards the development of 
better cancer treatments, resectable surgery still stands as the most efficient strategy for 
cancer patients, being the surgeries mainly performed through the techniques of robot 
assisted, laparoscopic, or the traditional open approach. Removal of primary tumor and 
adjacent tissue permits to cure more patients than any other form of cancer therapy, as it 
permits to remove almost 100% of tumor cells, while other therapeutic strategies only 
affect a smaller percentage of tumor cells. Nevertheless, even with a resection surgery, 
only 15%-20% of these PDAC patients are long-term survivors.
35
 Therefore, due to 
elevated rates of failure following curative resection, effective adjuvant strategies became 
an urgent need in order to improve long term survival of the patients. 
 
1.4.2. Radiotherapy 
Surgery and radiation are considered to be local treatments as they directly target 
the tumor in a specific area of the body. Nevertheless, more than 80% of the patients with 
PDAC cannot be submitted to surgery at the time of diagnosis, and half of these patients 
have already developed distant metastasis, making this type of cancer one of the most 
difficult to handle from a clinical point of view.
36
 
Radiotherapy appears as viable option for the treatment of cancer, as it is a non-
invasive treatment and patients usually present a faster and easiest recovery. Near 52% of 
cancer patients undergo radiotherapy at least once during their treatment course.
37
 The 
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mechanism underlying radiotherapy is irradiation with high-energy radiation (x-rays, 
gamma rays and fast-moving charged particles like electrons and protons) damaging 
intracellular components like DNA, thus leading to cell death.
38
 However, radiation lacks 
specificity, as it damages not only the solid tumors but also healthy tissue, suggesting that 
other complementary tools may be of extreme importance to overcome this obstacle. To 
this purpose, many studies are being addressed, by instance, Babaein and Ganjalikhani 
suggest the application of nanoparticles as radio sensitizer, this being considered a new 
promising strategy to improve efficiency of radiotherapy.
39
 
Considering PDAC, performance status, tumor size and cachexia of the patient have 
a significant influence on the outcome of (neo) adjuvant radiotherapy, making it a limited 
option for the treatment of these patients, thus paving the way for other therapeutic 
strategies, such as chemotherapy. Many times both therapeutic strategies are used in 
combination, chemo-radiation, in order to ameliorate the patients status and decrease side 
effects.
36
 
 
1.4.3. Chemotherapy 
Chemotherapy is still the golden standard treatment for the vast majority of 
unresectable tumors, either alone or in combination with surgery. Nowadays, a 
considerable number of drugs are available for the treatment of the innumerous cancer 
types (Table 2), and many others are in study phases, waiting to be approved for clinical 
practice. The three main goals of chemotherapy are to cure the patient from cancer, 
control tumoral growth and spreading, and provide palliative care to terminal patients. 
In the cases where there is the possibility to resect the tumor, the use of 
chemotherapy may be strategically applied in two different stages of the treatment either 
as a neoadjuvant care, in order to shrink the tumor, making the surgery more easy, or to 
sensitize the tumoral cell to radiation effect; or as adjuvant care, to improve chances of 
complete annihilation of tumoral cells after tumor removal, as many cells could be 
undetectable or left behind during surgery. 
 
1.4.3.1. Chemotherapy in PDCA 
So far, no treatment has had a significant impact on pancreatic cancer and most of 
the currently used drugs are to relief and control the patient symptoms.  Up to now, the 
standard care for patients with unresectable pancreatic cancer is either fluorouracil (5-FU) 
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combined with radiotherapy, introduced in 1969 after a trial study indicating an  
improved median survival from 6.3 to 10.4 months, when compared to radiotherapy 
alone,
40
 or gemcitabine, introduced by Burris et al in the late 1990s after a comparative 
study of the efficacy of gemcitabine against fluorouracil (5-FU). Despite, Burris and 
colleagues did not registered a significant increase in overall survival (4.41months for 5-
FU against 5.65 months for gemcitabine), gemcitabine exhibited a better clinical 
response, resulting in an improvement on patients symptoms, 23.8% when compared to 
4.8% of 5-FU, and became generally recognized as a standard treatment for unresectable 
pancreatic cancer.
41
 Along the years, many studies have questioned which of these two 
drugs achieved a better outcome for PDAC patients. However, none of these studies 
could fully elucidate this issue, since both drugs exhibit similarly low survival rates, 
proving that the treatments for pancreatic cancer have been failing to improve long-term 
survival. Gemcitabine (2’, 2’-difluorodeoxycytidined) is a nucleoside analog exhibiting a 
significant antitumor activity against different tumor cell lines in vitro, including 
pancreatic and other gastrointestinal tumors. Gemcitabine is a pro-drug that is internalized 
by the cells through membrane transporters, being then converted into the active form 
through phosphorylation promoted by deoxycytidine kinase (dCK). Its cytotoxicity is 
exerted by gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP) 
through incorporation into DNA, thus inhibiting DNA synthesis, through inhibition of 
ribonucleotide reductase and deoxycytidine monophosphate deaminase (the primary 
enzyme responsible for gemcitabine degradation), and by stimulation of deoxycytidine 
kinase (the enzyme responsible for gemcitabine activation).
42
 Nevertheless, gemcitabine 
alone produces only an 11% response rate with a median survival of 5.4 months in PDAC 
patients, being generally accepted that there is no particularly effective chemotherapy for 
patients with pancreatic cancer. The standard therapy currently ranges from palliative 
treatment, to a single agent chemotherapy, 5-fluorouracil (5-FU) or gemcitabine, or to a 
5-FU/gemcitabine-based combined regimen. In this context, it became mandatory to 
develop new drugs and new therapeutic strategies in order to improve the current state of 
care of PDAC patients. 
 
1.4.3.2. Emerging chemotherapeutic agents in PDAC 
In many patients, chemoresistance to gemcitabine treatment is observed after a 
certain period of time. A sub-population of cells, termed cancer stem cells (CSCs), may 
be responsible for this phenomenon, as they display increased resistance to the action of 
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this chemotherapeutic drug, fueling back the tumor, improving tumor aggressiveness, 
thus leading to relapse.
43
 
The search for new drugs that could improve patient’s survival and surpass acquired 
chemoresistance led to the discovery of paclitaxel as a possible chemotherapeutic agent 
that could be administrated along with gemcitabine. Paclitaxel belongs to the class of 
taxanes, showing antimicrotubular activity, by inhibiting the depolymerisation of 
microtubules.
44
 More recently, a new therapeutic strategy,  consisting of human albumin 
nanoparticles bound to paclitaxel, nab-paclitaxel, was developed in order to promote an 
efficient delivery of paclitaxel into tumoral cells.
45
 Promising data have emerged from a 
pilot Phase I/II study where advanced PC patients were submitted to a chemotherapeutic 
regiment of a combination of nab-paclitaxel and gemcitabine.  The median survival rate 
registered was 8.7 months, and the overall response rate was 23% (Table 2).
46
 
Another recent chemotherapeutic regiment with proven efficacy in metastatic solid 
cancers, such as colon and pancreatic cancer, is FOLFIRINOX, which is the combination 
of several drugs: fluorouracil, irinotecan, oxaliplatin and folinic acid. Irinotecan promotes 
cellular toxicity via specific inhibition of the eukaryotic enzyme DNA topoisomerase I. 
Preclinical studies have indicated that when irinotecan is administered before fluorouracil 
and folinic acid results in a synergistic antitumor activity.  Oxaliplatin exerts its cytotoxic 
effect through the formation of platinum-DNA adducts that are responsible for blocking 
DNA replication. Single-agent oxaliplatin has low activity in many tumours, nevertheless, 
when combined with fluorouracil or irinotecan, a synergistic effect is observed in the 
treatment of solid tumors.
47,48
 Due to the relatively non-overlapping toxicities of 
fluorouracil, folinic acid, irinotecan, and oxaliplatin, a regimen combining these agents 
was studied in a phase I clinical trial showing significant responses in patients with 
advanced pancreatic cancer.
48,49
 In 2011, Thierry Conroy and colleagues performed this 
clinical trial in order to elucidate the therapeutic potential of FOLFIRINOX in 
comparison with a gemcitabine monotherapy, in patients with a low severe status of 
illness.
49
 They observed a substantial increase in patient’s survival, with a median overall 
survival of 11.1 months in the FOLFIRINOX group as compared to 6.8 months in the 
gemcitabine group. Moreover, the objective response rate was 31.6% in the 
FOLFIRINOX group versus 9.4% in the gemcitabine group, as described in Table 2. 
However, patients of the FOLFIRINOX group exhibit more severe side effects, revealing 
an undesirable toxicity. Nevertheless, FOLFIRINOX was considered to be a valuable 
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option for the treatment of patients with metastatic pancreatic cancer and to have good 
performance status.
49
 
Table 2-Examples of experimental chemotherapeutic regiments for PDAC.GEM – gemcitabine 
treatment alone (adapted from Chan SL  et al, 2014).
50
Year of publication 
and 
reference 
Agent Arm 
Nº 
patients 
Percentage of patients 
(%) 
Response 
rate (%) 
Median overall 
survival 
(months) 
Locally 
advanced 
pancreatic 
cancer 
Metastatic 
pancreatic 
cancer 
2002 
51 
Fluorouracil 
GEM + 
Fluorouracil 
160 10.6 89.4 6.9 6.7 
GEM 162 9.9 90.1 5.6 5.4 
2003 
52 
5-fluoruracil + 
leucovorin + 
epirubicin + 
carboplatin 
5-Fluoruracil + 
Leucovorin + 
Epirubicin + 
Carboplatin 
71 49.2 50.7 14 7.9 
GEM 67 47.4 52,2 5.9 5.9 
2005 
53 
Oxaliplatin 
GEM + 
Oxaliplatin 
157 30 70 26.8 8.8 
GEM 156 32 68 17.3 6.9 
2006 
54 
Irinotecan 
 
GEM + Irinotecan 60 22 78 15 6.4 
GEM 70 14 86 10 6.5 
2011 
49 
FOLFIRINOX 
FOLFIRINOX 171 0 100 31.6 11.1 
GEM 171 0 100 9.4 6.8 
2013 
46 
Nab-paclitaxel 
GEM + nab-
paclitaxel 
431 0 100 23.0 8.5 
GEM 439 0 100 7 6.7 
 
 
Pancreatic cancer is a very heterogeneous and highly complex disease, with a wide 
variety of activated tumor pathways. Although patients’ survival rates treated with the 
therapeutic regimen presented in Table 2 remain largely unsatisfactory, these drugs still 
hold the best treatment for pancreatic cancer. These data point out the urgent need for 
additional investigation towards the discovery of new and more efficient multitargeted 
therapeutic strategies for PC. 
 
2. Gene Therapy 
 
Regardless of gene therapy concept emerged only in the middle of 1960s, it was not 
until the 1980s that the first in vitro studies were performed, and only 10 years later 
clinical trials involving gene therapy strategies were accomplished.
55
 Nevertheless, the 
real advent in gene therapy would be boosted by one of the greatest achievements in 
science – “The Human Genome Project”. Sequencing the entire human genome, in order 
to build genetic and physical maps spanning the human genome, map all the human 
genes, and label their functions, as well as other parts of the genome has been a 
remarkable task. Consequently, an enormous amount of genetic information was created 
and most importantly, many new genes were identified,
56
 thus, paving the way to 
personalized medicine.
57
 Therefore, gene therapy holds great promise to cure many 
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diseases such as cancer, degenerative neurologic disorders and all sorts of inherited 
genetic diseases. Genes are the raw material for gene therapy, as it consists in transferring 
exogenous genetic material, not only DNA, but also RNA molecules, into target cells, 
aiming at replacing, correcting or balance defective genes that are backing different sort 
of diseases, ultimately improving patients prognosis. Moreover, gene therapy is not only 
considered to be a valuable alternative to conventional therapies, but may also 
complement and improve them.  
After the first gene therapy clinical trial accomplished in 1989 by Rosenberg et al.,
58
 
more than 2076 new clinical trials were approved (Figure 2), in a clear majority related to 
cancer treatment(63,8%), followed by monogenic diseases (8.9%), infectious diseases 
(8.2%) and cardiovascular diseases (8.1%), as mentioned in Wiley database on gene 
therapy clinical trials  (http://www.wiley.co.uk/genmed/clinical).  
 
 
Figure 2 - Distribution of completed or ongoing clinical trials according to the targeted diseases. 
(From:  http://www.wiley.co.uk/genmed/clinical, updated June 2014) 
 
Nevertheless, up to date very few gene therapy products are available in the market, 
being China the pioneer in 2003, commercializing the first gene therapy product, 
Gendicine, an adenovirus vector carrying the human p53 gene, for the treatment of head 
and neck squamous cell carcinoma.
59
 More recently, in Europe, a new gene therapy 
product, consisting of alipogene tiparvovec (Glybera(®)) that makes use of an adeno-
associated virus (AAV) vector, was approved for the treatment of familial lipoprotein 
lipase deficiency.
60
 A broader and safer use of gene therapy (GT) products still remains a 
major milestone to be achieved. 
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2.1. Strategies of Gene Therapy 
 
2.1.1. Insertion of therapeutic genes  
The more common approach in gene therapy consists in the insertion of a normal 
gene in a non-specific region of the host genome, in order to replace a dysfunctional or 
absent gene, or simply the introduction of a new therapeutic gene, aiming at achieving a 
specific therapeutic effect. Diverse strategies can be endorsed, such as using tumor 
suppressor genes, immune-stimulatory genes, survival genes or suicide genes. As an 
example, a Phase I trial is being conducted towards the treatment of high grade gliomas, 
using neural stem cells transduced with an adenovirus containing the gene that encodes a 
rabbit carboxylesterase that can convert the pro-drug,CPT-11 (irinotecan) into its active 
metabolite, SN-38, in a more efficient manner than the endogenous human form. This 
therapy allows a tumor-localized production of SN-38, significantly increasing the 
therapeutic efficacy of irinotecan.
61
 In this case, the purpose of the insertion of the 
therapeutic gene (a gene encoding the rabbit carboxylesterase) was not to act as single 
therapy, but rather to be used to complement and reinforce the therapeutic regiment of 
irinotecan in high-grade glioma patients.
62
 Concerning pancreatic cancer, several clinical 
trials are being conducted using gene insertion technology. In 2001 a Phase I clinical trial 
demonstrated the efficiency of a tumor vaccine, consisting of lymphoblastoid cells 
transduced with a gene encoding the mutated ki-ras-p21 oncogene, establishing a tumor 
antigen approach.
63
 Transduced cells induced an increase in the immunoreactivity, 
suggesting that autologous cellular vaccine hold great hope for future therapeutic 
application in pancreatic cancer. 
In general, gene insertion strategy offers innumerous therapeutic possibilities, 
including those transferring extra copies of a normal gene to overcome the loss of 
function of a certain gene, thus restoring a normal phenotype; introducing therapeutic 
genes coding, for instance, coding for foreigner antigens or cytokines that activate cells of 
the immune system, so as to aid killing of diseased cells; genes encoding toxic 
compounds (suicide genes or prodrugs), thus killing diseased cells directly, or by 
promoting ectopic expression of tumor suppressor genes, as it will explored further ahead 
in this work. 
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2.1.2. Gene silencing 
Regulating genome expression in a post-transcriptional manner is a gene therapy 
strategy that can offer promising results. This approach consists in inhibiting the 
expression of genes that are responsible for supporting pathological conditions in a vast 
number of diseases. In cancer, oncogenic genes promote the establishment of tumorigenic 
features such as abnormal cell proliferation, tumor growth and bypass of apoptotic 
signaling pathways. Therefore, restraining the aberrant oncogenic expression constitutes 
an attractive approach for the development of new cancer therapies.   
Since the discovery of RNAi therapeutic, in which small RNA molecules, such as 
siRNAs and miRNAs, are able to regulate the expression of specific genes in a 
complementary binding manner leading to the silencing or degradation of the mRNA, 
many new opportunities have emerged towards the design of innovative RNAi 
therapeutic strategies. Although, siRNAs and miRNAs are both responsible for post-
transcriptional regulation, and display many similarities in terms of biogenesis, the main 
difference lies on their mode of target recognition. While siRNAs form a perfect duplex 
with their targets at only one site, directing the cleavage of the target mRNAs at the site 
of complementarity, miRNAs bind to the target at the 3′ untranslated regions (UTRs) 
through imperfect complementarity at multiple sites, inducing translational repression or 
transcript degradation, depending on the degree of complementarity between RNAi 
molecule and the target mRNA.
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Gene therapy presents endless opportunities, whether it is making use of DNA genes 
or small interfering RNA molecules to surpass disease related mechanisms. However, 
several crucial steps regarding the transference of genetic material into target cells remain 
a challenge, namely reach the specific cells and overcome the cell barriers, such as 
cytoplasm membrane, endocytic vesicles and nucleus envelope, in the case of plasmid 
DNA delivery. Therefore, much work has been devoted to the design of improved 
strategies for a successful intracellular delivery of therapeutic genetic material.  
 
2.2. Delivery systems 
The development of competent “molecular shuttles”, i.e., delivery vectors that 
mediate an efficient delivery of genetic material into target cells, is a critical and 
demanding task, and until now, many different approaches have been designed to reach 
this goal. 
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An important feature to be highlighted in the development process of the delivery 
systems is their ability to be used in systemic therapies, as these strategies encounter 
diverse hurdles such as blood clearance, strong interaction with blood components and 
accumulation in specific organism niches, such as the liver or lungs that could 
significantly reduce the gene delivery efficiency into target cells.
65
 Furthermore, the 
development of strategies for proper cellular internalization, release and distribution into 
the cell cytoplasm, subcellular compartments or nucleus also present challenging 
difficulties, since DNA genes should be delivered into the cell nucleus while in the case 
of RNAi therapeutics, RNA molecules should reach cytoplasm in order to incorporate 
into RISC complex.
66
 
A total of 2076 gene therapy protocols were approved for clinical trials until now, 
and the vast majority involves the use of viral vectors (67%), due to the high transgene 
delivery/expression exhibited by these systems (Figure 3).  
 
 
Figure 3 – Distribution of completed or ongoing clinical trials according to the diseases targeted. 
(http://www.wiley.com//legacy/wileychi/genmed/clinical) Update June 2014. 
Nonetheless, several concerns, mainly related with safety issues, limited capacity to 
carry genetic material and high costs and difficulty to produce in large scale, have 
prompted investigators to look for other reliable options, such as non-viral vectors.    
Since 2008, the number of non-viral based clinical trial, such as naked DNA and 
lipofection, increased from a total of 270 and 105, respectively, to 365 and 113 clinical 
trials. However, when compared with other gene therapy approaches, such as viral 
vectors, the number of clinical trials based on non-viral vectors is still largely inferior. 
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Overall, these facts show that there is an urgent need for the development of 
innovative gene delivery systems. Regarding recent reports in gene therapy research, 
optimization of previous strategies, and development of new ones towards a more 
efficient and safer gene delivery hold great promising results for therapeutic applications. 
Non-viral gene therapy research has been expanding at an increasing pace to look for 
new methods for nucleic acid delivery, since, despite their lower transfection efficacy 
when compared to viral vectors, they exhibit promising features in terms of safety and 
versatility.  Moreover, in comparison to viral vectors, non-viral systems are inexpensive 
and easy to be submitted to quality control evaluation and to scale-up production.
67,68
  
During the development of gene delivery systems it should be taken in consideration that 
their stability in biological fluids must be guaranteed, as well as their ability to escape the 
immunological surveillance and clearance mechanisms. Cellular barriers, such as the 
plasma and nuclear membranes, the endocytic pathway and potential degradation by 
cytoplasmic enzymes, constitute further obstacles that must be considered. Therefore, 
appropriate systems must be devised to ensure that the various physiological/cellular 
barriers associated to transfection process are surpassed, thus allowing the efficient 
delivery of nucleic acids into the target cells (Figure 4).
69–71
 
 
 
Figure 4 - Physiological/cellular barriers to transfection. A successful nucleic acid delivery system 
should reach the target tissue/organ, avoid enzymatic degradation and diffuse through the extracellular 
matrix, reach the target cell, cross the plasma membrane, escape the endosome and/or avoid degradation in 
the cytoplasm, release the nucleic acids into the cytoplasm and ensure that the nucleic acids reach their 
target, either in the cytoplasm or the nucleus(adapted from Faneca et al, 2013).
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Several parameters must meet the unanimity among peers for an accurate and 
efficient design of delivery systems. Preferably, these delivery systems should: (i) protect 
nucleic acids from degradation; (ii) be effectively internalized in specific target 
tissues/organs/cells, including non-dividing cells; (iii) promote release of the carried 
genetic material into the cytoplasm (antisense oligonucleotides, siRNAs, miRNAs) or 
nucleus (plasmid DNA, splice-switching oligonucleotides); (iv) exhibit high biological 
activity at low doses; (v) display no cellular toxicity; (vi) have a good biosafety profile 
for in vivo therapeutic applications; (vii) be easy to produce and have a reasonable shelf-
life to allow the transport, distribution and, consequently, their widespread use. 
The classification for delivery vectors is commonly divided into two different 
categories, according to their nature, non-viral vectors and viral vectors, which will be 
described further ahead. 
 
2.2.1. Non-viral vectors 
Non-viral systems that were already developed for gene therapy usage present 
some clear advantages over viral systems, mostly related with nonpathogenic features, 
cost-effectiveness and easiness of production. Nevertheless, regarding nucleic acid 
delivery and consequent gene expression they are still highly compromised, as usually a 
lower percentage of cells are effectively transfected in vivo, and gene expression remains 
transient.
68,73,74
 
Non-viral vectors can be divided in three major groups; naked DNA, physical and 
chemical approaches. For naked DNA, or pDNA, a low rate of cellular uptake gave to this 
strategy a very limited use, owing to rapid degradation by nucleases in the serum and 
clearance by the mononuclear phagocyte system.
75
 Within the group of physical systems, 
there are several different known strategies, for instance, electropermeabilization was 
developed as an in vivo electroporation strategy to deliver plasmid DNA by means of 
series of electrical pulses that enhance cell membrane permeability, thus permitting the 
DNA to enter the cell.
76
 Furthermore, sonoporation, which consists in the use of low-level 
ultrasound to enhance the internalization of plasmid-DNA into target cells, was developed 
as a non-invasive alternative method.
77
 Laser irradiation, making use of an alternative 
energy source, is able to locally disrupt cell membrane allowing the efficient delivery of 
nucleic acid, although the underlying mechanism is not yet fully understood.
78
 
Magnetofection makes use of magnetic fields to enhance transfection, by coupling 
magnetic nanoparticles to DNA which are then concentrated preferentially into the target 
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cells by the influence of an external magnetic field.
79
 Ballistics or gene-gun is a strategy 
where naked DNA plasmid is moved into target cells, on an accelerated particle carrier, 
and is also used to increase gene transfer in vivo although it is generally less effective 
than the others strategies.
76
 In spite of having established utility for applied research, 
these methods are prone to cause substantial cell damage. Therefore it became crucial to 
invest in safer and more efficient carriers for gene transfer.  
The chemical systems (namely liposomes, polymers and inorganic nanoparticles) are 
the most well studied and have been shown to improve transfection efficiency and 
biocompatibility, therefore, being appropriate for clinical applications. Lipid-based 
nanocarries are one of the most widely used strategies for the delivery of nucleic acids or 
to entrap drugs, both in an aqueous and a lipid phase. Liposomes, phospholipid vesicles 
with a bilayer membrane structure, offer several advantages over other delivery systems, 
as they are considered to be non-toxic, biodegradable, and most importantly, non-
immunogenic, as most of them are typically composed of naturally occurring lipids.
80
 
Among these, cationic liposomes constitute promising systems for the bench-to-bedside 
transposition of nucleic acid-based therapeutics.
81
 Some polymers are also an attractive 
solution for gene delivery as they exhibit interesting features, such as improved 
biodistribution, reduced toxicity, diverse architecture, and are non-immunogenic and 
easily eliminated from the organism.
82
 Also, inorganic nanocarriers were demonstrated to 
be suitable gene delivery systems, presenting low toxicity and properties that permit 
controlled delivery into target cells. The vast majority of inorganic materials used for the 
development of nanosystems such as calcium phosphate, gold, carbon materials, silicon 
oxide and iron oxide, offer wide availability, rich functionality and good 
biocompatibility.
83
 
 
2.2.1.1. Cationic liposomes 
Since cationic liposomes were first described by Felgner el al.,
84
 a vast number of 
cationic liposome formulations have been established, some of them demonstrating to be 
highly effective both in vitro and in vivo models of disease.
85
 However, very few of these 
lipid-based systems reached the clinical trial phase and their applicability was shown to 
have limited therapeutic efficacy.
86
 In this context, an enormous effort is currently being 
made to increase the efficiency of cationic liposomes as gene delivery systems, including 
the synthesis of new cationic lipids and the design of new cationic liposome-based 
formulations.  
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Cationic lipids are the structural basis of cationic liposomes, and are usually mixed 
with neutral charged lipids, aiming at achieving a high nucleic acid delivery capacity. 
Cationic lipids include a group of amphiphiles that exhibit a positive charge which 
triggers their interaction with negatively charged nucleic acids leading to the formation of 
cationic liposome/DNA complexes (lipoplexes). Among the most extensively used 
cationic lipids are 1-palmitoyl-2-oleoyl-sn-glycero-3-ethylphosphocholine (EPOPC) and 
1,2-dioleoyl-3-trimethylammonium propane (DOTAP), usually in combination with 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and/or cholesterol as “helper 
lipids”. These helper lipids sustain a valuable advantage that is mostly related with 
fluidity features and lipid exchange, which consequently influences the gene delivery 
efficiency of the complexes and their cytotoxicity.
87
 Small modifications in the 
composition/structure of cationic lipids could result in a significant change in the 
biological activity of the lipoplexes. Therefore, a complete understanding of the 
relationships between cationic lipids composition/structure and their biological activity, 
as well as their cytotoxicity, is crucial for the development of efficient gene delivery 
systems. 
 Several other factors have major impact in the gene delivery capacity of the 
lipoplexes as it is the charge ratio between cationic lipids and DNA, zeta potential and 
particle size.  A tight balance between the three parameters should be attained aiming at 
achieving maximum efficacy in gene delivery. Cationic lipid/DNA charge ratio largely 
influences particle size, as neutral zeta potential promotes a mean diameter of the 
particles that can easily exceed 1000 nm, whereas, low cationic lipid/DNA ratios result in 
lipoplexes with small size distribution, but exhibiting negative surface charge. In the case 
of the lipoplexes prepared with an excess of cationic liposomes (complexes with a 
positive lipid/DNA charge ratio) a homogeneous size distribution (mean diameter near 
200 nm) and a positive surface charge were observed.
88
 In this regard, lipoplexes with a 
positive zeta potential usually mediate a much higher transfection activity than those with 
a negative zeta potential, which is most probably due to the interaction of the positively 
charged complexes with the negatively charged cell membrane components, such as 
proteoglycans.
88,89
  In accordance with previous reports, in most of the cases, lipoplexes 
that exhibit a slight positive charge and a mean diameter higher than 300 nm are more 
efficient in mediating transfection than those with the same lipid composition but with an 
excess of negative or positive charge.
90–92
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2.2.1.1.1. Strategies to enhance the biological activity of cationic 
liposome-based systems 
Although significant progress has been made regarding the development of 
lipoplex formulations, their efficiency is still below the required for their successful 
clinical application. In this regard, functional devices have been introduced in lipoplex 
formulations to help overcome the biological barriers associated to the transfection 
process, such as targeting a specific tissue or cell type, transposing the plasma membrane, 
escaping lysosomal degradation and overcoming the nuclear envelope.
89
 These devices 
include, for example, the use of targeting ligands to increase the specificity of cellular 
uptake. It has been demonstrated that adding cell-specific ligands to cationic liposome- 
based systems allows the use of lower doses of these systems and their cargo, while 
simultaneously facilitates tissue targeting, improving transfection efficiency and reducing 
side-effects.
89
 Figure 5shows several examples of cell-surface molecules and ligands 
which have already been explored in targeting strategies. 
 
 
Figure 5 - Cell-surface receptors and ligands used in gene therapy targeting strategies. By coupling 
specific ligands to cationic liposome-based systems it is possible to improve cell internalization and, in 
certain cases, achieve tissue and cell specificity (adapted from Faneca et al, 2013).
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Transferrin and folic acid (FA) are two strong examples of widely explored targeting 
ligands. For instance, taking advantage of the transferrin receptor (TfR), which is  
abundantly expressed in cancer cells and in certain tissues such as the nervous tissue and 
the endothelial tissue that composes the blood brain barrier (BBB), and its mechanism of 
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internalization and recycling to the cell surface, several reports have shown that the 
conjugation of transferrin to the surface of the liposomes improved their binding to this 
receptor in order to enhance both DNA
93
 and siRNA
94
 internalization. Regarding folic 
acid as a ligand, the fact that the folate receptor is overexpressed in innumerous types of 
cancer, including breast and ovarian cancers,
95,96
 offers the possibility to use this receptor 
to develop novel targeted-cationic liposomes-based strategies. Hence, the conjugation of 
folic acid by covalent coupling to cationic liposomes has been used to deliver different 
nucleic acid molecules, such as DNA,
97
 antisense oligodeoxyribonucleotides
98
 and 
siRNA
99
. Moreover, based on the electrostatic interaction between the folic acid and 
liposome, a new gene delivery system was generated by non-covalent association of FA 
to DOTAP:Chol or EPOPC:Chol cationic liposomes (folic acid-associated lipoplexes). 
The obtained results showed that these lipoplexes mediate a much higher transfection 
efficiency and antitumoral activity than plain lipoplexes (lacking folic acid).
91
 
In addition, endowing cationic liposomes with the ability to improve endosomal 
release of nucleic acids to avoid lysosomal degradation is another promising strategy. 
Although cationic liposomes can promote the destabilization of the endosomal membrane 
by themselves, several endosomolytic agents have been developed, based on known 
fusogenic or pore-forming proteins and peptides, in order to significantly improve the 
cytoplasmic availability of nucleic acid molecules.
100,101
 Some of the endosomolytic 
agents most applied to cationic liposome technology are the hemagglutinin subunit 2 
(HA2) fusion peptide of the Influenza vírus and GALA, a peptide composed of repeating 
sequences of Glu-Ala-Leu-Ala, as both undergoes a conformational change under acidic 
pH and assumes fusogenic properties that potentiate the destabilization of the endosomal 
membrane.
100
 Interestingly, human serum albumin (HSA) was also shown to undergo a 
low pH-induced conformational change, thereby acquiring fusogenic properties, 
promoting DNA release from the endocytotic pathway.
102,103
 Moreover, considering that 
this is one of the most abundant human proteins in plasma, its use in cationic liposomes 
coating exhibits a great potential to ameliorate some of the undesired interactions between 
cationic liposome/DNA complexes and serum components. The incorporation of HSA 
into lipoplexes increases their binding and uptake by target cells, and mediates a much 
higher gene expression than the corresponding plain lipoplexes, and although it is not yet 
clear, the internalization of these complexes is thought to be performed via non-specific 
cell surface receptors, as in coated pit-mediated endocytosis.
90,103,104
 Additionally, the use 
of HSA-coated nanosystems could overcome some of the problems associated with the 
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use of highly positively charged complexes for gene delivery in vivo.
90,103,104
 Our 
previous studies also demonstrated that the conjugation of HSA to EPOPC:Chol/DNA 
lipoplexes strongly enhances the transfection activity of lipoplexes not only in vitro, 
including in the presence of serum, but also in an animal model of mammary 
adenocarcinoma.
90,104
 Overall, these observations encourage the use of these HSA-based 
nanosystems in gene therapy approaches.  
 
2.2.1.1.2. Delivery of Oligonucleotides mediated by cationic 
liposomes 
As RNAi therapeutics presents an increasing pace of development, it became 
demanding for cationic liposome technology to follow this trend. Sequence specific 
oligonucleotides (ONs) aiming at blocking gene expression through translational arrest or 
mRNA degradation have been successfully used as therapeutic tools in a variety of 
diseases, including cancer.  
Regarding oligonucleotides delivery with recourse to cationic liposomes, several 
studies have reported both in vitro
105–107
 and in vivo
108,109
 effective applicability. On the 
other hand, a combined strategy, where delivery of therapeutic oligonucleotides was 
accompanied by chemotherapeutic drugs, reveled to be a promising strategy for cancer 
treatment.
110,111
 As an example, Yu-Li Lo and Yu Liu reported the use of PEGylated 
cationic liposomes to carry antisense oligonucleotide (ASOs) and epirubicin to an in vitro 
colorectal adenocarcinoma cell line, as a strategy to overcome multidrug resistance. In 
this study, the combined action of ASOs that  target selected suppressors of efflux pumps, 
with this antineoplastic agent intensified the epirubicin-mediated apoptosis.
111
 Thus, the 
development of cationic liposomes formulations aiming at simultaneously encapsulate 
therapeutic oligonucleotides and chemotherapeutic drugs may represent one of the most 
significant steps in order to attain greater and synergistic antitumor effect with these 
combined approaches to cancer treatment. 
 
2.2.1.2. Viral systems for gene delivery 
Viral vectors are usually associated with increased risk of immunogenicity, and 
others safety concerns, and are technically demanding. In this regard, many efforts have 
been made towards the development of safer and efficient viral vectors for application in 
gene therapy. As a desirable tool in biomedical technology, engineered viral vectors 
should exhibit the attracting characteristics of an efficient ability to infect host cells and 
transfer DNA without invoking an immune response or the uncontrolled insertion of 
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exogenous material into the genome as well as safety application problems. Among the 
advantages of viral vectors, when compared to non-viral vectors, is the more efficient 
gene transfer, usually a single dose of viral particles is sufficient to induce proper 
transgene expression.
112
 
 
 
Figure 6 - Principle of generation of a viral vector. (a) Converting a virus into a recombinant vector. 
Schematic of a generic viral genome is shown with genes that are involved in replication, production of the 
virion, and pathogenicity of the virus. The genome is flanked by cisacting sequences that provide the viral 
origin of replication and the signal for encapsidation. The packaging construct contains only genes that 
encode functions required for replication and structural proteins. The vector construct contains the essential 
cis-acting sequences and the transgene cassette that contains the required transcriptional regulatory 
elements. (b) The packaging and vector constructs are introduced into the packaging cell by transfection, by 
infection with helper virus, or by generating stable cell lines. Proteins required for replication and assembly 
of the virion are expressed from the packaging construct, and the replicated vector genomes are 
encapsidated into virus particles to generate the recombinant viral vector. (adapted from Verma IM, 
Weitzman MD, 2005).
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The most commonly used viral vectors are derived from adenovirus, retrovirus and 
adeno-associated virus (AAV). Other viral vectors that have been less extensively used 
are derived from herpes simplex virus 1 (HSV-1), vaccinia virus, or baculovirus. 
Retroviruses envelope contains a virus-encoded glycoprotein that specifies the host 
range or types of cells that can be infected by binding to a cellular receptor. The envelope 
protein promotes fusion with a cellular membrane on either the cell surface or in an 
endosomal compartment, afterwards the double-stranded DNA is transferred to the 
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nucleus, where it is integrated into the host cell genome by a mechanism involving the 
virus-encoded enzyme integrase, being stably maintained.
114
 
Adenoviruses are non-enveloped viruses able to transduce both, dividing and non-
dividing eukaryotic cells. They are often used as replication competent oncolytic viruses 
for delivery of DNA sequences into the desired target cell. Subsequently to infection, 
oncolytic adenoviruses replicate in a tissue-specific manner and spread their viral progeny 
to neighboring cells. These viral vectors exhibit low pathogenicity and cytotoxicity due to 
the low number of viral genes present in the Ad vector, minimizing immune 
response.
115
On the other hand, a suicide gene therapy using replication-deficient vectors 
has been used, and all trials reported that intraprostatic administration of a replication-
deficient adenoviral vector was well tolerated and no dose-limiting toxicity was 
observed.
116
 Still, extensive preclinical and clinical research, including trials with long-
term follow-up will be required to bring adenoviral gene therapy for cancer toward 
clinical implementation. 
 
2.2.1.2.1. Lentivirus vectors –particular focus in HIV 
Gene transfer vectors based on retroviruses, including oncogenic retroviruses and 
lentiviruses, provide effective means for the delivery, integration and expression of 
exogenous genes in mammalian cells. The inability of simple retroviral based vectors to 
transduce non-dividing cells has limited their potential utility for gene therapy. In contrast 
to simple retroviruses, lentiviruses present the ability to infect non-dividing cells. The 
capacity to efficiently transduce non-dividing cells, shuttle large genetic payloads and 
maintain stable long-term transgene expression are attributes that have brought lentiviral 
vectors (LVs) to the forefront of gene delivery vehicles for research and therapeutic 
applications in a clinical setting.
117
 Stable long-term transgene expression is a desirable 
characteristic for any research/clinical application involving transgene delivery in vivo. In 
pursue of this goal, lentivirus vectors have long demonstrated to be highly efficient to 
mediate long-term transgene expression in vivo.
118
 
Different types of lentivirus-based vectors have been produced, including those 
developed from the immunodeficiency viruses derived from human (HIV-1 and HIV-2). 
The mechanism by which lentiviruses infect non-dividing cells, namely HIV-1, is 
supposed to be related with the efficiency of uncoating, due to the capsid protein 
association with intracellular retroviral complexes, accounting for the disparity between 
lentiviruses and simple retroviruses in transduction of quiescent cells.
119
 HIV-1 based 
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vectors display competent transduction of non-dividing cells while retaining the ability to 
integrate transgenes into the target cell genome in the absence of an inflammatory 
response. However, safety concerns still remain as a major drawback with the use of 
lentiviral vectors. 
117
 
A gene therapy approach for pancreatic ductal adenocarcinoma demonstrated that 
the HIV-1-based lentiviral vectors are very efficient in gene transfer for PC-derived cells 
both in vitro and in vivo. The success of pancreatic cancer gene therapy strongly relies on 
the delivery vector, thus expression of selected tumor suppressor transgenes delivered by 
lentiviral vectors resulted in the inhibition of cell proliferation and the induction of cell 
death by apoptosis.
120
 Sicard F. et al developed a lentivirus based vector coding the anti-
miR-21 molecular sponges, after finding evidences that despite locked nucleic acid 
antagomiRs could successfully inhibited miR-21 function in vitro failed to target this 
miRNA in vivo.
121
 Their results demonstrated, for the first time, that miRNA antagonists 
are highly efficient in targeting miR-21, when delivered by LVs, both in vitro and in vivo, 
without impacting on endogenous miRNA biogenesis. Moreover, they also found that 
tumor cell proliferation and tumor progression are strongly inhibited following miR-21 
depletion promoted by miR-21 sponges transduced with LVs.  
Regarding this, HIV-1-based lentiviral vectors could be a powerful tool to deliver 
microRNA modulators in pancreatic cancer.  
 
3. MicroRNAs 
 
MicroRNAs were first identified in Caenorhabditis elegans in the beginning of the 
1990s, when Lee et al discovered that a small 22 nucleotide RNA sequence, lin-4, could 
negatively regulate the level of LIN-14 protein.
122
 It was suggested for the first time that 
this sequence was responsible for regulating translation via an antisense RNA-RNA 
interaction, since it bound in a complementary way to the 3’ untranslated region (UTR) of 
lin-14 mRNA. MicroRNAs are small endogenous non-coding RNAs with 20 to 22 
nucleotide length, but with a powerful task of modulating mRNA transcription in a 
posttranscriptionally manner. These tiny molecules constitute only 1% to 3% of human 
genome, however they are able to regulate a large portion of the genome.
123
  Around 100 
microRNA genes have been identified in invertebrates and up to 1000 in vertebrate and 
plants, all of which are available in miRBase.
124
 Bioinformatic algorithms have estimate 
that each microRNA can target hundreds of different mRNAs, hypothesizing that a large 
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proportion of the transcriptome is under the control of miRNA regulation.
125
 Therefore, 
microRNAs display extensive regulatory activity in virtually all biological processes such 
as cell cycle, cellular differentiation, survival, proliferation and apoptosis.
126
 
The biogenesis of microRNAs (Figure 7) involves a multi-step sequential process that 
is initiated in the nucleus, comprising the processing of a long primary transcript (the pri-
miRNA), performed by Drosha-DGCR8 complex, into 70 to 100nt hairpin precursors, the 
pre-miRNAs. Afterwards, the pre-miRNA is translocated to the cell cytoplasm, under the 
action of exportin-5, being further cleaved by the ribonuclease Dicer into a mature 
miRNA duplex.
127
 Subsequently, the mature miRNA duplex is integrated into the RNA 
induced silencing complex (RISC) that leads to the degradation of the duplex into a single 
stranded of miRNA, mature RISC.
128
 After the assembly of the microRNA into the RISC 
complex and its maturation, it can bind to its target mRNAs by complementary base 
pairing at their 3'UTR, through the seed sequence (7 to 8 nucleotides). The degree of 
complementarity between the miRNA and the target mRNA determines whether the 
miRNA will inhibit translation or, less frequently, induce degradation of the target 
mRNA.
127,128
  
 These regulatory molecules present a much simpler mechanism in plant than in 
metazoan organisms, as in plants  miRNAs  commonly exhibit  a nearly perfect 
complementarity to the target mRNA, prompting  mRNA cleavage by a RNAi-like 
mechanism, much similarly to siRNAs.
128
 However, mammalian miRNAs have an 
imperfect pairing with their targets, where the first 2-9 nucleotides of the miRNA, 
representing the seed sequence, display an almost perfect and contiguous base pairing, 
being responsible for the main miRNA-mRNA interaction, leaving the rest of the 14 to 20 
nucleotides (microRNA “tail”) with a more intermittent binding.123 
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Figure 7 - MicroRNA biogenesis (adapted from  V. Narry Kim, 2005).
128
 
 
Although it is assumed that microRNA function is control gene expression 
posttranscriptionally, by regulating mRNA translation or stability in the cytoplasm, the 
mechanistic details in repressing protein synthesis are not totally clarified.
126
 Moreover, 
emerging evidences of new functions of miRNAs indicate that miRNAs could regulate 
pre-mRNA processing in the nucleus or act as chaperones that modify mRNA structure or 
modulate mRNA–protein interactions.129 Additionally,  observations that mammalian 
miRNAs can either be imported into the nucleus or excreted from one cell to another 
through exossomes reinforce their widespread importance in cellular biology.
129,130
 
MicroRNA-mediated gene silencing involves translational repression and/or mRNA 
degradation through endonuclease cleavage of the target mRNA. However, some 
questions remain unanswered concerning mechanistic details of miRNA-mRNA 
regulation, as extensive base-pairing between the microRNA and the mRNA is not 
always sufficient to induce cleavage. Several different mechanisms have been proposed 
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for mRNA silencing mediated by microRNAs: by blocking translation elongation, 
through promoting premature dissociation of ribosomes (ribosome drop-off); or through 
the association of Argonaute-2 (AGO2) protein, from the RISC complex, with both 
eukaryotic translation initiation factor 6 (eIF6) and large ribosomal subunits; or 
competition between Argonaute proteins and eukaryotic translation initiation factor 
4E(eIF4E) for binding to the cap structure of the mRNA, preventing the large ribosomal 
subunit from assembling with the small subunit.
126
 Subsequently,  translational repression 
is accomplished as the targeted mRNA undergoes sequestration into P-bodies where they 
are shielded from the translation machinery, thus silenced, and may also be submitted to 
decay.
126,131
 Moreover, miRNA-mediated gene silencing also involves mRNA 
degradation, which is accomplished via deadenylation and decapping of the mRNA 
molecules, through the recruitment of the decay machinery components.
131
 
 
3.1. Other non-coding RNAs 
Apart from rRNAs (ribosomal RNAs), tRNAs (transfer RNAs), snRNAs (small 
nuclear RNAs) and more recently microRNAs and siRNA, other important non-coding 
RNAs (ncRNAs) have been discovered while eukaryotic transcriptomes were assessed. 
 Recently, Hirose T et al. reviewed their taxonomy: overall, eukaryotic ncRNAs can 
be classified either as small RNAs (~20–30 nucleotides (nt); e.g., miRNAs), intermediate 
sized RNAs (~30–200 nt; e.g., snRNAs), and lncRNAs (> ~200 nt).132 Small RNAs are 
non-coding RNA molecules smaller than 150 nt, and in this category we can find, for 
example, piRNAs (PIWI-interacting RNAs) and crRNAs (clustered regularly interspaced 
short palindromic repeats). piRNAs function as guide molecules to silence 
complementary transposon RNAs either by post-transcriptional cleavage or by 
transcriptional silencing, and are known to be highly heterogeneous sequences and not 
well conserved across species.
132
 As for crRNAs, these molecules are encoded by 
clustered, regularly interspaced, short palindromic repeats (CRISPR) loci in prokaryotes 
and are known to function as a genome defense mechanism against foreign genetic 
elements such as plasmids and viral genomes through antisense targeting.
132,133
 Regarding 
lncRNAs (non-coding RNA), these are recently discovered non-coding RNA molecules 
larger than 200 nt, known to occupy a considerable portion of whole ncRNAs and for 
being widespread in the nucleus and cytoplasm. They are also characterized by the lack of 
strong conservation among species and to display cell-type-specific expression patterns. 
Being precursors for small RNA molecules, responsible for processing of other RNAs or 
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key coactivators of proteins involved in transcriptional regulation are some of the most 
well described functions of lncRNAs.
132,134
 
Genetic and epigenetic events can disrupt ncRNA loci and their related proteins, and 
emerging evidence indicate a relevance of the dysregulation of these ncRNAs in many 
diseases such as cancer and neurological, cardiovascular and other human disorders.
135
 
Nevertheless, a special focus will be given to microRNAs as a hallmark of cancer, 
particularly in pancreatic cancer.  
 
3.2. MicroRNAs and Cancer 
Dysregulation in microRNA expression levels is considered to be associated to 
tumorigenesis, as more than 50% of miRNA genes are located in cancer associated 
genomic regions.
136
 MicroRNAs can target cancer related genes, therefore they can act as 
oncogenes (oncomiR), promoting proliferation and/or repressing apoptosis, or as tumor 
suppressors, by repressing genes responsible for the maintenance of tumorigenesis.
137
 The 
first reported case of abnormal miRNA expressions was found in B-cell chronic 
lymphocytic leukaemia (CLL).
136
 Posteriorly several genome-wide profiling studies were 
performed in various solid tumors, such as  breast cancer,  glioblastoma,  hepatocellular 
carcinoma, lung cancer, colon cancer and endocrine pancreatic tumours, and other 
anomalous microRNA expression patterns were identified.
136,138,139
 Both normal and 
tumoral tissues exhibit unique microRNA expression profiles, a specific signature being 
inherent to a variety of tumor types, which can be used to characterize and identify them. 
Interestingly, microRNAs were also identified in many human fluids, including human 
blood stream, as circulating microRNAs, making them a valuable tool as biomarkers for 
cancer diseases, as patients and control groups could be easily distinguished by analyzing 
a specific set of microRNAs. Furthermore, specific miRNA expression signatures have 
been identified as characteristic of some cancer subtypes, and therefore useful for tumor 
classification, but have also been associated with prognosis, staging, and response to 
therapy.
138,140,141
 
Special attention has been devoted to microRNAs involved in different cellular 
pathways of high importance to maintain cancer malignancy. Some of these microRNAs 
are pivotal players in several carcinogenic pathways, revealing a widespread monopoly 
over tumoral maintenance.
138
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MicroRNA-21 has attracted the attention of researchers in various fields, and is 
probably one of the most extensively studied miRNAs. Moreover, miR-21 was identified 
as the best hit in a number of profiling experiments designed for the detection of miRNAs 
dysregulated in cancer. It was shown to be strongly up-regulated in various types of 
cancer, including glioblastoma, breast, colon, lung, pancreas, prostate, gastric and 
hepatocellular carcinoma, acting in some pivotal signaling pathways promoting tumor 
growth, invasion and chemoresistance (Figure 8), thus, making miR-21 one of the most 
promising prognostic markers for cancer diagnose.
142
 
 
 
 
Figure 8 - Model of miR-21 network and feedback regulation. Maturation of miR-21from pri-miR-21 is 
shown in the center of the model. MiR-21 direct target genes are depicted on blue background. Genes 
shown on green background are regulated (probably indirectly) by miR-21 and are involved in miR-21 
processing from pri-miR-21 to pre-miR-21.(Adapted from Krichevsky A. and Gabriely G, 2009).
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Another example of well-studied microRNAs is the let-7 family, which is frequently 
downregulated in the vast majority of cancers. Let-7 tumor suppressor activity was found 
to exert an effect upon two of the most important oncogenic genes, RAS and c-MYC. 
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143,144
 This microRNA functions extend from suppressor of cell proliferation, to inducer 
of apoptotic signaling pathways and sensitizer to chemotherapeutic agents.
145,146
 
Much different microRNAs can be found dysregulated in cancer, some exerting 
oncogenic roles in signaling pathways that promote tumor growth, increased 
angiogenesis, stemness, etc., others prevented from regulating normal physiological 
events. One of the most aggressive characteristic of cancer is the ability of tumoral cells 
to escape from the primary tumor and invade healthy tissues, thus promoting metastasis 
formation. This event is also supported by the action of oncogenic microRNAs. Abba M. 
and colleagues reviewed the impact of microRNAs in the regulation of matrix 
metalloproteinase, which are enzymes responsible for the breakdown of collagen Type 
IV, thus responsible for extracellular matrix and tissue remodeling.
147
 However, these 
proteins are also endorsed in cancer progression, epithelial to mesenchymal transition 
(EMT) and metastization, being the normal physiological processes disrupted. Abba M 
and colleagues presented data comprising 55 different studies, where a group of 13 
miRNAs were distinguished by targeting both MMP-2 and MMP-9 in a large variety of 
cancers types. Amongst them, miR-10b, miR-21, miR-125b, miR-138 and miR-181b 
showed that the regulation of these MMPs, and thus the associated invasion of normal 
tissue by tumoral cells and the establishment of novel metastasis, are strongly determined 
by the action of a multiplicity of miRNAs.  
PDAC can also be distinguished by a specific dysregulated group of microRNAs 
responsible for backing it tumorigenic features. This group of miRNAs will be addressed 
below.  
 
3.3. Dysregulated microRNA in PDAC 
Pancreatic adenocarcinoma shares a common feature with other solid tumours: an 
abnormal expression of microRNAs, usually implicated in several supportive mechanisms 
of oncogenesis. Studies based on high-throughput microarray technologies were 
performed using available in vitro models as well as tumour samples, excised from PDAC 
patients, in order to establish a common expression pattern for this malignancy, and thus a 
tumoral microRNA signature for pancreatic cancer.
148–150
 Nevertheless, when it comes to 
identify a large group of differentially expressed microRNAs in PDAC, consensus among 
research groups has been an arduous issue, since numerous parameters, such as 
differences in measurement platforms and laboratory protocols, small sample sizes as 
well as variability among samples, can strongly influence the attained results and partially 
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the lack of reproducibility. However, a meta-review approach can give further insight into 
the analysis of experimental data resulting from numerous individual studies, 
consequently increasing statistical significance and subsequently discard inconsistent data 
among different profiling studies. By instance, in 2013, Ma M. et al reviewed eleven 
microRNA profile studies in PDAC, reporting 439 miRNAs differentially expressed, that 
gathered a total of 538 tumours and 206 noncancerous control samples. A group of 
microRNAs, which levels of expression were consistent across studies, was elected by the 
authors and is presented in Table 6.
151
 
Table 6- PDAC meta-signature from the vote-counting strategy (reported consistently in at least five 
studies) 
microRNA name 
Corrected 
p-value 
Permutation 
p-value 
No. of 
studies 
Up-regulated    
hsa-miR-155 6.17E-11 8.64E-13 8 
hsa-miR-100 3.32E-09 7.01E-11 7 
hsa-miR-21 2.75E-09 3.29E-11 7 
hsa-miR-221 1.56E-08 9.34E-10 7 
hsa-miR-31 1.44E-05 8.83E-07 5 
hsa-miR-143 6.78E-04 4.56E-06 5 
hsa-miR-23a 3.27E-03 5.09E-05 5 
Down-regulated    
hsa-miR-217 7.56E-07 4.37E-09 5 
hsa-miR-148a 2.00E-05 3.55E-07 5 
hsa-miR-375 1.08E-03 8.70E-06 5 
 
Exhaustive investigation has been devoted to microRNAs to further enlighten their 
role in signaling pathways responsible for supporting tumoral cells proliferation, survival 
and metastasis in pancreatic cancer. The importance of microRNAs that are often referred 
to exhibit an aberrantly expression pattern in pancreatic cancer will be reviewed. 
 
3.3.1. Up-regulated microRNAs in PDAC 
MiR-155 is known to play a crucial role in the post-transcriptional regulation of 
TP53INP1 (tumor protein 53-induced nuclear protein 1), which is under the direct 
control of p53, a tumor suppressor gene. TP53INP1 induces cell cycle arrest and 
apoptosis, and its expression is lost in early stages of pancreatic cancer. Gironella and 
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colleagues describe miR-155 as the responsible for TP53INP1 repressed expression and 
that the restoration of TP53INP1 levels is in accordance with the regression of 
tumorigenic features of pancreatic cancer.
152
  Furthermore, miR-155 was also shown to be 
involved in the control of invasiveness and migration ability of pancreatic tumoral cells 
by modulating the STAT3 pathway and reducing SOCS1 expression levels.
153
 
Additionally, abnormal levels of miR-155 were detected in noninvasive precursor lesions, 
a premature stage of pancreatic cancer, and increased oncogenic activity of miR-155 was 
related with poorer survival chances in PDAC patients, making this microRNA a 
fundamental biomarker in differentiation of this malignancy and a predictor for patient 
outcome.
154,155
 
Distinct roles can be attributed to miR-100 in different cancers, making it a quite 
contradictory microRNA, as it can behave either as an oncogene or a tumor suppressor 
gene, depending on the tumor type. In breast cancer, miR-100 was found to be 
downregulated and was related with progressive pathological feature and poor prognosis 
in patients. Reestablishment of miR-100 expression levels led to tumor growth inhibition 
by strongly reducing IGF2 (insulin-like growth factor 2) expression, a known oncogene. 
156
 Moreover, it was reported that this microRNA could also regulate the expression of 
HOXA1, a gene enrolled in EMT, either in breast cancer and in non-small cell lung 
cancer.
157,158
 Nevertheless, in non-small cell lung cancer elevated levels of miR-100 were 
detected, and an opposite effect of the regulation of HOXA1 was observed when in 
comparison with breast cancer cases, where it seems to increase tumoral cell survival and 
chemoresistance, exhibiting a dual and divisive role.
157,158
 Chen J. and colleagues 
reviewed this contradictory role of miR-100 in a variety of cancers, reporting several 
studies where this microRNA can display either oncogenic or tumor suppressor 
features.
159
 Concerning pancreatic ductal carcinoma, the consequences of miR-100 
overexpression are still poorly understood. It was reported that metastatic pancreatic cell 
lines present a greater expression of miR-100 than in non-metastatic cell lines.
160
 
Additionally, a functional link was established between miR-100 and IGF1-R (insulin 
growth factor 1 receptor), known to control the ability of pancreatic cancer cells to 
metastasize in vivo, as it is involved in the proliferation mechanisms in cancer. It was 
observed that after transfection with miR-100 inhibitors into S2VP10 pancreatic cancer 
cells the IGF1-R expression levels were decreased.
160
 Moreover, miR-100 was also 
described to be up-regulated in a genetically engineered mouse pancreatic cancer model, 
the p48-Cre/LSL-KrasG12D model, as well as in human pancreatic cancer stem cells, 
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demonstrating it widespread importance in the conservation of tumorigenic features of 
PDAC.
161,162
 
MiR-21, as in much other type of malignancies, is strongly up-regulated in PDAC. 
This microRNA has demonstrated to be enrolled in cell proliferation, survival and 
gemcitabine resistance in pancreatic ductal adenocarcinomas,
163,164
 and most importantly, 
it is detected in early pancreatic lesions know to be precursor of pancreatic cancer.
165
 
However, recent reports suggest complementary roles for miR-21 in pancreatic cancer. 
For instance, hypoxic microenvironment of pancreatic tumor was shown to regulate miR-
21 expression levels through increase of the HIF-1α expression, and hypoxic conditions 
are described as metastasis enhancer.
166
 Pancreatic tumoral cells were reported to improve 
their ability to invade and metastasize by inducing tumor-associated fibroblasts (TAFs) to 
express miR-21.
167
 Taken together, these findings provide evidence that miR-21 is a 
promising dual target, both in tumoral cells and in stroma cells.   
In parallel with miR-21, miR-221 was found to be up-regulated in pancreatic cysts 
with malignant potential and to drive invasive cancer, demonstrating that miR-221 
aberrant expression is also an early event in the development of pancreatic cancer.
168
 
MiR-221 was also reported to be a key player in diverse pathological pathways in PC 
such as cell proliferation, survival, migration, invasion, metastasis and, finally, 
acquisition of the epithelial-mesenchymal transition (EMT) phenotype by regulating the 
platelet-derived growth factor (PDGF) signaling cascade.
142
 Moreover, these events have 
demonstrated to be partially a consequence of the downregulation of the miR-221 target, 
p27
Kip1
.
169
 Some other mRNA targets of miR-221 were highlighted by Sarkar S.et al, 
revealing that the inhibition of miR-221 could decrease the proliferative capacity of the 
pancreatic cancer cells by rescuing the tumor suppressor activity of PTEN, p27
kip1
, 
p57
kip2
, and PUMA, which are well-known tumor suppressors.
170
 
Although some microRNAs were not referred in Table 6, many different studies 
highlighted their importance in promoting tumorigenesis, as it is the case of the 
microRNAs miR-10b and miR-196a. Studies in breast cancer have always focused on 
miR-10b due to its involvement in metastasis formation.
171,172
 Regarding pancreatic 
cancer, miR-10b up-regulation was also demonstrated to have a relevant role in 
invasiveness features of tumor cells, thus leading to a possible poor prognostic for 
patients.
173
 Preis M. and colleagues, analyzed several samples of PDAC and found that 
miR-10b was one of the most frequently and consistently overexpressed microRNAs. 
Their data also suggested that lower levels of miR-10b were associated with improved 
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response to multimodality neoadjuvant therapy, higher probability of surgical resection, 
delayed time to metastasis, and increased survival.
174
 More recently, a study revealed 
some possible mechanistic properties of miR-10b in promoting invasiveness in pancreatic 
cancer, as Tat-interacting protein 30 (TIP30) was identified as its direct target. MiR-10b 
was shown to suppress TIP30 expression, which in turn enhances EGFR signaling, 
facilitates EGF-TGF-β cross-talk and enhances the expression of EMT-promoting genes, 
whereas decreasing the expression of several metastasis-suppressing genes.
175
 
MiR-196a biological relevance in pancreatic cancer is still largely unclear, despite 
being mentioned in several genomic profiling studies as one of the most differentially 
expressed microRNAs in pancreatic cancer. Recently, Huang and colleagues suggested 
that the nuclear factor kappa-B-inhibitor alpha(NFKBIA), an inhibitor of the NF-κB 
transcription factor, which is implicated in the progression of pancreatic cancer, is a target 
of the miR-196a in PDAC.
176
 They registered increased levels of miR-196a in four 
different pancreatic cell lines and enhanced expression of NFKBIA after miR-196a down-
regulation, which promoted inhibition of migration, suggesting a direct regulation 
mechanism of miR-196a in migratory ability of pancreatic tumoral cells. Reinforcing this 
data, miR-196a was also pointed as an important modulator in abnormal physiological 
processes, such as apoptosis, invasion, and proliferation in pancreatic cancercells.
177
 
Regardless of all these evidences relatively to the oncogenic role of miR-196a in 
pancreatic cancer, as far as we know, no attempt was been made to use this promising 
microRNA as a therapeutic strategy for the treatment of PDAC.  
 
3.3.2. Downregulated microRNAs in PDAC 
Dysregulated microRNAs in cancer also include miRNAs that are partially or 
strongly inhibited, enhancing a tumorigenic phenotype. The downregulated microRNAs 
in PDAC highlighted by Ma M. et al are miR-217, miR-148a and miR-375, since they 
gather more consensuses among the majority of genomic microRNA profile studies.   
Emerging evidences points towards a tumor suppressor function of miR-217 in 
several types of cancer. Low cellular levels of this microRNA were associated with 
improved invasion ability, increased cell motility and cell proliferation in both renal cell 
carcinoma and hepatocellular carcinoma.
178,179
 In addiction, it was described that miR-
217 downregulation was associated with drug-resistance in chronic myelogenous 
leukemia.
180
 The molecular mechanisms involving miR-217 were investigated in PDAC 
by Wu-Gan Zhao and colleagues, who analyzed this microRNA expression profile in 
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normal and tumoral tissues as well as in PDAC cell lines, reporting a different profile in 
healthy and malignant samples, being miR-217 significantly downregulated in PDAC 
tissues and cell lines. Furthermore, a significant suppression of cell growth was observed 
after ectopic expression of miR-217, both in vitro and in vivo, which was inversely 
correlated with KRAS expression, due to direct post-translational regulation. Moreover, 
the expression of miR-217 had also the ability to affect other downstream molecular 
effectors, indicating a regulatory role in KRAS signaling pathway.
181
 Restraining of 
KRAS protein expression in a miR-217 dependent manner promote the decline of 
anchorage-independent colony formation in PDAC cells. Remarkably, after in vivo 
xenograft treatment with miR-217 expression vector it was observed a decrease of tumor 
growth, revealing a therapeutic potential for PDAC.
181
 
Similarly to other dysregulated microRNAs in PDAC, miR-148a was also described 
as aberrantly under expressed in hepatocellular carcinoma, gastric cancer and non-small 
lung cancer, being associated with more aggressive features and poor survival rates.
182–184
 
The major pathway in which miR-148a seems to play a pivotal role in malignancy control 
are intrinsically related with the epithelial to mesenchymal transition (EMT), 
predominantly acting as a metastasis suppressor.
182–184
 Particularly in gastric cancer, the 
inhibition of EMT through miR-148a action is partially attributed to the downregulation 
of vimentin and to the up-regulation of E-cadherin. In addition, miR-148a was also found 
to inhibit cancer metastasis by suppressing TGFβ-induced EMT through  SMAD2, its 
direct functional target.
185
 In breast cancer, restoration of normal miR-148a expression 
levels had a great impact in angiogenesis via targeting insulin-like growth factor-I 
receptor (IGF-IR) and insulin-receptor substrate-1(IRS1) and suppressing their 
downstream serine/threonine-specific protein kinase(AKT) and mitogen-activated protein 
kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathways.
186
 
Moreover, a tumor suppressor role was also recognized to miR-148a in hepatocellular 
carcinoma stem cells. This microRNA was shown to attenuate the CSCs-like properties 
through the inhibition of transforming growth factor beta/SMAD2 (TGF-β/SMAD2) 
signaling pathway upon treatment with Glabridin.
187
 Importantly, it was also stated that 
miR-148a could sensitize cancer cells to the chemotherapeutic action of cisplatin and, in a 
lesser extent, to 5-flurouracil (5-FU) in oesophageal cancer, thus attenuating 
chemoresistance.
188
 Notably, miR-148a gene expression inactivation was shown to be a 
consequence of DNA hypermethylation in PDAC-derived cell lines and PDAC samples, 
compared with adjacent samples of non-pathologic tissue. Moreover, evidences of 
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aberrant hypermethylation of the miR-148a coding region were reported to occur early in 
human PDAC precursor PanIN lesions.
189
 Therefore, this epigenetic event is deeply 
involved in the premature loss of miR-148a expression in pancreatic cancer.
189
 To further 
elucidate the molecular mechanisms where miR-148a acts as a tumor suppressor in 
pancreatic cancer, it is important to identify its direct functional targets and, to date, few 
of them have been acknowledged in PDAC. In 2011, Sven-T Liffers and colleagues 
observed, through luciferase based reporter assays, that the protein phosphatase CDC25B 
was a candidate target of miR-148a
190
 Moreover, using an in vitro model based on 
lentiviral-mediated stable miR-148a overexpression in the IMIM-PC2pancreatic 
carcinoma cell line, they demonstrated that miR-148a overexpression had an inhibitory 
influence on the growth potential of pancreatic cancer cells. More recently, two 
oncogenic genes, cholecystokinin-B receptor (CCKBR) and B cell lymphoma 2 (Bcl-2), 
were found to be under the post-transcriptional regulation of miR-148a. This microRNA 
was found to not only inhibit the proliferation of pancreatic cancer cells, but also to 
promote cells apoptosis in vitro through the suppression of CCKBR and Bcl-2 
expression.
191
 Controversially, another research group described miR-148a as an 
“inappropriate therapeutic tool” against pancreatic cancer, as they observed that there was 
no dramatic effect on cell proliferation and cell chemo-sensitivity in four PDAC cell 
lines.
192
 Additionally, after substantial overexpression of miR-148a it was observed that 
this microRNA faintly modulates protein expression. More importantly, in vivo data 
demonstrate that modulating miR-148a expression either in the epithelial tumor cells 
and/or in the tumor microenvironment does not impede tumor growth. Moreover, they 
also evaluated cell sensitivity to gemcitabine and concluded that no correlation exists 
between miR-148a expression levels in several PDAC cell lines and intrinsic sensitivity 
to gemcitabine. Neither transient nor stable overexpression of miR-148a improves 
PDAC-derived cell lines sensitivity to gemcitabine in vitro. Interestingly, a recent study 
provided evidences for a different approach, using miR-148 as a molecular tool for PDAC 
by engineering an oncolytic virotherapy strategy, that ultimately exhibited promising 
results for the treatment of pancreatic cancer.
193
 MicroRNA-148a, along with miR-216a, 
was used to generate miR-targeted pancreatic adenovirus. As miR-148a and miR-216a are 
highly expressed in normal pancreatic tissue, and their expression is lost in tumoral 
pancreatic cells, these microRNAs could selectively control E1A expression and viral 
replication in normal cells, by selectively binding to pre-design binding sites, leaving the 
oncolytic virus to target strictly tumoral cells. Thus, the developed targeted therapy with 
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oncolytic adenoviruses was able to preserve the normal pancreatic function of the non-
neoplastic pancreas, improving their safety profile, and to promote an effective antitumor 
response.
193
 
In the past few years, miR-375 mechanisms in PDAC have been studied, since it is 
considered one of the most consistently downregulated miRNAs in pancreatic cancer. 
However, a limited number of studies on pancreatic cancer have been focused on the 
targeting and on the clinical and prognostic significance of miR-375. A large study, 
involving the analysis of miR-375 expression in normal pancreatic tissue and tumoral 
samples of PDAC, identified miR-375 as candidate with a strong potential for future 
clinical applications.
194
 It was demonstrated that miR-375 might be used to classify 
normal, chronic pancreatitis and cancerous tissues, allowing to discriminate between 
neoplastic and non-neoplastic processes in pancreatic cancer. In other types of cancer, 
miR-375 is also described as an important mediator of normal cellular function. In breast 
cancer, it was identified as targeting short stature homeobox 2 (SHOX2), readily 
mediating EMT suppression. In addition, epigenetic silencing of miR-375 in HER2-
positive breast cancer cells conferred trastuzumab treatment resistance.
195,196
 
Corroborating the same antitumorigenic profile, a study performed in non-small-cell lung 
cancer (NSCLC) also found miR-375 significantly down-regulated.
197
 Moreover, the 
authors showed that this miRNA could be an important biomarker for survival, as patients 
with low miR-375 expression had worse overall survival rates than those with high miR-
375 expression. Overall, miR-375 is involved in the suppression of core hallmarks of 
cancer, such as cell growth, invasion, migration, metastasis and proliferation, by targeting 
several important oncogenes (Figure 9), like AEG-1, YAP1, IGF1R and PDK1, thus 
making it an encouraging target to address in many antitumor strategies.
198
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Figure 9 - MicroRNA-375 targets and regulation in cancer. Mir-375 exerts tumor suppressor role upon 
several different targets, displaying a wide intervention in major tumorigenic pathways. ATG7- autophagy-
related protein 7; YAP1- Yes-associated protein 1; AEG-1 - astrocyte elevated gene-1 protein ; PDK1-3-
phosphoinositide-dependent protein kinase 1; 14-3-3Z-  14-3-3 zeta protein ; IGF1R- insulin-like growth 
factor-I receptor; SP1- Transcription factor Sp1 ; JAK2- Janus kinase 2 ; (adapted from Yan JW, 2013)
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Indeed, miR-375 was first identified as a pancreatic islet-specific miRNA that 
regulates the glucose-induced insulin secretion, consequently being an important 
participant in glucose homeostasis by controlling the growth and morphogenesis of the 
pancreatic islet, and later as a lost microRNA in pancreatic malignant cells
199
 
Several studies search for the impact of this lost in PDAC, for example, Jian Zhou 
and colleagues provided data correlating miR-375 restoration levels with induced 
apoptosis and abrogation of cell proliferation in vitro.
200
 In addiction, the low levels of 
this microRNA was also associated with lymph nodes metastasis formation and advanced 
stage of the disease.
199
 One of the potential mechanisms relaying beneath miR-375 action 
is associated with the repression of the 3-phosphoinositide-dependent protein 
kinase 1 (PDK1) expression, consequently promoting a decrease in the tumorigenicity of 
pancreatic cells through the regulation of the Akt signaling pathway. Inhibition of PDK1 
by miR-375 includes the inhibition of cell proliferation and the induction of apoptosis and 
cell cycle arrest at G0/G1 phase in PDAC cells.
179
 Moreover, the chemo-preventive agent 
benzyl isothiocyanate (BITC), known for inhibiting the growth of pancreatic cancer cells 
in vitro, was reported to be capable of modulating the levels of miR-375, along with miR-
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221, in order to diminish the cell viability and sensitize pancreatic tumoral cells to its 
antiproliferative action.
201
 
Although not emphasized in Table 6, microRNA-139-5p was also reported as  a 
tumor-suppressor microRNA  in a variety of cancer types, such as colorectal cancer, 
glioma, esophageal squamous cell carcinoma, hepatocellular carcinoma and PDAC, 
nevertheless its mechanisms of regulation were not addressed until recently in this last 
case.
202–205
 Several oncogenes may be potential targets of miR-139-5p in pancreatic 
cancer, probably most of them related with metastasis induction since miR-139-5p was 
found to regulate translocation-associated of Notch protein (NOTCH1) and type I insulin-
like growth factor receptor (IGF1-IR) in colorectal cancer, inhibiting cell proliferation 
and metastasis and promoting apoptosis and cell cycle arrest.
202,206
 MicroRNA-139-5p 
was also shown to be involved in the regulation of c-Fos and Rho-kinase 2 in 
hepatocellular carcinoma, contributing to the repression of cell invasiveness.
205,207
 
Moreover, in gastric cancer, miR-139-5p was found to regulate the human epidermal 
growth factor receptor 2 (HER2), which has been associated with metastasis and poor 
prognosis.
208
 MicroRNA-139-5p epigenetic silencing was described as an important event 
in a mechanism supporting invasiveness through HER2-mediated up-regulation of C-X-C 
chemokine receptor type 4 (CXCR4). This chemokine receptor has been extensively 
associated with cancer metastasis,
209
 including pancreatic cancer.
210–212
 Additionally 
CXCR4 was also reported to be a cancer stem cell-specific marker for pancreatic 
cancer.
213
 Regarding the importance of CXCR4 in PDAC tumorigenicity, it could be of 
utmost importance unveil the existence of a correlation between miR-139-5p and CXCR4 
in pancreatic cancer, since it could hold the key for the metastasis control therapeutics.  
Other dysregulated microRNAs were addressed in many molecular mechanistic 
studies in PDAC, such as miR-125, miR-10a miR-15a/b, miR-let7 and miR-17-5p, and 
their extreme importance in hallmark tumorigenic pathways were confirmed.
173,214–220
 
Nevertheless, to our knowledge, no substantial effort has been made in order to take 
advantage of the known role of these microRNAs to create novel microRNA-based 
therapeutic approaches to PDAC. There is an urgent need for new findings in the 
translational research field with prognostic, predictive and therapeutic value. 
Taken together, these findings suggest that the microRNA regulating role in 
pancreatic cancer is poorly understood, and that only few work has accomplished the goal 
of unraveling the mechanisms supporting either oncogenic or tumor suppressor roles of 
the previously described microRNAs. Moreover, these evidences also prompted us to 
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hypothesize that most of these highlighted microRNAs are, indeed, profoundly embedded 
in some of the most important and mentioned hallmarks of pancreatic cancer, such as 
invasion, migration and metastasis formation. Therefore, this group of microRNAs can be 
associated to the known aggressive profile of PDAC, such as the resistance to the overall 
available treatments, providing a more real picture of the true nature of this belligerent 
type of cancer.  
 
3.4. Strategies used for the modulation of microRNA expression 
Proper delivery of miRNA-targeting agents or microRNA mimics is limited by 
several critical hurdles, such as reduced in vivo stability, inappropriate biodistribution, 
lack of cell specificity, disruption and saturation of endogenous RNA machinery, and 
potential side effects. In order to overcome these barriers and translate microRNA 
innovations into clinical applicability, appropriate approaches, including delivery 
systems, must be design. Anti-miRNA oligonucleotides (AMOs) are molecular tools able 
to induce microRNA silencing either in vitro or in vivo, since these compounds have the 
ability to tightly bind and inactivate the miRNA action.
221
 Similarly, microRNA 
replacement therapy, in which the lower endogenous levels of microRNAs are augmented 
with recourse to oligonucleotide mimics, is another strategy to modulate intracellular 
microRNA levels.
222
 Oligonucleotides constitute an important tool for the manipulation 
of miRNA function in biological systems, mainly due to their unique characteristics (low 
size, low immunogenicity, high target affinity). Chemical modifications of 
oligonucleotides confer nucleases resistance and increase their binding affinity to their 
targets, consequently improving their performance.
223
 Locked Nucleic Acid (LNA™) 
nucleosides are a successful example of this type of microRNA expression modulators, 
consisting of a class of nucleic acid analogues containing one or more LNA nucleotide 
monomers with a bicyclic furanose unit locked in a RNA-mimicking sugar conformation. 
Thus, conformational restriction is translated into exceptional hybridization affinity 
towards complementary single-stranded RNA molecule, and its efficiency has been 
proven both in vitro and in vivo.
224–226
 
Gene therapy has the potential to reverse the cause of diseases, which is the major 
goal of biomedical research, rather than treat the symptoms. Therefore, therapeutic 
approaches making use of microRNA technology had already been study in order to 
manage malignancy in different types of cancer. For instance, in lung cancer, the 
downregulated miR-29 was subject of microRNA replacement therapy using a cationic 
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liposome-based system, consisting of DOTAP, cholesterol and  D-α-
Tocopherylpolyethyleneglycol 1000 succinate (vitamin E TPGS), to efficiently 
deliver miR-29b both in vitro and in vivo.
227
 This strategy not only promoted a reduction 
in the expression of key miR-29b targets but also in cell growth and clonogenicity of in 
vitro non-small carcinoma cells. In addition, systemic delivery of these lipoplexes 
containing miR-29b increased the tumor miR-29b levels, consequently downregulating 
the tumoral mRNA targets, and significantly inhibited tumor growth in vivo. As an 
example of anti-sense microRNA strategy in tumors, it was recently used chlorotoxin-
coupled stable nucleic acid lipid particles (SNALPs), encapsulating antisense 
oligonucleotides against miR-21, in glioblastoma tumoral cells. In vitro studies revealed 
an efficient miR-21 silencing that resulted in increased levels of the tumor suppressors 
PTEN and PDCD4, caspase 3/7 activation and decreased tumor cell 
proliferation. Moreover, the targeted nanoparticles demonstrated to have excellent 
features for in vivo application.
228
 
Another work demonstrated that exosomes, small endosomal-derived vesicles that are 
secreted by a variety of cell types and tissues, could efficiently deliver let-7a miRNA to 
EGFR-expressing breast cancer cells in vivo.  The authors engineered the donor cells to 
express the transmembrane domain of platelet-derived growth factor receptor fused to the 
GE11 peptide (targeting EGFR positive cells), loaded with let-7, that were posteriorly 
intravenously administrated to a xenografts breast cancer mouse model, resulting in 
significant inhibition of tumor development.
229
 The biocompatibility and toxicity profiles 
of exosomes, which notably are natural carriers of miRNA in vivo, support their 
application in drug delivery systems. Viral vectors have also been shown to be highly 
effective in gene transfer into cancer, and particularly oncolytic adenoviruses have been 
considered as highly eligible vehicles for delivery of therapeutic genes to treat cancer due 
to their tumor-restricted replication capabilities. Wenjia Lou and colleagues, proposed to 
use oncolytic adenovirus co-expressing miRNA-34a and IL-24 in a hepatocellular 
carcinoma xenografts mouse model in order to achieve a synergistic antitumoral effect.
230
 
Their data demonstrated that miRNA-34a can be efficiently expressed after transduction 
with oncolytic adenovirus, and miRNA-34a and IL-24 can be efficiently co-expressed by 
a single oncolytic adenovirus. Moreover, simultaneous expression of miRNA-34a and IL-
24 showed no effect on adenovirus replication in HCC tumor cells. The mature miRNA-
34a exerted it antitumor action by inducing apoptosis through downregulation of Bcl-2 
and suppressing metastasis and angiogenesis by targeting c-MET and SIRT1 genes. In 
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addition, IL-24 can also exert dramatic antitumor activity by itself, further reinforcing the 
obtained result in which AdCN205-IL-24-miR-34a could dramatically inhibit the tumor 
cell growth in vitro, and resulted in complete tumor regression without tumor recurrence 
in vivo.
230
 
Our group demonstrated that an almost complete abrogation of up-regulated 
microRNA in PDAC was obtained by the intracellular delivery of antisense 
oligonucleotides using a human serum albumin –cationic lipoplexes nanosystem. MiR-21, 
miR-221, miR-222 and miR-10b expression levels in a PDAC cell line were thoroughly 
inhibited, resulting in a significant increase in the levels of their targets. In this study we 
also showed that the modulation of miR-21 levels in combination with low amounts of 
the chemotherapeutic drug sunitinib resulted in a strong and synergistic antitumor effect, 
demonstrating that this combined strategy could be of great importance for therapeutic 
application in PDAC.
231
 
Herein, many different options have been explored for efficient delivery of 
microRNA mimics or antagomiR. Nevertheless, effective microRNA therapeutics are still 
been evaluate regarding their toxicity and safety features in a clinical context.  
 
3.5. MicroRNA Gene Therapy in clinical trials 
More than prognostic biomarkers or diagnose tools, microRNAs are stepping into 
a new era of therapeutic strategies against several diseases. The first case of a microRNA-
based gene therapy product achieving a clinical trial was Miravirsen and has currently 
completed a Phase 2 clinical trial. Miravirsen was developed by Santaris Pharma, a 
Danish RNAi therapeutics company and is a LNA-based microRNA inhibitor targeting 
miR-122, a liver specific microRNA shown to be crucial for the functional infection of 
Hepatitis C virus, constituting the first microRNA-based therapy for a disease.
232,233
 
Another microRNA therapeutic based company, Regulus Therapeutics, has put focus on 
cardiovascular diseases, and although their studies did not reach clinical trials, substantial 
work was performed regarding antagomir strategies in non-human primates. MicroRNA-
33 inhibition, using modified antisense oligonucleotides against miR-33a and miR-33b in 
African green monkeys, demonstrated to promote a decrease in the very-low-density 
lipoprotein(VLDL)-triglycerides and an increase in high-density lipoprotein (HDL), 
endorsed by a significant reduction on the repression of miR-33 predicted target genes, 
without displaying significant side-effects. These data provide evidences that 
pharmacological inhibition of miR-33a and miR-33b is a promising therapeutic strategy 
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to raise plasma HDL and to lower VLDL triglyceride levels, providing treatment of 
dyslipidaemias that increase cardiovascular disease risk.
233,234
 Still, considering cardiac 
diseases, an American company (miRagen Therapeutics) developed other antagomir 
strategies dedicated to miRNA-based drugs for the treatment of cardiac and muscular 
diseases. This company has some LNA-based antagomirs with great potential for 
human clinical trials, namely MGN-1374, MGN-4893, MGN-9103, targeting miR-208 in 
chronic heart failure, miR-15/miR-195 in cardiac ischemic injury and miR-451 in 
polycythemia vera,respectively.
233,235–237
 
Although several key microRNAs were subject of interest in the regulation of cancer 
malignancy, clinical trials designed to test microRNA-based gene therapy approaches for 
this disease were quite scarce. In this regard, new gene therapy strategies have been 
designed in order to restore normal expression levels of such microRNAs, by 
incorporating oligonucleotides against microRNAs or microRNAs mimic into target cells.  
Some microRNAs have demonstrated to be potential clinical targets for cancer therapy, 
specifically let-7, miR-29, miR-21 and miR-34a.
238
 Regarding miR-34 family members, 
which are transcriptionally induced by p53, and miR-34a that is specially enrolled in the 
p53 transcriptional network, its suppression in cancer cells is tightly related to resistance 
to apoptosis induced by p53-activating agents, although, as illustrated in Figure 10, many 
other cancer processes are controlled by miR-34a.
239–241
 Moreover, this microRNA can 
act synergistically with conventional cytotoxic therapies in different cancer types, making 
it a very interesting option for microRNA-based therapies.
242
 
 
 
Figure 10 – Oncogenic process inhibited by the tumor-suppressor activity of miR-34a. 
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Mirna Therapeutic, an American company pioneer in microRNA therapeutics, 
developed the first microRNA replacement therapeutic targeting cancer, using miR-34 
mimics incorporated into a lipid-based particle (MRX34), already in clinical 
trials.
242
Precedingin vitro and in vivo studies in hepatocellular carcinoma models showed 
inhibition of tumor cells in vitro, efficient delivery of the lipid nanoparticles to the liver, 
and a significant tumor regression, some mice were even tumor-free, as well as prolonged 
survival of treated mice carrying this type of tumor.
242
 
Much work has been devoted to miR-34a in PDAC. In 2011 an in vivo study was 
performed using a lipid-based nanosystem, for intravenous administration, containing a 
miRNA expression plasmid to deliver into pancreatic cancer cells, the miR-34a in 
conjunction with miR-143/145 being chosen as therapeutic microRNAs to manage PDAC 
tumorigenicity.
243
 The obtained results pointed for a successful microRNA modulation, 
since the restoration of the miR-34a levels in cancer cells promoted both pro-apoptotic 
and antiproliferative effects in pancreatic cancer xenografts. Thus, the systemic miRNA-
coding plasmid delivery mediated by nanovectors resulted in the growth inhibition of 
both subcutaneous and orthotopic pancreatic cancer xenografts, demonstrating to be a 
highly effective tool to addressed PDAC.
243
 MicroRNA-34a also accounts for the 
regulation of pancreatic cancer stem cells features, such as self-renewal capacity, 
consequently representing an important tumor suppressor to fight tumor-initiating cells in 
PDAC.
244
 
More recently, another miR-34a delivery strategy was developed, this one 
comprising nanocomplexes containing a tumor-targeting and cell-penetrating bifunctional 
CC9 peptide.
245
 The authors showed in vitro that treatment with these nanocomplexes 
resulted in increased levels of miR-34a that promoted the downregulation of its target 
genes, namely E2F3(transcription factor E2F3), Bcl-2 (B-cell lymphoma 2), c-myc and 
cyclin D1, and ultimately the cell cycle arrest, apoptosis and migration suppression. 
Treatment with these nanocomplexes in vivo significantly repressed tumor growth and 
prompted cancer cell apoptosis.
245
 
Therefore, the novel MRX34 therapeutic may be a suitable tool for the treatment of 
pancreatic cancer, as such remarkable scientific data impels this hypothesis.  
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3.6. Other RNAi-based therapeutic in clinical trials 
Despite microRNA gene therapy in cancer has still a long way to go, siRNA 
therapeutics present a boarder number of option to be used in a clinical context, as many 
siRNA strategies reach clinical trials.   
CALLA-01, a siRNA nanoparticle product in phase I trial, was firstly developed by 
Calando Pharmaceuticals. They developed a system consisting of a cyclodextrin-
containing polymer and human transferrin, incorporating a siRNA targeting M2 subunit 
of ribonucleotide reductase (R2), promoting tumor growth repression in solid 
tumors.
246,247
 Since then, many more have followed Calando Pharmaceuticals steps, as 
new siRNA-based therapeutics underwent preclinical and clinical phases.
247
For instance, 
a therapeutic strategy involving siRNA was accomplished in a human trial for dual 
targeting of VEGF and kinesin spindle protein (KSP), in patients with liver metastasis 
from endometrial cancer.
248
 A lipid-based nanoparticle formulation was used for 
intracellular delivery of siRNA molecules into tumoral cells, leading to dual 
downregulation of VEGF and KSP, through siRNA-mediated mRNA cleavage. 
Moreover, antitumor activity, including complete regression of liver metastases was 
observed in patients. It was also shown that the intravenous administration of the 
nanoparticles was safe and well tolerated, providing proof-of-concept for RNAi 
therapeutics in humans and forming the basis for further development in cancer 
therapy.
248
 Overall, the increasing number of fruitful clinical studies using siRNA 
prompted this new field of gene therapy to experience a fast expansion.
249
 
Regarding pancreatic cancer, one siRNA-based therapy have been successfully 
developed by Silenseed Ltd, an Israeli company, that uses a RNA interference approach 
to efficiently target KRAS in PDAC patients.
250
 Acknowledging that 90% of pancreatic 
cancer cases exhibits KRAS mutations, robustly affecting its signaling pathway, leading 
to pancreatic neoplasia, this siRNA-based therapy holds promising results towards PDAC 
management in a clinical context.
251
 Moreover, the therapeutic strategy of silencing 
KRAS has proven to be an effective approach to control pancreatic tumor 
proliferation.
250,252
 Hence, they designed a siRNA delivery system comprising of a 
biopolymeric cylindrical implant that permits anti-KRASG12D siRNA drug released 
throughout a period of months into a tumor (Local Drug EluteR, LODER).Collected data 
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from in vitro and in vivo experiments provide evidences of significant decrease in KRAS 
levels, leading to inhibition of proliferation and epithelial–mesenchymal transition, as 
well as reduced tumor growth.
250
 This therapeutic strategy has now entered in a Phase I 
clinical trial aiming at evaluating firstly the safety of the implantation of a single dose of 
siG12D LODER (Local Drug EluteR targeting G12D K-Ras mutations) followed by a 
dose-escalation phase in patients diagnosed with operable adenocarcinoma. In a posterior 
Phase II clinical trial it will be assessed the efficiency of the administration of a single 
dose siG12D LODER in combination with chemotherapeutic regiments, such as 
gemcitabine or FOLFIRINOX, in patients with unresectable locally advanced pancreatic 
cancer.
247
 
Taken together, these facts also envision an auspicious future for microRNA based 
therapies. 
 
3.7. Therapeutic perspective of using microRNA modulation as an antitumor 
tool in PDAC 
MicroRNAs represent a fine-tuning in molecular pathways, more than massive 
modulators in cell physiologic events. Nevertheless they are of great importance for the 
regulation of normal cell functions. Since their discovery, many studies had focused on a 
one-to-one relationship between microRNA and genes. Over the time, this view was 
quickly surpassed by novel discoveries which illustrated a much more complex network 
between these two players, and an intricate regulation of biological systems sustained by 
differential microRNA expression pattern.
253
 
Understanding the full extent of microRNAs functional activity, from their biology to 
their molecular properties, has allowed the development of bioinformatics tools that make 
use of computational algorithms, based on specific base-pairing  rules and cross-species 
conservation requirements, to predict the targeting of a given mRNA by a specific 
microRNA.
254
 Consequently, a huge amount of data has emerge from the interface of the 
bioinformatics and biologic system studies, arising MiRnomics as a new field in science, 
and several public microRNA databases were made available online for the scientific 
community, as it is PicTAR, microBASE, TargetScan, miRanda, just to mention a few of 
them.
255,256
 Nevertheless, bioinformatics tools may deliver false positive microRNA-
mRNA correlation, as the biological context of these RNA molecules interactions are not 
taken in consideration or poorly estimated, enhancing the need for an integrative 
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approach with experimental studies in order to establish a comprehensive view on this 
computational predictions.
253
 
Acknowledging that microRNA present two extremely important features in terms of 
regulation of genome expression, as it is multiplicity and cooperativity, where one 
miRNA can target more than one gene (multiplicity), and one gene can be controlled by 
more than one miRNA (cooperativity),
257
 the hypothesis of obtaining a wide control over 
cell tumorigenic properties through the modulation a small group of microRNAs, with 
high multiplicity scores seems a thrilling opportunity to boost microRNA therapeutics. 
The relevance of these small regulatory RNA molecules in cancer had been largely 
foreseen as potential diagnostic and prognostic molecular markers, taking advantages of 
circulating microRNAs in exossomes, or for the identification of tumor subtypes 
according to their microRNA profile. However, microRNAs can also be seen as highly 
promising therapeutic agents, mostly due to the ability that a single microRNA has to 
target several crucial pathways in tumorigenesis maintenance.  
Recent developments in RNAi therapeutics in cancer constitute an evidence of the 
remarkable opportunity to efficiently combine miRNA with chemotherapeutic regiments 
as a novel strategy for cancer therapy. Many different approaches for tumor delivery of 
microRNAs have been presented, and many others are still being developed, in order to 
be applied in a clinical context for the treatment of pancreatic cancer.  
To our knowledge, up to date no scientific studies were performed in order to 
discover the efficacy of a combined therapy of new chemotherapy regimens, such as 
FOLFIRINOX, with microRNA expression modulation, although it could hold promising 
results, as a synergistic effect would be expected. Ji et al (2009) conducted a study in 
which they demonstrated that in vitro miR-34a restoration levels was followed by 
sensitization of pancreatic tumoral cells to the action of chemotherapy agents such as 
docetaxel, gemcitabine and cisplantin.
258
 Also, albumin coated lipoplexes could be 
considered to deliver antisense oligonucleotides, aiming at inhibiting overexpressed 
microRNAs, as a gene therapy approach for PDAC.
231
 The combination of gene delivery 
with current standard chemotherapeutic agents can promote significant anti-tumor activity 
in pancreatic tumoral cells, as describe by Passadouro M et al and Xu J and colleagues, 
thus holding great hope in achieving novel therapeutic strategies to improve PDAC 
treatment and patient survival.
231,259
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Hence, novel strategies that encompass the combination of the modulation of 
differentially expressed microRNAs with different chemotherapeutic regiments may hold 
great importance for future management of cancer. 
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Chapter 3 
 
 
 
MicroRNA inhibition combined with 
chemotherapeutic drugs as a novel 
therapeutic strategy for pancreatic 
cancer 
 
Marta Passadouro; Maria C. Pedroso de Lima; Henrique Faneca, MicroRNA 
modulation combined with sunitinib as a novel therapeutic strategy for pancreatic 
cancer. International Journal of Nanomedicine (9), July 2014: 3203–3217. 
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1. Introdution 
 
Pancreatic ductal adenocarcinoma (PDAC) is the most predominant type of pancreatic 
cancer, accounting for more than 90% of new pancreatic cancer cases.
6
 This disease still 
remains a therapeutic challenge, since only minor significant advances have been 
achieved, and always with a modest clinical impact.
4
 Despite its moderate incidence when 
compared to other carcinomas, PDAC has one of the highest mortality rates and  very low 
survival improvements have been made over the past 30 years.
3
 This fact is mainly due to 
asymptomatic features leading to a late diagnosis in an advanced state of the disease, 
where early and aggressive metastization to distant organs has already occurred. The 
overall median survival is 2-8 months, and only 1-4% of all patients with pancreatic 
carcinoma survives for 5 years.
260
 Therefore there is a pressing need for developing new 
and efficient therapeutic strategies for pancreatic cancer.  
Accumulated evidence has shown that microRNAs are key regulators in cancer, 
managing a variety of biological processes relevant for tumor development such as 
proliferation, angiogenesis and metastization, and therefore they constitute highly 
promising targets for anti-tumor therapies.
261
 These endogenous small non-coding RNA 
molecules of approximately 22 nucleotides display a critical role as epigenetic regulators 
of gene expression, acting post-transcriptionally, through binding to their target mRNA 
resulting in translation inhibition. Microarray technology has enabled to reveal 
differential microRNA expression patterns depending on the tissue, cell type and even 
developmental stages of a tumor. In the latter case, the cellular phenotype originated by 
the disruption of microRNA regulation is not yet well established, demanding a deeper 
and meticulous investigation.
262
 
At early stages of cancer progression profound alterations occur in microRNA levels, 
and oncomiR become overexpressed whereas tumor-suppressor microRNAs become 
downregulated, leading to tumor growth and/or repression of apoptosis. A large number 
of  studies  have shown that microRNAs, such as the aberrantly expressed miR-21, miR-
221, miR-222 and miR-10b, act as leading mediators in cancer, due to their ability to 
support tumoral development and cancer cell resistance to chemotherapy.
194,263,264
 MiR-
21 was shown to regulate the function of several tumor suppressor genes, including 
PTEN, a phosphatase and tensin homolog gene that is a negative regulator of the 
PIK3/Akt survival pathway.
164,265–267
 Mir-221 and miR-222 are known to target the 
cyclin-dependent kinase inhibitor p27
Kip1
, which exerts its anti-proliferative action at the 
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G1 phase of the cell cycle, its function being frequently inactivated in many lethal human 
epithelial cancers.
268,269
 A few studies have identified miR-10b as a tumor promoter that 
determines the extent of the expression levels of Homeobox D10 gene, and consequently 
RHOC pro-metastatic gene, as a downstream signaling target, both of these genes being 
involved in metastatic processes in several types of cancers.
173,270
 
The increase of tumor suppressor gene expression has been a successful assignment in 
antitumor strategies, namely by promoting cell chemosensitivity to a broad range of 
therapeutic drugs used in cancer treatment.
271
 By instance, downregulation of miR-21 was 
reported to directly reinforce susceptibility of breast cancer cells to chemotherapy.
265
 This 
gene expression modulation involves the use of oligonucleotides against the 
overexpressed microRNAs. In this regard, cationic liposome/DNA complexes 
(“lipoplexes”) have been extensively studied aiming at developing appropriate non-viral 
gene delivery nanosystems.
69,272
 Much effort has been devoted to the synthesis of new 
cationic lipids, selection of different helper lipids and association of proteins or fusogenic 
peptides aiming at enhancing lipoplex biological activity.
68,88,273,274
 Coating cationic 
liposomes with the most abundant plasma protein, albumin, alleviates some of the 
undesired interactions between cationic liposome/DNA complexes and serum 
components and facilitates intracellular gene delivery by inducing lipoplex binding and 
uptake into target cells and by promoting endosome membrane destabilization under 
acidic conditions.
90,103
 Our previous observations indicated that association of albumin to 
lipoplexes, prepared with EPOPC:Chol cationic liposomes at the 4/1 lipid/DNA (+/−) 
charge ratio, strongly increases their transfection activity with reporter and therapeutic 
genes in several types of cells, both in vitro and in vivo, showing the high gene delivery 
efficiency of this nanosystem.
104,275
 Nevertheless, the HSA-EPOPC:Chol/DNA (+/−) 
(4/1) lipoplex nanoformulation was never tested as an oligonucleotide delivery system. 
Although gemcitabine constitutes the current frontline therapy for pancreatic cancer, 
with a better outcome in unresectable tumor cases, new drugs are becoming the focus of 
attention for the treatment of progressive pancreatic neuroendocrine tumors, namely 
sunitinib malate which has been recently approved for this purpose in clinical 
trials.
8,276
Sunitinib is a competitive inhibitor of the catalytic activity of a strictly related 
receptor tyrosine kinases (RTKs) group, including vascular endothelial growth factor 
receptors (VEGFR) and platelet-derived growth factor receptors (PDGFRs), and due to its 
multi-targeted profile, the activity of sunitinib is likely mediated by multiple distinct anti-
tumour mechanisms.
277
This drug acts by blocking the activity of those RTKs in major 
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pathways related with tumor growth, proliferation and metastasis dispersal, thus  
exhibiting a potent antitumor and antiangiogenic effect.
278
 For patients with advanced 
stage of pancreatic adenocarcinoma, who had been first submitted to gemcitabine-based 
treatments with no significant results, there are no reliable second line therapies and 
sunitinib has already been pointed out as a promising drug for treating such patients.
279
 
Considering the  instrumental role of microRNAs in tumorigenesis and the success of 
combining several drugs targeting major effectors of the tumorigenic process  as the most 
promising treatment for this disease, we evaluated the potential of a new therapeutic 
strategy based on the combination of low amounts of chemotherapeutic drugs and 
oligonucleotides against different microRNAs, delivered by the developed albumin-
associated nanosystem, aiming at achieving a significant and synergistic antitumor effect 
in PDAC. 
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2. Materials and methods 
 
Cell lines and culture conditions  
The Hs766T cell line was obtained from American Type Culture Collection (ATCC) 
(Manassas, VA, USA) and used as an in vitro tumoral model for human metastatic 
pancreatic carcinoma. The cells were maintained in adherent culture using Dulbecco’s 
Modified Medium (DMEM) from Invitrogen (Life Technologies, Carlsbad, CA, 
USA) supplemented with 10% fetal bovine serum (FBS) from Gibco (Life Technologies, 
Carlsbad, CA, USA) and 100 μM each of penicillin and streptomycin from Sigma-
Aldrich (Munich, Germain). HPNE, an immortalized normal pancreatic epithelium cell 
line, was kindly provided by Dr. Ming-Sound Tsao from the Ontario Cancer Institute, 
Toronto, Ontario, Canada. HPNE cells were grown in keratinocyte serum-free medium, 
purchased from Gibco (Life Technologies, Carlsbad, CA, USA), supplemented with EGF, 
bovine pituitary extract from Invitrogen (Life Technologies, Carlsbad, CA, USA) and 
with 1x antibiotic-antimycotic from Gibco (Life Technologies, Carlsbad, CA, USA). Both 
Hs766T and HPNE cells were grown at 37ºC, under 5% of CO2, in humidified 
atmosphere. 
 
Antisense inhibitors and drugs 
Anti-microRNA oligonucleotides (AMOs) againstmiR-221, miR-222, miR-21 and 
miR-10b and scrambled oligonucleotides (control), as well as 5`-fluorescein-labelled 
oligonucleotides, for confocal microscopy, and digoxigenin (DIG)-labelled 
oligonucleotides, for miR-21 detection, were all purchased from Exiqon (Vedbaek, 
Denmark) as miRCURY locked nucleic acids (LNA
TM
). 
The chemotherapeutic drugs docetaxel and gemcitabine were purchased from Sigma-
Aldrich (Munich, Germany) and stock solutions were prepared in distilled water and 
subsequently stored at -20ºC and at room temperature, respectively. Sunitinib malate 
(Sutent®) was kindly offered by Pfizer (Basel, Switzerland) and the stock solutions were 
prepared in DMSO from Sigma-Aldrich (Munich, Germany) and stored at -20ºC. 
 
Preparation of cationic liposomes and lipoplexes 
Small unilamellar cationic liposomes were prepared with lipids (Avanti Polar Lipids, 
AL, USA) dissolved in CHCl3. The cationic lipid 1-palmitoyl-2-oleoyl-sn-glycero-3-
ethylphosphocholine (EPOPC) and cholesterol (Chol) were mixed at 1:1 molar ratio and 
76 
 
dried under a nitrogen flux. The dried lipid film was then rehydrated with deionized water 
to a final lipid concentration of 4 mM. The obtained multilamellar liposomes were then 
submitted to sonication for 3 min and extruded 21 times, through two staked 
polycarbonate filters of 50 nm pore diameter using a Lipofast device (Avestin, Toronto, 
Canada), in order to obtain small unilamellar liposomes. Finally, the liposome suspension 
was diluted 3 times with deionized water and filter-sterelized using a 0.22 μm pore-
diameter filter (Schleicher & Schuell, Dassel, Germany). The suspension was stored at 
4ºC until use. For intracellular distribution studies, EPOPC:Chol liposomes were labelled 
with 0.1% carboxyfluorescein-dioleoylphosphatidylethanolamine (carboxyfluorescein-
PE). Lipoplex preparation was performed by adding the components in the following 
order: HEPES-buffered saline solution (HBS) (100 mM NaCl, 20 mM Hepes, pH 7.4); 
liposome suspension in the appropriate amount to achieve the 4/1 (+/-) lipid/LNA charge 
ratio; and human serum albumin (HSA) solution at a ratio of 32 μg of HSA/μg of AMOs. 
This mixture was incubated at room temperature for 15 min and the necessary amount of 
LNAs was gently added and submitted to a further 15 min incubation period. 
 
Mean diameter and zeta potential  
Nanosystems were characterized with respect to their mean diameter and zeta 
potential using a Zetasizer Nano ZS (Malvern Instruments Ltd, Worcestershire, UK), 
which measures these parameters by a phase analysis light scattering method. The 
analysis was performed at 25°C in HEPES-buffered saline solution, and lipoplexes were 
prepared immediately before analysis. 
 
Transfection assays  
Transfection assays were performed in Hs766T cells using HSA-
EPOPC:Chol/AMOs (+/-) 4/1 lipoplexes containing AMOs or scrambled 
oligonucleotides. For RNA expression analysis, 1.5x10
5
 cells/well were seeded in 12-well 
culture plates, 24 h before transfection, aiming at achieving 80% of confluence. For the 
target protein analysis, 3x10
5 
cells/well were seeded in 6-well culture plates, 24 h before 
transfection. For cell viability assays, 0.35 x10
5
 cells/well were seeded in 48-well culture 
plates, 24 h prior to transfection. Before transfection cell medium was replaced by 
DMEM-HG medium without serum or antibiotics and after that 0.15 ml of lipoplexes per 
1 ml of DMEM medium were gently added to each well and incubated with cells for 4 h 
(5% CO2 at 37ºC). After this period of incubation, cell medium was replaced by DMEM-
77 
 
HG with serum and antibiotics, and cells were further incubated for 48 h and 72 h for 
RNA and protein analysis, respectively, and during both incubation periods for cell 
viability assays.  
 
Intracellular distribution of lipoplexes and oligonucleotides 
In order to evaluate intracellular distribution of the nanosystems, Hs766T cells, 
seeded in 12-well culture plates (previously covered with coverslips) 24 h before 
transfection, were incubated with lipoplexes prepared from carboxyfluorescein-labelled 
EPOPC:Chol liposomes. Cells were incubated with lipoplexes for a period of 4 h in 
DMEM-HG (without serum or antibiotics). The transfection medium was then removed 
and cells were carefully washed twice with a phosphate-buffered saline solution (PBS) 
and incubated for 30 min with 200 nM of Lysotrack Red DND-99 purchased from 
Molecular Probes (Life Technologies, Carlsbad, CA, USA) which labels acidic 
compartments of living cells. Cells were washed three times with PBS and fixed with 4% 
of paraformaldehyde solution for 15 min at room temperature. Nuclei labeling was 
accomplished through a5 min incubation at room temperature with the fluorescent DNA 
binding dye Hoechst 33342 (1 μg/ml) (Invitrogen Life Technologies, Paisley, UK). Cells 
were then mounted in Mowiol 40-88 from Sigma-Aldrich ( Munich, Germany) and 
images were taken in a confocal microscope (LSM-510 META, Zeiss), using a 40x 
objective. For evaluation of cytoplasmic delivery of AMOs, lipoplexes were prepared 
with 100 nM of 5`-fluorescein-labeled AMOs and cells were submitted to the previously 
described protocol in order to acquire confocal microscopy images. 
 
Extraction of total RNA and cDNA synthesis 
Total RNA was isolated from transfected cells and purified using the miRCURY 
RNA Isolation Kit - Cell and Plant (Exiqon, Vedbaek, Denmark), following 
manufacture’s protocol. Briefly, after cell lysis, the total RNA was adsorbed to a silica 
matrix, washed with the recommended buffers, eluted with elution buffer by 
centrifugation and quantified in a Nanodrop UV-Vis spectrophotometer (Thermo Fisher 
Scientific, Wilmington, USA).  
For quantification of microRNA expression levels,  one-first strand cDNA synthesis 
reaction was performed with Universal cDNA Synthesis Kit (Exiqon, Vedbaek, 
Denmark), providing a template for all microRNA real-time assays, by performing a 60 
min incubation at 42ºC, followed by a heat–inactivation step of the reverse transcriptase 
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for 5 min at 95ºC. Finally, cDNA was diluted 1:60 with RNase free water and stored at 
4ºC. For determination of target mRNA expression levels, cDNA synthesis was 
performed using the One Strand cDNA Synthesis Kit purchase from BioRad (Hercules, 
CA, USA). cDNA was then incubated for 5 min at 25ºC, 30 min at 42ºC, followed by a 
heat–inactivation step of the reverse transcriptase for 5 min at 85ºC. Finally, cDNA was 
diluted 1:3 with RNase-free water and stored at 4ºC. 
 
Quantitative real-time PCR 
For quantification of microRNA expression levels, the resulting cDNA was 
submitted to real-time qRT-PCR using the specific primer set for each microRNA in 
analysis, specifically miR-221, miR-222, miR-21, miR-10b and the reference RNA 
(U6snRNA), in combination with miRCURY LNA Universal RT microRNA PCR system 
from Exiqon (Vedbaek, Denmark). A master mix was designed for each primer set, 
according to the recommendations for the real-time PCR setup of individual assays 
suggested in the used kit. For each reaction, performed in duplicate, 6 µl of master mix 
were added to 4 µl of template cDNA. The reactions were monitored using a real-time 
instrument ABI Prism 7300 qPCR System from Applied BioSystems (Life Technologies, 
Carlsbad, CA, USA). The PCR conditions were 10 min at 95ºC, for polymerase 
activation, and 40 cycles of amplification with 10 s at 95ºC and 1 min at 60ºC, ramp-rate 
1.6ºC/s.  Threshold values for threshold cycle determination (Ct) were generated 
automatically by the SDS Optical System software.  
For quantification of target mRNA expression levels, the resulting cDNA was 
subjected to real-time qRT-PCR using the specific primer set for each target mRNA in 
analysis, obtained from Qiagen (Hilden, Germany), and iQ SYBR Green Supermix Kit 
from BioRad (Hercules, CA, USA). Each reaction was performed in duplicate, by adding 
10 µl of master mix to 2.5 µl of template cDNA. The reaction conditions consisted of 
enzyme activation at 95ºC for 10 min, followed by 40 cycles at 95ºC for 15 s 
(denaturation), 30 s at 55ºC (annealing) and 35 s at 72ºC (elongation).  
For both miRNA and mRNA quantification, a melting curve protocol was started 
immediately after amplification and consisted of 1 min heating at 55º followed by 80 
steps of 10 s, with a 2ºC increase at each step. Threshold values for threshold cycle 
determination (Ct) were generated automatically by the SDS Optical System software. 
Relative miRNA and mRNA levels were determined following the ΔΔCt method in 
comparison with control cells. 
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Western blot analysis 
Seventy-two hours after transfection,  Hs766T cells were washed twice with a 
phosphate-buffered saline solution (PBS) and solubilized in RIPA buffer (25 mM Tris-
HCl, pH7.7; 150nM NaCl; 1%NP-40; 1% sodium deoxycholate; 0.1% SDS) containing a 
protease inhibitor cocktail from Sigma-Aldrich (Munich, Germany), 2 mM dithiothreitol 
and 0.1 mM phenylmethylsulfonyl fluoride. The whole-cell suspension was subjected to 
sonication for 3 s and centrifuged at 14.000 rpm for 8 min at 4ºC. The supernatant was 
collected and stored at -20ºC until use. Protein concentration was determined using the 
Bio-Rad Dc protein assay from BioRad (Hercules, CA, USA). Heat-denaturated protein 
samples (40 μg per lane) were ressuspended in loading buffer (20% glycerol, 10% SDS, 
0.1% bromophenolblue), loaded and resolved onto a 10% polyacrylamide gel for 
electrophoretic separation. After electrophoresis, the proteins were transferred to a 
polyvinylidene fluoride (PVDF) membrane from Millipore (Bedford, MA, USA). The 
membrane was then blocked for non-specific binding for 60 min in a Tris-buffered saline 
solution (TBS) containing 1% of Tween 20 and 5% of bovine serum albumin (BSA), 
followed by incubation overnight at 4ºC with primary antibodies: rabbit monoclonal 
antibody against p27
Kip1
 protein (Cell Signaling Technology, MA, USA), rabbit 
monoclonal antibody against PTEN protein (Cell Signaling Technology, MA, USA), 
rabbit monoclonal antibody against HoxD10 protein (Abcam, Cambridge, UK) and 
mouse monoclonal antibody against RHOC protein  (Abcam, Cambridge, UK). The 
primary antibodies were diluted at 1:2000 in TBS-5% milk or TBS-5% BSA. The 
membrane was washed three times with TBS-1% Tween 20 for 10 min and then 
incubated for 1 h at room temperature with goat-anti rabbit antibody (GeHealthcare, 
Hatfield, UK) at a dilution of 1:10000, as a secondary antibody for p27
Kip1
, PTEN and 
HoxD10, and with a goat-anti mouse antibody from (GeHealthcare, Hatfield, UK) at a 
dilution of 1:10000, as a secondary antibody for RHOC. The membrane was washed 
thoroughly in a TBS-1% Tween-20 solution, and the bound antibody was detected using 
the enhanced chemiofluorescence detection reagent (ECF), purchased from GeHealthcare 
(Hatfield, UK), according to manufacturer’s recommendations. Images were obtained 
using a VersaDoc Imaging System Model 3000 from BioRad (Hercules, CA, USA) and 
detection was performed at 570 nm. The analysis of band intensity was made using the 
Quantity One software from BioRad (Hercules, CA, USA). 
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Fluorescence in situ hybridization 
Fluorescence in situ hybridization was performed as described by Lu et al. 
280
 with 
some modifications. Briefly, Hs766T cells were seeded onto multi-chambered coverglass 
slides from Lab-Tek (Rochester, NY, USA) appropriate for confocal microscopy. Forty-
eight hours after transfection with lipoplexes containing anti-miR-21 or scrambled 
(control) oligonucleotides, cells were washed with PBS, fixed with 4% paraformaldehyde 
for 30 min at room temperature and permeabilized at 4ºC in 70% ethanol for 4 h. Cells 
were then incubated with fresh acetylation solution [0.1 M triethanolamine and 0.5% 
(v/v) acetic anhydride] for 30 min at room temperature, rinsed twice in Tris-buffered 
saline (TBS) and pre-hybridized in the absence of LNA probe in the hybridization buffer 
[50% formamide, 5 x SSC (0.75NaCl, 0.075M sodium citrate), 5 x Denhardt’s solution 
(1% Ficoll (type 400), 1% polyvinylpyrrolidone, and 1% BSA), 250 µg/ml yeast tRNA, 
500 µg/ml salmon sperm DNA, 2% (w/v) blocking reagent from Roche (Basel, 
Switzerland), 0.1% CHAPs, 0.5% Tween 20] for 2 h at 52ºC. The hybridization step was 
carried out overnight, at the same temperature, using the digoxigenin-labelled (DIG-
labelled) LNA probe for miR-21 and a scrambled probe. Three stringency washes were 
performed also at 52ºC to completely remove the non-hybridized probe. Endogenous 
peroxidase activity was inactivated by incubation in 3% hydrogen peroxide in TBS with 
0.1% Tween 20 (TBS-T) for 30 min, followed by three washes with TBS-T. The slides 
were then placed in blocking solution (10% heat-inactivated goat serum and 0.5% 
blocking agent in TBS-T) for 1 h at room temperature and incubated for the same period 
of time with an anti-DIG antibody from Roche (Basel, Switzerland) conjugated with the 
hydrogen peroxidase purchased from Sigma-Aldrich (Munich, Germain).. To amplify the 
antibody signal, slides were further incubated with a TSA plus Cy3 solution 
(PerkinElmer, Waltham, MA) for 10 min in the dark, in accordance with the 
manufacturer’s protocol. Cells were finally stained with the fluorescent DNA-binding dye 
Hoechst 33342 (1 µg/ml) (Invitrogen Life Technologies, Paisley, UK) for 5 min in the 
dark, washed with cold PBS, and mounted in Mowiol (Sigma-Aldrich, Munich, 
Germany). Confocal images were acquired in a point scanning confocal microscope Zeiss 
LSM 510 Meta (Zeiss, Göttingen, Germany), using a 60x oil objective.  
 
Cell viability assays 
Cellular viability and proliferation were evaluated by a modified Alamar Blue assay, 
under different experimental conditions.
281
 This assay measures the redox capacity of 
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tumoral cells and allows the determination of cell viability without cells detachment. To 
evaluate the effect of the combined strategies involving AMOs and chemotherapeutic 
drugs, cells were seeded onto 48-well culture plates and transfected, as mentioned above. 
Twenty-four hours cells after transfection, cells were treated with different amounts of 
drugs for a period of 24 h and cell viability was then measured. Briefly, 300 µl of 
DMEM-HG medium containing 10% (v/v) Alamar Blue dye (prepared from a 0.1 mg/ml 
stock solution of Alamar Blue) were added to each well and cells were  incubated  at 37º 
C for 1 h in a 5% CO2 humidified atmosphere. One-hundred fifty microliters of 
supernatant were collected from each well, transferred to 96-well plates and absorbance 
was measured at 570 and 600 nm in a SPECTRAmax PLUS384 spectrophotometer 
(Molecular Devices, Union City, CA). Cell viability (as a percentage of untreated control 
cells) was calculated according to the equation (A570-A600) of treated cells x 100/(A570-
A600) of control cells. 
 
Statistical Analysis 
Data are presented as the mean ± standard deviation (SD). The data were analyzed 
using the Graph Path Prism (version 5.0) software (La Jolla, USA). Statistical analyses 
were performed by analysis of variance (ANOVA) using Dunnett’s Multiple Comparison 
test or Student’s t test. P value <0.05 was considered statistically significant. P< 0.05 (*), 
P < 0.01 (**) and P < 0.001 (***). 
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3. Results and discussion 
 
3.1. Efficient oligonucleotide delivery mediated by HSA-
EPOPC:Chol/AMOs (+/-)(4/1) lipoplexes 
Cationic liposomes brought new insights into bionanotechnology by facilitating the 
introduction of nucleic acids into target cells, thus allowing a controlled modification of 
their genetic expression profile and consequently a specific effect.
72,88,89
 However, most 
of the nanosystems based in cationic liposome have been applied for DNA delivery, but 
whether these carriers have the ability to promote efficient and controlled release of 
oligonucleotides into tumor cells has yet to be demonstrated.  Therefore, our initial 
studies addressed the potential of a previously developed gene delivery formulation, 
HSA-EPOPC:Chol/DNA (+/-) (4/1), to efficiently release anti-microRNA 
oligonucleotides (AMOs) targeting overexpressed microRNAs involved in cancer, 
towards the generation of  a new therapeutic approach.  
The analysis of the physicochemical properties of our HSA-EPOPC:Chol/AMOs (+/-) 
(4/1) formulation reveals a neutral zeta potential (0.4±1.5 mV), which is most probably 
due to the presence of HSA that masks the positive charge from cationic liposomes and a 
mean diameter of approximately 450 nm. This neutral zeta potential indicates that the 
interaction of lipoplexes with the negatively charged cellular membrane is not due to 
electrostatic interactions, but rather to the interaction of the associated HSA with 
cytoplasmic membrane receptors.
90
 The cellular internalization of these lipoplexes, 
prepared from carboxyfluorescein-labeled liposomes, was evaluated in a PDAC cell line 
(Hs766T cells) by confocal microscopy. 
Cellular internalization of HSA-EPOPC:Chol/AMOs (+/-) (4/1) lipoplexes, prepared 
from carboxyfluorescein-labelled liposomes, was evaluated in a PDAC cell line (Hs766T 
cells) by confocal microscopy.  
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Figure 11 - Internalization of HSA-EPOPC:Chol/AMOs (+/-)(4/1) lipoplexes in Hs766T pancreatic 
adenocarcinoma cells. (A) Cells were transfected with lipoplexes prepared from carboxyfluorescein-
labelled EPOPC:Chol liposomes and stained with LysoTracker red (200 nM), for acidic compartment 
labeling, and Hoechst 33342 (1μg/ml), for nucleus labeling. (B) Cells were transfected with lipoplexes 
containing fluorescein-labeled oligonucleotides and stained with Hoechst (1μg/ml), for nucleus labeling.  
Confocal microscopy images (x40 magnification), are representative of triplicates of two independent 
experiments. DIC means differential interference confocal microscopy. Bars correspond to 20 µm. 
 
As illustrated in Figure 11A, an intense green fluorescence, corresponding to 
lipoplexes, was observed throughout the cytoplasm of almost all cells, demonstrating 
efficient cellular internalization of this nanosystem. Moreover, the results presented in 
Figure 1A show that lipoplexes (green fluorescence) were not co-localized with the 
lysosomal compartments (red fluorescence), suggesting their successful release from the 
endolysosomal pathway to the cytoplasm, consequently avoiding nucleic acid degradation 
inside the lysosomes.   
In order to evaluate the efficacy of the HSA-EPOPC:Chol/AMOs (+/-) (4/1) 
nanosystem to mediate the intracellular delivery of AMOS, Hs766T cells were transfected 
with lipoplexes prepared with fluorescein-labeled oligonucleotides. As shown in Figure 
11B, 4 h after transfection, fluorescent particles (green dots) were homogeneously 
distributed throughout the cytoplasm of almost all cells. This observation suggest that the 
HSA-EPOPC:Chol/AMOs (+/-) (4/1) lipoplex formulation has the ability to efficiently 
complex AMOs, promote binding and internalization into tumor target cells and deliver 
their content into the cell cytoplasm, showing that this nanosystem presents a great 
A 
B 
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potential to be used in antitumor strategies involving the delivery of anti-microRNA 
oligonucleotides.   
 
3.2. Robust microRNA inhibition after transfection with HSA-
EPOPC:Chol/AMOs (+/-)(4/1) lipoplexes 
Each type of cancer can be characterized by a distinct microRNA signature and  
emerging evidences indicate that some microRNAs, such as miR-221/miR-222,  miR-21 
and miR-10b, display a frontal role in managing tumor survival and aggressiveness.
282
 
Mir-221 and miR-222 are known to target the tumor suppressor gene coding for the 
cyclin-dependent kinase inhibitor p27
Kip1
 and their role was established in PDCA, as key 
inhibitors of cell cycle arrest, apoptosis and sensitization of cells to gemcitabine.
194,269,283
 
Upregulation of these two microRNAs is often related with poor patient survival 
rate.
284,285
  MiR-21 has been identified as an upregulated microRNA in almost all cancer 
types, including PDAC, and among other important microRNAs involved in tumoral 
regulation, miR-21 stood out as the one with most significant expression in PDCA 
associated to metastatic status or proliferation index.
286,287
 Studies performed by Nakata 
and colleagues indicated that miR-10b is also an upregulated microRNA in pancreatic cell 
lines, with up to 10-fold increased levels as compared to  normal cells.
173
 Moreover, these 
authors showed that transfection with miR-10b was associated with invasiveness of 
pancreatic cancer cell lines, making miR-10b another important microRNA to be 
manipulated towards the development of new PDAC therapies.  
In order to determine the expression profile of miR-221, miR-222, miR-21 and miR-
10b in an in vitro metastatic model of pancreatic adenocarcinoma, the levels of these 
microRNAs were measured in Hs766T cells. As illustrated in Figure 12, these four 
microRNAs are differentially expressed in this cell line.  
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Figure 12- Relative microRNA expression levels in Hs766T cells when compared with the HPNE cell 
line. Hs766T and HPNE cells were submitted to RNA extraction 48 hours after seeding. MiR-221, miR-
222, miR-21 and miR-10b expression levels were quantified through qRT-PCR and presented as fold 
increase units relative to the levels registered with HPNE control cells. U6 snRNA was used as the internal 
sample normalizer. Results are presented as mean ± S.D obtained from triplicates of three independent 
experiments. *p<0.05 and  **p<0.01 correspond to values that differ significantly from those obtained with 
HPNE cells. 
 
The microRNA cluster miR-221/miR-222 is more prominently overexpressed (14-
fold and 8 fold-increase, respectively), than miR-21 and miR-10b, both exhibiting a 3-
fold-increase in their expression levels, when compared with those obtained in an in vitro 
model of normal pancreatic epithelium (HPNE cell line).   
Following the demonstration of the feasibility of the HSA-EPOPC:Chol-based 
nanosystem to mediate efficient delivery of AMOs, we evaluate the effect of 
intracellularly delivered anti-microRNAs to promote microRNA silencing. For this 
purpose, Hs766T cells were transfected with lipoplexes containing antisense 
oligonucleotides targeting miR-221, miR-222, miR-21 or miR-10b (a scrambled 
oligonucleotide was used as a control), and  the expression levels were analyzed for each 
microRNA after 48h. As shown in Figure 13 A, a significant reduction in the levels of all 
tested microRNAs was obtained when cells were transfected with 80 nM of AMOs.  
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Figure 13 - MicroRNA modulation in Hs766T cells. (A) RT-PCR quantification of miR-221, miR-222, 
miR-21 and miR10b levels in Hs766T cells transfected with HSA-EPOPC:Chol/AMOs (+/-) (4/1) 
lipoplexes containing 80 nM of AMOs. As control, Hs766T cells were transfected with the same lipoplex 
formulation prepared with 80 nM of scrambled oligonucleotides.  MicroRNA levels were assessed 48 hours 
after transfection and are presented as mean ± S.D obtain from triplicates of five independent experiments. 
***p<0.001) corresponds to values that differ significantly from those obtained in the control condition. (B) 
Confocal analysis of FISH staining in Hs766T cells transfected with lipoplexes containing 80 nM of AMOs 
against miR-21 (antimiR-21) or 80 nM of scrambled oligonucleotides (control). After 48 hours, cells were 
subjected to miR-21 labeling with 5´-DIG (digoxigenin) LNA probes (red dots), as described in Material 
and Methods. Nuclear staining was accomplished using Hoescht 33342 (1 μg/ml). Results are representative 
of triplicates of three independent experiments. Bars correspond to 20 µm.  
 
In the case of miR-21, nearly to 99% of microRNA silencing was achieved. A similar 
inhibition pattern was observed for miR-10b, with a 94% decrease in its levels, and a 
maximum inhibition of 79% and 89% was attained for the expression levels of miR-221 
and miR-222, respectively. Concentrations of AMOs higher than 80 nM did not show 
further significant improvement in reducing the levels of microRNAs and lower 
concentrations resulted in a lesser efficacy of microRNAs inhibition (data not shown), 
A 
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revealing that 80 nM was the optimal AMOs concentration to promote microRNA 
silencing.  
The efficient miR-21 silencing in Hs766T cells was also evident from fluorescence in 
situ hybridization experiments. Figure 13 B displays typical images obtained from these 
essays, showing a huge decrease in miR-21 staining (red dots) in the cell cytoplasm 
following transfection with our nanosystems containing anti-miR-21 oligonucleotides, 
when compared to that observed in cells transfected with lipoplexes prepared with 
scrambled oligonucleotides. These results are in agreement with those showing the high 
intracellular delivery of AMOs promoted by HSA-EPOPC:Chol/AMOS (+/-)(4/1) 
lipoplex formulation  (Figure 11B), thus demonstrating the efficacy of the developed 
nanosystem to mediate microRNA silencing.  
 
3.3. MicroRNA targets are differentially modulated in PDAC  
In previous reports, p27
kip1
 protein was shown to play an important role in regulating 
cell cycle arrest, being described as a potential target in prostate cancer therapeutic,
284
 and 
both miR-221 and miR-222 were considered as potent regulators of cell cycle through 
p27
kip1
 protein.
283
 
On the other hand, Meng and colleagues and Liu and colleagues pointed miR-21 as 
responsible to directly modulate the expression of PTEN gene in hepatocarcima (HCC), 
showing that the decrease of miR-21 levels results in the decline of HCC cell 
proliferation, acceleration of apoptosis and cell invasiveness decay.
266,288
 PTEN is a 
tumor suppressor factor playing a dual phosphatase activity in the PI3K signaling 
pathways, which in turn controls major biological processes such as cellular growth, 
proliferation and protein synthesis, by directly acting as a central negative regulator. 
Several reports have suggested dysregulation of PTEN as an important mediator of 
carcinogenesis in pancreas.
289,290
 However, tumor samples collected from pancreatic 
cancer patients exhibit  only an estimated 1% of PTEN mutations, which points towards 
the hypothesis of a post-transcriptional regulation of the expression levels of PTEN gene, 
most likely involving microRNAs as the most important mechanism in this process.
291
 
MiR-10b, was also identified as a microRNA with altered expression patterns in 
several cancers, being associated to suppression of  Homeobox D10 (HoxD10) protein 
synthesis and consequently allowing the expression of RHOC gene, as a downstream 
signaling target, which is known to be involved in metastatic processes by inducing cell 
migration.
270,292–294
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The recognized oncomiR activity of these four microRNAs and their demonstrated 
deregulation in PDAC make them promising targets for new therapeutic strategies 
involving AMO delivery. In this regard, we further evaluated the effect of microRNA 
silencing on the mRNA and protein levels of the molecular targets p27
kip1
, PTEN, 
HoxD10 and RHOC, aiming to analyze the potential of the developed nanosystem in a 
therapeutic context and clarify the mechanisms involved in an antitumor response.  
Forty-eight hours after transfection of Hs766T cells with lipoplexes containing 
antimiR oligonucleotides, mRNA levels were quantified by RT-qPCR. Our results show 
that, despite successful microRNA inhibition mediated by the developed nanosystem 
(Figure 13A), the antimiR oligonucleotides targeting miR-221 and miR-222 were not able 
to significantly increase the p27
kip1 
mRNA levels (Figure 14A).  
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Figure 14 – Target mRNA expression levels after microRNA silencing. mRNA levels were quantified 
by RT-qPCR, 48 hours after transfection of Hs766T cells  with lipoplexes containing 80 nM of AMOs or 
scrambled oligonucleotides (control). (A) p27
kip1
 mRNA levels after cell treatment with scrambled, anti-
miR-221 or anti-miR-222 oligonucleotides. (B) PTEN mRNA levels in Hs766T cells after transfection with 
scramble or anti-miR-21 oligonucleotides. (C) HoxD10 and RHOC mRNA levels after Hs766T cell 
treatment with scrambled or anti-miR-10b oligonucleotides. Results are presented as mean ± S.D obtained 
from triplicates of four independent experiments. **p<0.01, ***p<0.001 correspond to values that differ 
significantly from those obtained in the control condition. 
 
The lack of total inhibition of miR-221 and miR-222 levels observed after cell 
transfection might be responsible for this effect. In fact, the remaining miR-221 and miR-
222 in cell cytoplasm could be sufficient to induce the post-transcriptional inhibition of 
p27
kip1 
gene. On the other hand, it is also possible that miR-221 and miR-222 are not able 
to induce cleavage of p27
kip1 
mRNA, but rather its translational repression by a less 
efficient mechanism, justifying the absence of a significant increase in the p27
kip1 
mRNA 
levels after treatment with antimiR-221 or antimiR-222 oligonucleotides.
295
 As shown in 
Figure 14B, miR-21 silencing resulted in an increase of approximately 40% in PTEN 
mRNA levels after cell treatment with AMOs, which is most probably due to the almost 
total miR-21 silencing induced by the antimiR-21 oligonucleotides (Figure 13). 
Regarding miR-10b inhibition, two targets were addressed: HoxD10, as a direct target, 
and RHOC, as downstream target but still the main regulator of an important pathway 
C 
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related with cell migration.
173
 Transfection of Hs766T cells with 80 nM of antimiR-10b 
oligonucleotides promoted a 1.9-fold increase in the mRNA levels of Homeobox D10 
gene and 27% decrease in the mRNA levels of RHOC, when compared to that observed 
with cells treated with scrambled oligonucleotides (Figure 14C). This result meets the 
expected outcome, since HoxD10 exerts its regulatory role on the transcription levels of 
its downstream target, RHOC, negatively setting the expression levels of this gene.
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Although no significant changes in p27
kip1
 mRNA levels were observed after cell 
treatment with AMOs targeting miR-221 and miR-222, Western blot analysis showed an 
approximately 1.1-fold and 1.6-fold increase of p27
kip1
 protein levels  following treatment 
with antimiR-221 and antimiR-222 oligonucleotides, respectively (Figure 15 A and B). 
The difference found for the increase of p27
kip1
 expression could be due either to an 
insufficient miR-221 inhibition (Figure 13), thus avoiding significant increase of the 
protein levels, or to a predominant role of miR-222 in the post-transcription regulation of 
p27
kip1
gene. The combination of both antimiR oligonucleotides, simultaneously targeting 
miR-221 and miR-222, did not result in a significant increase of the p27
kip1
mRNA and 
protein levels, when compared to that observed with anti-miR-222 alone (data not 
shown). 
Regarding PTEN protein expression levels, it was observed that the almost total miR-
21 silencing (Figure 13), promoted by transfection of Hs766T cells with lipoplexes 
containing 80 nM of AMOs against this microRNA, resulted in a substantial enhancement 
in the PTEN levels. In fact, in these conditions an increase of 60% in the expression 
levels of this protein, when compared to that observed with Hs766T cells treated with the 
same amount of scrambled oligonucleotides, showing that our strategy successfully 
modulate PTEN protein levels.  
In the case of HoxD10 and RHOC, although mRNA levels were modulated towards 
an antitumoral profile, the analysis performed by Western blot showed no significant 
alterations in the protein levels after miR-10b silencing. 
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Figure 15 – Western blot analysis of target protein levels after microRNA silencing. Protein was 
extracted from Hs766T cells, 72 hours after transfection with HSA-EPOPC:Chol/AMOs (+/-) (4/1) 
lipoplexes containing 80 nM of AMOs or scrambled oligonucleotides (control), as described in Material 
and Methods. (A) Protein levels and (B) representative Western blot image of p27
kip1
 protein quantification 
after treatment with scramble, anti-miR-221 or anti-miR-222 oligonucleotides. (C) Protein levels and (D) 
representative Western blot image of PTEN protein quantification after treatment with scrambled or 
antmiR-21 oligonucleotides. (E) Protein levels and (F) representative Western blot image of HoxD10 and 
RHOC protein quantification after treatment with scrambled or anti-miR-10b oligonucleotides. Results are 
presented as target protein-expression levels relative to control, corrected for individual α-tubulin or β-actin 
signal intensity, and are the mean ± S.D. obtained from four independent experiments. *p<0.05, **p<0.01 
correspond to values that differ significantly from those obtained in the control condition. 
 
Despite the effective silencing of miR-10b induced by AMOs treatment, the inability 
to successfully change HoxD10 and RHOC protein levels led us to consider that both 
effectors might have a multiplicity of regulators in PDAC that promote their translational 
repression, which probably demands a more broad strategy to modulate their expression 
levels. 
Overall, the obtained results show that transfection of PDAC cells with the HSA-
EPOPC:Chol/AMOs (+/-) (4/1) nanosystem, containing AMOS targeting miR-21, miR-
221 or miR-222, promote a significant post-transcriptional modulation of important tumor 
suppressor genes, such as PTEN and p27
kip1
, respectively.  
 
3.4. Combination of oligonucleotides against miR-21 with sunitinib 
results in a synergistic antitumor effect in PDAC 
 Gemcitabine has long been the only standard treatment for pancreatic cancer, but 
increasing resistance over time impelled medicine to seek other drugs in order to improve 
patient survival. Docetaxel has been used in combination with gemcitabine as front line 
therapy to reduce the size of the tumor and overcome its metastatic phase.  Nevertheless, 
none of these drugs or their combination revealed to be an effective treatment for 
pancreatic cancer.
296
 On the other hand, sunitinib malate, a potent RTK’s inhibitor, has 
been demonstrating to be a successful drug in pancreatic cancer clinical trials and is 
revealing new data that points towards a more meaningful treatment for this disease.
297
 
The possibility of combining the inhibition of microRNAs, thus sensitizing cancer cells 
by decreasing some of their main regulators of tumorigenesis, with chemotherapeutic 
drugs that have shown high potential in clinical trials, emerged as a promising antitumor 
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strategy. Indeed,  combining two or more therapeutic approaches with different 
mechanisms can exert a synergistic effect over cancer progression and tumor resistance to 
chemotherapeutic drugs.
298
 
 In this regard, we investigated whether a two-step sequential treatment, involving the 
modulation of aberrantly expressed microRNAs, to sensitize tumoral cells to the action of 
drugs, and the subsequent treatment with chemotherapeutic agents could result in a 
significant and synergistic antitumor effect. For this purpose, we evaluated the in vitro 
antitumor activity mediated by HSA-EPOPC:Chol/AMOs (+/-) (4/1) lipoplexes, 
containing oligonucleotides against miR-221, miR-222 or miR-21 (since these AMOs 
presented the most promising results in terms of tumor suppressor gene modulation in our 
PDAC model), in combination with small amounts of chemotherapeutic drugs, docetaxel, 
gemcitabine or sunitinib malate. From the results obtained using different doses for each 
chemotherapeutic agent (data not shown), only the lower concentration resulting in a 
small but still significant effect on tumor cell viability was chosen to be applied in the 
combined strategies (1 µM docetaxel, 5 µM gemcitabine and 15 µM sunitinib). These low 
amounts of drugs were used to avoid the adverse effects that are usually associated to the 
higher clinical doses of chemotherapeutic agents. As illustrated in Figure 16, treatment of 
Hs766T cells with 1 µM of docetaxel or 5 µM of gemcitabine or 15 µM of sunitinib 
malate resulted in a decrease of approximately 16%, 10% and 18% in cell viability, 
respectively.  
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Figure 16- Cell viability after treatment with anti-miR oligonucleotides and chemotherapeutic drugs. 
Hs766T cells were transfected with lipoplexes containing 80 nM of antimiR-21, antimiR-221, antimiR-222 
or scrambled (control) oligonucleotides. After 24 hours, cells were incubated in the absence or presence of 
1 μM of docetaxel (A), 5 μM of gemcitabine (B) or 15 μM of sunitinib (C), for 24 hours. Cell viability was 
measured by the Alamar Blue assay as described in Material and Methods. Data are expressed as the 
percentage of non-treated control (NTC) cells and correspond to mean ± S.D. obtained from triplicates of 
three independent experiments. *p<0.05, ***p<0.001 correspond to values that differ significantly from 
those obtained in the control condition.  
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 The impact of microRNA inhibition per se on cell viability was even smaller than 
that observed with the low amounts of chemotherapeutic drugs alone, this being verified 
for any of the three studied microRNAs, miR-21, miR-221 or miR222 (Figure 16). 
Although target protein expression levels were substantially increased upon microRNA 
silencing (Figure 15), a reduction of only approximately 5% in the viability of Hs766T 
cells was obtained when compared to that observed in the control condition (cells treated 
with scrambled oligonucleotides). Nevertheless, in agreement with other authors, this is 
an expected result, since this kind of approach represents a fine-tuning of molecular 
signaling, rather than a single molecular effector with major impact on cell 
metabolism/viability.
299,300
 
 Combination of AMOs with chemotherapeutic drugs did not result in any significant 
therapeutic effect in the case of docetaxel or gemcitabine, as no further considerable 
reduction in cell viability was achieved (Figure 16A and B). However, when Hs766T 
cells were sequentially treated with AMOs (against miR-21, miR-221 or miR-222) and 
sunitinib, a substantial reduction in cell viability was observed as compared to the extent 
of cell death (21%) registered with scrambled oligonucleotides and sunitinib (Figure 
16C). Importantly, cell  treatment involving the combination of oligonucleotides antimiR-
21 with sunitinib resulted in a cell viability decrease of approximately 45%, showing that 
this combined strategy promoted a significant and synergistic antitumor effect, which was 
much higher than that observed with any of the two strategies by themselves (Figure 
16C). PTEN, a direct miR-21 target, is an important cell cycle regulator and therefore its 
upregulation (Figure 15C and D) strongly affects apoptosis signaling pathways, inducing 
cell sensitization to sunitinib.  Moreover, miR-21 has been pointed to have great impact in 
almost all types of cancers, since it targets many important protein mediators involved in 
tumorigenesis, which could also contribute to the high and synergistic antitumor effect of 
this combined strategy.
110,301,302
 On the other hand, miR-221 or miR-222 inhibition 
followed by treatment with sunitinib promoted a smaller, but still considerable, increase 
in the antitumor effect, inducing a decrease of 32% in cell viability (Figure 16C). A 
similar result was obtained with a combined treatment involving simultaneous 
transfection with anti-miR-221 and anti-miR-222 oligonucleotides (data not shown). 
Although different modulation of p27
kip1
 expression levels was obtained with anti-miR-
221 or anti-miR-222 oligonucleotides (Figure 15A and B) a similar reduction in cell 
viability was observed, showing that these microRNAs may also target other molecular 
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regulators with a crucial role in carcinogenesis that have not been addressed in this 
study.
170
 
 The results obtained with these combined approaches, involving the PDAC cell 
treatment with AMOs (against miR-21, miR-221 or miR-222) and sunitinib (Figure 16C), 
are still more remarkable considering the fact that the same combined strategies involving 
the drugs gemcitabine or docetaxel (Figure 16A and B), which represent the therapeutic 
front-line for PDAC, promoted a much lower antitumor activity. 
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4. Conclusion 
 
Overall, our results clearly show that the HSA-EPOPC:Chol/AMOs (+/-) (4/1) 
nanosystem has the ability to efficiently deliver antisense oligonucleotides into PDAC 
cells, inducing an almost total inhibition of microRNAs (miR-21, miR-10b, miR-221 and 
miR-222) aberrantly expressed in this cancer model. Moreover, our data constitute 
evidence that the strong reduction in the levels of these microRNAs resulted in a 
significant modulation of their targets, this being particularly evident for miR-21 and 
miR-221/miR-222, where their inhibition promoted a significant increase in the levels of 
their protein targets, PTEN and p27
Kip1
 protein, respectively. The notable synergistic 
antitumor effect observed with combination of microRNA inhibition and low amounts of 
the chemotherapeutic drug sunitinib, show that this combined strategy could be of great 
importance for application in PDAC due to the association of reduced side effects, 
promoted by lower drug concentrations, with a high therapeutic activity. 
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Chapter 4 
 
 
MiR-139-5p: a new player in 
pancreatic cancer CXCR4 mediated-
metastasis. 
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1. Introduction 
 
Pancreatic cancer is a highly aggressive pathology, as patients are frequently 
diagnosed at a late stage of tumor development and commonly present early 
dissemination to distant organs, declining survival possibilities.
4
 Nevertheless, the 
biological mechanisms underlying the development of metastatic progression and the 
dissemination of tumoral cells into distant organs, remain largely unknown. Therefore, a 
better understanding of the biology behind pancreatic cancer invasion and the seeding of 
metastasis is urgently needed. Moreover, managing the progression and development of 
metastasis could promote a better quality of life for PDAC patients, as they could subsist 
as chronic cancer patients rather than in an acute life-threatening situation with limited 
survival chances.  
The development of metastasis is the major cause of morbidity and mortality in the 
majority of cancers. Metastization is conventionally defined as a process resulting from 
cumulative genetic alterations within cells of a tumour mass that ultimately tend to 
disseminate from the primary tumor site. Metastatic cells acquire distinct properties such 
as loss of cell adhesion, acquisition of an invasive potential, transport through the 
circulation, extravasation, formation of micro-metastases, and finally the ability to induce 
an angiogenic switch to form macro-metastasis.
303
 Nevertheless, new findings are 
changing the paradigm, stating that metastatic ability may be an innate property shared by 
a cell population, termed cancer stem cells (CSCs) present early in tumor development.
304
 
Invasion and metastization are frequently mediated by inflammatory intermediates, 
including cytokines and chemokines, which facilitate tumor dissemination. The CXC 
motif chemokine receptor 4 (CXCR4) is a stromal cell-derived factor-1 (SDF1-α) 
receptor secreted by leukocytes such as lymphocytes, monocytes, natural killer cells, as 
well as vascular smooth muscle cells, endothelial cells and astrocytes.
305–307
 C-X-C motif 
chemokine 12 (CXCL12), commonly set as SDF1-α, is the specific ligand of CXCR4, 
and the interaction between these two molecules results in a chemotaxis process, mainly 
responsible for attracting CXCR4-expressing cells to fluid-filled cavities with high 
concentrations of CXCL12, to where many tumoral cells disseminate and metastases 
develop.
308
 
It has been shown that CXCL12/CXCR4 axis promotes progression and 
dissemination of various carcinomas, including pancreatic cancer,
210,309,310
 as metastatic 
cancer cells subvert the physiological function of CXCR4/CXCL12 in controlling cell 
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migration and homing.
311
 Moreover, CXCR4 overexpression in PDAC was found to be 
strongly correlated with advanced metastatic stage of disease and a molecular marker for 
CSC’s.312,313 
MicroRNAs are an abundant class of endogenous small RNA molecules, 
approximately 22 nucleotides in length, and are known key regulators of gene expression 
by directly binding to the 3′ untranslated regions (UTRs) of targeted mRNAs. Translation 
inhibition or mRNA cleavage is attained through nearly perfect or perfect 
complementarity binding of the microRNA.
123
 The pivotal role of microRNAs in cancer 
progression, including PDAC, prompted the development of anti-tumor therapies 
targeting microRNAs.
261
 Accumulated evidence has demonstrated that microRNAs are 
aberrantly expressed in cancer and different types of tumors can be distinguished by a 
microRNA signature.
138,314
 In 2006, Lee et al, discovered a unique miRNA signature 
capable of distinguishing pancreatic cancer from normal and benign pancreas and miR-
139-5p was found to be strongly downregulated in tumoral samples, indicating a possible 
tumor-suppressor activity of this microRNA in normal pancreatic cells.
315
 
In a preliminary survey, we used three computational algorithms (in-silico prediction), 
including Target-Scan, PicTar and miRBase to search for potential targets of miR-139-5p, 
and CXCR4 was consistently found to be a predicted target for this microRNA. 
A recent report indicated CXCR4 as a possible target for miR-139-5p in gastric 
cancer, since epigenetic silencing of miR-139-5p was shown to be directly involved in the 
induction of C-X-C chemokine receptor type 4 overexpression.
208
 Additionally, the 
authors of this study observed that high levels of CXCR4 and reduced levels of miR-139 
were correlated with lymph node metastasis in human metastatic gastric tumors. A tumor 
suppressor role was also attributed to miR-139-5p in esophageal squamous cell carcinoma 
and in colorectal cancer, as this microRNA was able to inhibit cell proliferation and 
metastasis formation.
202,204
 
Considering the anti-metastatic potential of miR-139-5p, the aim of this work was to 
elucidate the role of this microRNA in the C-X-C chemokine receptor type 4 (CXCR4) 
post-translational regulation in PDAC and further clarify how miR-139-5p contributes to 
the control of invasive features of pancreatic cancer cells. Additionally, a combined 
antitumor strategy involving the miR-139-5p expression followed by treatment with small 
amounts of chemotherapeutic drugs was evaluated as an antitumor strategy towards 
treatment of PDAC.  
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2. Materials and methods 
 
Materials 
Sunitinib malate (Sutent®) was kindly offered by Pfizer (Basel, Switzerland) and 
stock solutions were prepared in DMSO (Sigma, Germany) and stored at -80ºC or 
4ºC.Docetaxel and gemcitabine were acquired from Sigma (Munich, Germany) and stock 
solutions were prepared in distilled water and subsequently stored at -20ºC and at room 
temperature, respectively.  
 
Cells and culture conditions  
Primary Human Pancreatic Cancer Cells  
The 354 primary human pancreatic cancer cells were freshly isolated from early 
passage human pancreatic adenocarcinoma xenografts, as previously described by 
316,317
, 
being designated as a tumor-derived primary cell line. 354 cells were maintained in RPMI 
medium (from Life Technologies, Carlsbad, CA, USA) supplemented with 20% fetal 
bovine serum (FBS),  from Gibco (Life Technologies, Carlsbad, CA, USA) and 100 μM 
each of penicillin and streptomycin from Sigma-Aldrich (Munich, Germain), fungizone 1 
μg/ml and 0.5 mM L-glutamine, both purchased from Gibco (Life Technologies, 
Carlsbad, CA, USA) . Cells were cultured as adherent cells (monolayer) at low passages 
and grown at 37ºC, under 5% of CO2, in humidified atmosphere. 
 
Pancreatic tumor cell lines 
The Hs766T, Panc-1 and MiaPaCA cell lines were obtained from American Type 
Culture Collection (ATCC) (Manassas, VA, USA) and used as in vitro tumoral models 
for human pancreatic adenocarcinoma. The cells were maintained in adherent culture 
using Dulbecco’s Modified Medium (DMEM) from Invitrogen (Life Technologies, 
Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) from Gibco (Life 
Technologies, Carlsbad, CA, USA) and 100 μM each of penicillin and streptomycin from 
Sigma-Aldrich (Munich, Germain). Hs766T cells were grown at 37ºC, under 5% of CO2, 
in humidified atmosphere. 
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Production of lentiviral vectors and cell transduction. 
Viral vectors encoding eGFP and human miR-139-5p precursor stem loop or control 
eGFP, were produced in human embryonic kidney (HEK) 293T cells using a four-
plasmid system, as described previously.
318
 Briefly, the viral particles were produced by 
transient calcium phosphate transfection of 4 x10
6
 human embryonic kidney 293Tcells 
plated in 10 cm Petri dishes (Falcon; Becton Dickinson, Rutherford, NJ) with 13 µg of 
pCMVDR-8.92 packaging construct, 3.75 µg of pMD.G, 3 µg of pRSV-Rev, and 13 µg 
of the interest  vector. Forty-eight hours later, the supernatants were collected, filtered, 
and concentrated by ultracentrifugation, and the viral particle content of batches was 
determined by assaying HIV-1 p24 antigen (RETROtek, Gentaur, Paris, France). Viral 
stocks were stored at -80ºC until use.  
For the lentiviral transduction of Hs766T and 354 cells, cells were plated onto six-
well plates at a final density of 3.5 × 105 cells/well. Twenty-four hours after plating, 10 ng 
and 30 ng of virus, coding for either miR-139-5p and eGFP or control eGFP were added 
per 1 × 10
5
of Hs766T and 354 primary pancreatic tumor cells, respectively; and 8 mg of 
polybrene (hexadimethrine bromide) were also added to each well, to increase the 
efficiency of infection. Cell culture medium was replaced 6 h after infection and cells 
were further grown for 48 h, after which were plated onto 10 cm dishes. Infected cells 
were selected by growing cells in a culture medium containing 1 µg/ml of puromycin. 
 
Extraction of total RNA and complementary DNA synthesis 
Total RNA was isolated from Hs766T and 354 adherent and tumorsphere cells 
transduced with lentiviral vectors and purified, using the miRCURY RNA Isolation Kit - 
Cell and Plant (Exiqon, Vedbaek, Denmark), following manufacture’s protocol. Briefly, 
after cell lysis, the total RNA was adsorbed to a silica matrix, washed with the 
recommended buffers and eluted with 40 µl elution buffer by centrifugation and 
quantification was assessed using a Nanodrop UV-Vis spectrophotometer (Thermo Fisher 
Scientific, Wilmington, USA).  
For quantification of microRNA and mRNA expression levels, one first-strand 
complementary DNA (cDNA) synthesis reaction was performed using the NCode VILO 
miRNA cDNA Synthesis Kit from Invitrogen (Life Tecnlologies Inc, Alcobendas, Spain). 
The resulting cDNA, providing a template for all microRNA and mRNA real-time assays, 
was obtained by performing a 60 min incubation at 37ºC, followed by a heat–inactivation 
step of the reverse transcriptase for 5 min at 95ºC. 
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Quantitative real-time PCR 
For quantification of microRNA and mRNA expression levels, the resulting cDNA 
was diluted 5 times in RNAse-free water and submitted to real-time qRT-PCR. For 
evaluation of miR-139-5p expression levels, a specific forward primer was designed for 
this microRNAand the reference RNA (Snord44) from Qiagen (Hilden, Germany), in 
combination with a reverse Universal qPCR Primer from Invitrogen (Invitrogen, Life 
Tecnlologies Inc, Alcobendas, Spain). 
A master mix was designed for each primer set, according to the recommendations 
for the real-time PCR setup of individual assays suggested in the used kit. For each 
reaction, performed in duplicate, 5 µl of master mix were added to 4 µl of template 
cDNA. The reactions were monitored using a real-time instrument ABI Prism 7300 qPCR 
System from Applied BioSystems (Life Technologies, Carlsbad, CA, USA). The PCR 
conditions were 10 min at 95ºC, for polymerase activation, and 40 cycles of amplification 
with 10 s at 95ºC and 1 min at 60ºC, ramp-rate 1.6ºC/s.  Threshold values for threshold 
cycle determination (Ct) were generated automatically by the SDS Optical System 
software.  
For quantification of CXCR4 mRNA expression levels, the resulting cDNA was 
subjected to real-time qRT-PCR using the specific primer set for each target mRNA in 
analysis, obtained from Qiagen (Hilden, Germany), and iQ SYBR Green Supermix Kit 
from BioRad (Hercules, CA, USA). Each reaction was performed in duplicate, by adding 
6 µl of master mix to 4 µl of template cDNA. The reaction conditions consisted of 
enzyme activation at 95ºC for 10 min, followed by 40 cycles at 95ºC for 15 s 
(denaturation), 30 s at 60ºC (annealing) and 35 s at 72ºC (elongation).  
For both miRNA and mRNA quantification, a melting curve protocol was started 
immediately after amplification and consisted of 1 min heating at 55º followed by 80 
steps of 10 s, with a 2ºC increase at each step. Threshold values for threshold cycle 
determination (Ct) were generated automatically by the SDS Optical System software. 
Relative miRNA and mRNA levels were determined following the ΔΔCt method in 
comparison with control cells. 
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Western blot analysis 
After stable transduction with lentiviral vectors, Hs766T and 354 cells were seeded 
in 12 well plates and incubated during 72 hours. Cells were then washed twice with a 
phosphate-buffered saline solution (PBS) and solubilized in RIPA buffer (25 mM Tris-
HCl, pH7.7; 150nM NaCl; 1%NP-40; 1% sodium deoxycholate; 0.1% SDS) containing a 
protease inhibitor cocktail from Sigma-Aldrich (Munich, Germany), 2 mM dithiothreitol 
and 0.1 mM phenylmethylsulfonyl fluoride. The whole-cell suspension was subjected to 
sonication for 3 s and centrifuged at 14.000 rpm for 8 min at 4ºC. The supernatant was 
collected and stored at -20ºC until use. Protein concentration was determined using the 
Bio-Rad Dc protein assay from BioRad (Hercules, CA, USA). Heat-denaturated protein 
samples (40 μg per lane) were ressuspended in loading buffer (20% glycerol, 10% SDS, 
0.1% bromophenolblue), loaded and resolved onto a 10% polyacrylamide gel for 
electrophoretic separation. After electrophoresis, the proteins were transferred to a 
polyvinylidene fluoride (PVDF) membrane from Millipore (Bedford, MA, USA). The 
membrane was then blocked for non-specific binding for 60 min in a Tris-buffered saline 
solution (TBS) containing 1% of Tween 20 and 5% of bovine serum albumin (BSA), 
followed by incubation overnight at 4ºC with a primary  rabbit polyclonal antibody 
against the CXCR4 protein (AbCam Inc., Cambridge, MA, USA). The primary antibody 
was diluted at 1:2000 in TBS-5% milk or TBS-5% BSA. The membrane was washed 
three times with TBS-1% Tween 20 for 10 min and then incubated for 1 h at room 
temperature with goat-anti rabbit antibody (GeHealthcare, Hatfield, UK) at a dilution of 
1:10000, as a secondary antibody for anti-CXCR4 primary antibody. The membrane was 
washed thoroughly in a TBS-1% Tween-20 solution, and the bound antibody was 
detected using the enhanced chemiofluorescence detection reagent (ECF), purchased from 
GeHealthcare (Hatfield, UK), according to manufacturer’s recommendations. For 
normalization purposes an anti-α-tubulin antibody was used. Images were obtained using 
a VersaDoc Imaging System Model 3000 from BioRad (Hercules, CA, USA) and 
detection was performed at 570 nm. The analysis of band intensity was made using the 
Quantity One software from BioRad (Hercules, CA, USA). 
 
Pancreatic tumorsphere formation assay 
Pancreatic cancer spheres were generated and expanded in DMEM:F12 (Invitrogen, 
Karlsruhe, Germany), supplemented with B-27 (GIBCO, Karlsruhe, Germany) and bFGF 
(PeproTech EC, London, UK). Ten-thousand cells per milliliter were seeded in ultra-low 
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attachment flasks (Corning B.V., Schiphol-Rijk, Netherlands), as described previously.
319
 
After 7 days incubation, 1 ml of medium containing spheres was diluted in 7 ml of 
CASYTON buffer (Roche, Basel, Switzerland) and the number of spheres was counted 
and their size measured in an Innovatis CASY Cell Counter.   
 
 Flow cytometry analysis 
Hs766T and 354 cells were seeded in a 12-well plate, washed twice with a 
phosphate-buffered saline solution and harvested 72h after incubation.   A single cell 
suspension was prepared with a phosphate-buffered saline medium, containing 3% 
flebogamma, acquired from Grifols Movaco (Barcelona, Spain) and cells were incubated 
for 20 minutes on ice.  Cells were then washed twice with PBS and briefly centrifuged 
prior incubation with anti-CXCR4-APC antibody (Beckton Dickinson, Heidelberg, 
Germany)  for surface staining of CXCR4 receptor, and left in the dark at 4ºC for 30 
minutes. Cells were incubated with the appropriate isotype-matched control antibody, 
APC-mouse IgG2a (Biolegend, San Diego, CA). Subsequently, cells were incubated for 5 
minutes at 4ºC with DAPI for exclusion of dead cells (eBiosciences, San Diego, CA). 
Samples were analyzed by flow cytometry using a FACS Canto II (BD) and data were 
analyzed with FlowJo 9.2 software (Ashland, OR). 
 
Fluorescence in situ hybridization 
Fluorescence in situ hybridization was performed in cultured Hs766T adherent cells, 
as described by Lu and Tsourkas
280
 with some modifications. Briefly, transduced Hs776T 
cells were seeded onto multi-chambered coverglass slides (Lab-Tek; NalgeNunc, 
Rochester, NY) appropriate for confocal microscopy imaging. Following 72 h of 
incubation, the cells were washed with PBS, fixed with 4% paraformaldehyde for 30 min 
at room temperature and permeabilized at 4ºC in 70% ethanol for 4 hr. Cells were then 
incubated with fresh acetylation solution [0.1 M triethanolamine and 0.5% (v/v) acetic 
anhydride] for 30 min at room temperature, rinsed twice in Tris-buffered saline (TBS) 
and pre-hybridized in the absence of the LNA probe in hybridization buffer [50% 
formamide, 5 x SSC, 5 x Denhardt’s solution, 250 µg/ml yeast tRNA, 500 µg/ml salmon 
sperm DNA, 2% (w/v) blocking reagent, 0.1%CHAPs, 0.5% Tween) for 2 h at  56ºC. The 
hybridization step was carried out overnight at the same temperature, using the double 
DIG-labelled(5’, 3’- digoxigenin-labelled) LNA probes for miR-139-5p  and a scrambled 
probe as a negative control. Three stringency washes were also performed at 56ºC to 
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completely remove the non-hybridized probe. Endogenous peroxidase activity was 
inactivated by incubation in 3% hydrogen peroxide in TBS with 0.1%Tween-20 (TBS-T) 
for 30 min, followed by three washes with TBS-T. The slides were then placed in 
blocking solution (TBS-T, 10% heat-inactivated goat serum, 0.5%blocking agent) for 1 h 
at room temperature and incubated for the same period of time with an anti-DIG antibody 
(Roche, Amadora, Portugal) conjugated with the hydrogen peroxidase. To amplify the 
antibody signal, slides were further incubated with a TSA plus Cy3 (PerkinElmer, 
Waltham, MA) solution for 10 min in the dark, in accordance with the manufacturer’s 
protocol. The cells were finally stained with the fluorescent DNA-binding dye Hoechst 
33342 (Invitrogen Life Technologies, Paisley, UK) (1 µg/ml) for 5 min in the dark, 
washed with cold PBS, and mounted in Mowiol (Fluka; Sigma). Confocal images were 
acquired in a point scanning confocal microscope Zeiss LSM 510 Meta (Zeiss, Göttingen, 
Germany), with a 60 x oil objective. Digital images were acquired using the LSM 510 
META software. All instrumental parameters pertaining to fluorescence detection and 
image analyses were held constant to allow sample comparison.  
 
Immunocytochemistry 
Immunocytochemistry experiments were performed in transduced Hs766T cells, 
according to established protocols. Briefly, following 24 h of incubation after seeding, 
cells were washed twice with PBS and fixed with 4% paraformaldehyde in PBS for 20 
min at room temperature. The cells were then permeabilized for 5 min with 0.2% Triton 
X- 100 and non-specific binding epitopes were blocked by incubating the cells for 30 min 
with a 5% BSA solution prepared in PBS. Cells were incubated overnight at 4ºC with a 
rabbit monoclonal primary antibody against the CXCR4 protein (BioLegend, San Diego, 
CA, USA)(1: 100) and α-tubulin (1: 100), prepared in PBS containing 1% BSA. 
Following two washing steps with PBS, cells were incubated for 2 h at room temperature 
with the respective secondary antibody (anti-rabbit Alexa Fluor-594conjugate; Molecular 
Probes, Leiden, the Netherlands) diluted 1:500 in PBS containing 1% BSA. Finally, all 
coverslips containing the samples were rinsed twice in PBS and incubated in the dark 
with DAPI (1 µg/ml) for 5 min, before being mounted on glass slides using Moviol 
(Sigma). The samples were then observed by epifluorescence microscopy under a Zeiss 
Axiovert microscope, equipped with a 20 x objective and the rhodamine, DAPIand FITC 
filters. Representative images were taken for each condition, using the same exposure 
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time for each filter, to allow comparison of fluorescence intensity between different fields 
and conditions. 
 
Invasion and migration assays 
Invasion assays were performed using modified Boyden chambers filled with 
Matrigel (BioCoat, BD Biosciences, Heidelberg, Germany). Cells were starved during 6 h 
in DMEM medium without serum, and then added to the Matrigel-coated inserts. Seven-
hundred and fifty microliters of serum-free DMEM medium, DMEM supplemented with 
20% of bovine serum or DMEM with 300ng/ml of recombinant SDF1-α were added to 
the lower chamber, followed by incubation for 24 h at 37ºC. Invading cells were washed 
with PBS containing 1 mM CaCl2 and 0.5 mM MgCl2,fixed in 4% PFA, stained with 
DAPI and then analyzed by confocal microscopy. The ratio of the number of cells in the 
lower chamber to that of seeded cells was calculated using Imaris Software for 3D and 
4D Imaging. 
 
Cell viability assays 
Cell viability and proliferation were evaluated by a modified Alamar Blue assay, 
under different experimental conditions.
281
 This assay measures the redox capacity of 
tumoral cells and allows the determination of cell viability without cells detachment. To 
evaluate the effect of the combined strategies involving miR-139-5p ectopic expression in 
combination with chemotherapeutic drugs, Hs766T transduced cells were seeded onto 48-
well culture plates followed by incubation for 24 h at 37ºC. Cells were then treated with 
different amounts of drugs for a period of 24 h and cell viability was then measured. 
Briefly, 300 µl of DMEM-HG medium containing 10% (v/v) Alamar Blue dye (prepared 
from a 0.1 mg/ml stock solution of Alamar Blue) were added to each well and cells were  
incubated  at 37º C for 1 h in a 5% CO2 humidified atmosphere. One-hundred fifty 
microliters of supernatant were collected from each well, transferred to 96-well plates and 
absorbance was measured at 570 and 600 nm in a SPECTRAmax PLUS384 
spectrophotometer (Molecular Devices, Union City, CA). Cell viability (as a percentage 
of untreated control cells) was calculated according to the equation (A570-A600) of treated 
cells x 100/(A570-A600) of control cells. 
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Statistical Analysis 
Data are presented as the mean ± standard deviation (SD). The data were analyzed 
using the Graph Path Prism (version 5.0) software (La Jolla, USA). Statistical analyses 
were done by analysis of variance (ANOVA) using Dunnett’s Multiple Comparison test 
or Student’s t test. P value <0.05 was considered statistically significant. P< 0.05 (*), P < 
0.01 (**) and P < 0.001 (***). 
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3. Results and Discussion 
 
3.1. MiR-139-5p is downregulated in pancreatic tumor cell lines and in 
primary pancreatic derived-cancer cells.  
An abnormal microRNA expression profile is a hallmark of cancer, contributing to 
the dysregulation of crucial signaling pathways that support normal cell functioning. 
MiR-139-5p was reported to be down-regulated in patient’s pancreatic tumor samples,315  
suggesting its involvement in the development and progression of this type of cancer. We 
assessed and compared miR-139-5p expression levels in Hs766T cells and 354 primary 
PC cells, which were compared with those in normal pancreatic epithelial cells. 
Moreover, we evaluated the expression levels of the predicted miR-139-5p target, 
CXCR4. 
 
 
 
Figure 17 - MicroRNA-139-5p and CXCR4 mRNA expression levels in pancreatic cancer cells. Cells 
were submitted to RNA extraction 48 hours after seeding and then miR-139-5p and CXCR4 expression 
levels were quantified through qRT-PCR and presented as fold increase units relative to the levels 
registered with normal pancreatic epithelium control RNA sample. Snord44 and RPL13 were used for 
microRNA and mRNA internal gene normalizers, respectively. (A) Hs766T cell line, **P<0.01, n=3. (B) 
354 primary PC cells, ***P<0.001 and *P<0.05, n=4. P corresponds to values that differ significantly from 
those obtained with normal epithelial pancreatic cells.  
 
As shown in Figure17, miR-139-5p is down-regulated by 2-fold in Hs766T cells, 
whereas in 354 primary derived-tumor cells an extensive repression of this microRNA is 
observed, as concluded by the extremely low values observed, when compared to miR-
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139-5p expression levels in normal pancreatic epithelial tissue. Moreover, CXCR4 
mRNA expression levels were found to be overexpressed both in Hs766T and in 354 
primary PC cells, by 3.5-fold and 5.2-fold, respectively, as compared to normal 
pancreatic epithelium cells. MiR-139-5p and CXCR4 mRNA were also quantified in 
Panc-1 and MiaPaCa cells and presented a similar expression profile as in Hs766T and 
354 primary PC cells (data not shown). These data indicate that there is an inverse 
correlation between miR-139-5p and CXCR4 expression levels both in pancreatic tumor 
cells lines and primary pancreatic cancer cells and corroborate previous reports
315
 stating 
that miR-139-5p was profoundly repressed in several pancreatic patient tumors and 
pancreatic cell lines. Moreover, the observed up-regulation of CXCR4 is consistent with 
previous findings of its involvement in tumor progression.
309,310,320,321
 
 
3.2. Significant and stable miR-139-5p expression was established in 
pancreatic cancer cell lines and in a primary pancreatic tumor cell 
culture. 
To characterize the functional role of miR-139-5p in human pancreatic cancer, we 
developed a lentivirus based-system to constitutively express this repressed microRNA in 
the metastatic pancreatic cancer cell line, Hs766T, and in the 354 primary derived-tumor 
cells and evaluated the miR-139-5p and CXCR4 mRNA levels in both pancreatic cancer 
models, which were compared with those non-transduced cells, as illustrated in Figure 18. 
114 
 
 
 
Figure 18- MicroRNA-139-5p and CXCR4 expression in Hs766T cells and 354 pancreatic derived-
tumor cells following transduction with lentiviral vectors: Cells were transduced with a lentivirus vector 
coding for eGFP and miR-139-5p and with a lentivirus vector coding for eGFP alone (empty vector) as a 
control. A two weeks period of incubation was considered for a stable and constitutively expression of both 
miR-139-5p and control eGFP. RNA isolation and FISH staining were performed 48h after cells were 
seeded. Results are presented as fold increase units relative to the levels registered with pancreatic tumor 
cells transduced with control lentivirus vector.(A) MiR-139 quantification through qRT-PCR.Snord44 
snRNA was used as reference.***P<0.001 when compared with control transduced cells, n=4 (B) FISH 
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staining in Hs766T transduced cells. Cells were subjected to miR-139-5plabeling with a specific LNA 
probes (red dots), as described in Material and Methods. Nuclear staining was accomplished using Hoescht 
33342 (1 μg/ml). Control experiments targeting the endogenous U6snRNA (positive control) and without 
LNA probe (negative control) were performed in parallel (not shown). Images were obtained by confocal 
microscopy with a 40×EC Plan-Neofluar. Scale corresponds to 20 µm. (C) CXCR4 mRNA quantification in 
Hs766T and 354 primary PC cells through qRT-PCR. RPL13 mRNA was used as reference, n=4.  
 
As demonstrated in Figure 18 A, a significant increase in miR-139-5p expression 
levels was observed after lentiviral transduction, (628-fold increase in Hs766T cells and 
1313-fold increase in 354 primary PC cells) when compared to tumoral cells infected 
with a lentivirus coding for eGFP alone. Moreover, images obtained from in situ 
hybridization experiments, show an efficient miR-139-5p overexpression in Hs766T cells 
transduced with a lentivirus vector coding for eGFP and miR-139-5p, when compared 
with cells transduced with a lentivirus vector coding for eGFP alone (control), as reflected 
by the presence of a substantial amount of miR-139-5p staining (red dots) in the cell 
cytoplasm (Figure 18 B). These data show that two stable pancreatic cancer in vitro 
models were established with a consistent and effective overexpression of miR-139-5p.   
Following the demonstration of the stable expression of miR-139-5p both in Hs766T 
and 354 primary PC cells, we evaluated the effect of this tumor suppressor microRNA on 
the expression of its predicted target, CXCR4. For this purpose, CXCR4 messenger RNA 
(mRNA) levels were quantified by qRT-PCR in transduced cells 48h after seeding. Our 
results show that, despite successful miR-139-5p stable overexpression (Figure 18 A and 
B), no decrease of the CXCR4 mRNA levels was observed (Figure 18 C).  
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3.3. Total CXCR4 protein in metastatic pancreatic cancer cells was 
significantly reduced by ectopic miR-139-5p overexpression. 
 
 
 
Figure 19 – Expression levels of CXCR4 after miR-139-5p ectopic expression in pancreatic cancer 
cells. Protein was extracted from transducedHs766T and 354 primary PC cells, 72 hours after seeding. A 
monoclonal antibody against CXCR4 protein was used for CXCR4 detection and an anti-α-tubulin 
monoclonal antibody was used as control.Results are presented as target protein-expression levels relative 
to control, corrected for individual α-tubulin signal intensity. (A) Representative gel showing CXCR4 
protein levels in Hs766T transduced cells. (B) Quantification of CXCR4 bands observed in (A). 
***p<0.001correspond to values that differ significantly from those obtained with control transduced cells, 
n=3. (C) Representative gel showing CXCR4 protein levels in 354 primary PC transduced cells. (D) 
Quantification of CXCR4 bands observed in(C), n=4. 
 
Although no significant changes in CXCR4 mRNA levels were observed, Western 
blot analysis of protein levels shows that after cell ectopic expression of miR-139-5p, an 
approximately 48% reduction in CXCR4 protein levels in Hs766T cells was obtained 
(Figure 19 A and B). The fact that no alterations on CXCR4mRNA levels were observed 
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in Hs766T cells, despite protein levels were affected, leads us to hypothesize that the 
translational repression of CXCR4 mRNA may have occurred through miRNA-mediated 
gene silencing involving mRNA sequestration in P-bodies where they are shielded from 
the translation machinery, rather than through mRNA degradation by mRNA decay 
machinery in these cells.
126
 On the other hand, no significant changes in CXCR4 protein 
levels were detected in 354 primary PC cells, as shown in Figure 19 C and D, suggesting 
that CXCR4 may not be a preferential target of miR-139-5p in these cells. 
 
3.4. Cell surface CXCR4 expression is strongly reduced upon miR-139-
5p overexpression. 
The functional role of CXCR4 strongly depends on its cellular localization and the 
surface expression of this receptor is crucial to allow binding to its specific ligand stromal 
cell-derived factor-1α (SDF-1α). Therefore, we investigated whether the expression of 
CXCR4 at the surface of PDAC cells could be affected by the ectopic expression of miR-
139-5p. Similarly to other chemokine receptors, CXCR4 can exhibit different cellular 
localizations due to intracellular trafficking, as CXCR4 may cycle between the cell 
surface and endocytic compartments, upon spontaneous or ligand-dependent 
internalization.
322
 Moreover, an intracellular pool of CXCR4 that integrates a recycling 
mechanism, allowing a rapid response to SDF1-α, may be responsible for a fine-tuning 
mechanism of control for its membranarlevels.
322,323
 Importantly, CXCR4 presented at the 
cell surface and in the intracellular pool, account for the total content of this chemokine 
receptor in the cell. However, only cell surface localization of CXCR4 allows direct 
interaction and binding to the SDF1-α, thus promoting the activation of CXCR4 
signalling cascade, which ultimately induces cell proliferation, migration, survival, 
among other biological events.
324
 Therefore, we determine the surface expression of 
CXCR4 in Hs766T cells and in 354 primary PC cells, with and without miR-139-5p 
ectopic expression, by FACS analysis (Figure 20). 
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Figure 20 – Cell surface expression of CXCR4, after miR-139-5p ectopic expression in pancreatic 
cancer cells. Cells were seeded and incubated for a period of 72 hr. Subsequently, cells werewashed with a 
phosphate-buffered saline solution harvested. A single cell suspension was prepared in FACS buffer (PBS 
with 3% flebogamma) and subsequently incubated with an antibody against human CXCR4, stained with 
12G5 APC, and a mouse APC isotype as control, prior flow cytometry analysis.Viable cells were gated 
based on morphologic features, including cell volume (given by the forward scatter, FSC) and cell 
complexity (given by the side scatter, SSC).Mean fluorescence values (geometric mean) are indicated for 
each plot. (A) Fluorescent intensity plots of Hs766T cells transduced without and with miR-139-5p. (B) 
Quantification of CXCR4 fluorescent intensity plots presented in (A). ** p<0.01correspond to values that 
differ significantly from those obtained with control transduced cells, n=4. (C) Fluorescent intensity plots of 
354 primary PC transduced cells without and with miR-139-5p. (D) Quantification of CXCR4 fluorescent 
intensity plots presented in (C). 
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As observed in Figure 20, an overall 33.4% decrease in the CXCR4 surface 
expression in Hs766T cells overexpressing miR-139-5p was obtained (Figure 20 A and 
B). In contrast, in 354 primary pancreatic tumoral cells no significant change in the 
surface expression of CXCR4 was detected (Figure 20C and D), which is consistent with 
the results obtained from Western blot analysis. Taken together, data from the previous 
experiments with 354 PC cells indicate that miR-139-5p might be exerting its tumor 
suppressive role in other molecular targets than CXCR4. 
 
3.5. MiR-139-5p affects sphere formation capacity of pancreatic cancer 
cells. 
Since this chemokine receptor was identified as a molecular modulator of the tumor 
microenvironment, angiogenesis and, most importantly, cancer stem cells (CSCs) 
niche,
313
 we assessed the role of miR-139-5p–CXCR4 axis in stemness features after 
restoring miR-139-5p expression. Cancer stem cells (CSCs) are a subpopulation of tumor 
cells that exhibit the ability to self-renew, to differentiate into the heterogeneous lineages 
of cancer cells and to fuel tumor growth.
325
 Furthermore, CSCs display strong resistance 
to chemotherapeutic agents, being implicated in tumor relapses and metastatic spread.
326
 
Several studies have reported the presence of a subpopulation exhibiting chemoresistance 
and CSCs characteristics and CXCR4 was shown to have a pivotal role in cell-stemness 
maintenance.
214,327,328
 Therefore, this subpopulation with CSCs properties might be a 
potential target to overcome tumor growth and chemoresistance. In this context, we 
investigated the tumor suppressor role of miR-139-5p in the ability of Hs766T and 354 
primary PC cells to form spheres, consequently promoting clonogenic tumor growth. 
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Figure 21 – Quantification and measurement of pancreatic tumorspheres. Cells were seeded in non-
adherent flash and incubated in DMEM:F12 supplemented with B-27 and bFGF for 7 days at 37ºC. After 
incubation, medium containing spheres was dilute in CASYTON buffer and proceeded to sphere counting 
and measurement with Innovatis CASY Cell Counter.  The solid, circular formations represent pancreatic 
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tumorspheres. Results were normalized and presented as percentage values.Scale bars indicate 100 µm (A) 
Pancreatic tumorspheres from Hs766T cells transduced with a control vector and (B) with miR-139-5p 
expression vector. (C) Quantification of Hs766T tumorspheres. *p<0.05; **p<0.01 corresponds to values 
that differ significantly from those obtained with control transduced cells. n=3. (D) Pancreatic tumorspheres 
from 354 primary PC cells transduced with a control vector and (E) with the miR-139-5p expression vector. 
(F) Quantification of 354 primary PC tumorspheres.*p<0.05; ***p<0.001 correspond to values that differ 
significantly from those obtained with control cells, n=3. 
 
As illustrated in Figure 21 (panels A, B and C) transduction of miR-139-5p in 
Hs766T cells was determinant in decreasing clonogenic spheres in number and size. As 
observed, the number of pancreatic tumorspheres, ranging from 40µm to 80 µm, 
diminished by approximately 22% upon transduction with miR-139-5p, when compared 
with control cells, whereas the median size tumorspheres (80-120 µm) did not show a 
significant reduction in number, a decrease of 11.8% being observed when compared with 
control tumorspheres with the same size. However, a trend of miR-139-5p to promote a 
decrease in the number of pancreatic tumorspheres larger than 120 µm was observed, as a 
substantial reduction was obtained for Hs766T tumorspheres expressing miR-139-5p, 
nearly 67%, when compared to control cells. This data indicate that the tumor suppressor 
action of miR-139-5pconditioned the formation of spheres with larger numbers of cells, 
leading to less potential clonogenic spheres.  Sphere-forming capability of 354 primary 
pancreatic tumoral cells, transduced with control and miR-139-5p vectors, was also 
evaluated. As illustrated in Figure 21 (panels D, E and F), a more consistent role of miR-
139-5p was noticed in terms of reducing the number of tumorspheres in all evaluated 
sizes, since it was obtained a 36.3% reduction for tumorspheres with 40-80µm, a 30.4% 
decrease for tumorspheres with 80-120 µm and a 34.8% decrease for tumorspheres larger 
than 120 µm, when compared to control tumorspheres with the same sizes.   
 
3.6. Cells ectopically expressing miR-139-5p do not exhibit prominent 
formation of filopodia or polarized morphology 
CXCR4 is a chemotaxis mediator after binding to SDF1-α, triggering a cellular 
signaling cascade that ultimately results in cell motility.
329
 This led us to address the role 
of miR-139-5p in the regulation of CXCR4-dependent motility. Several reports indicate 
cell polarization and filopodia formation as requirements for chemokine-mediated-
directed migration.
330–332
 Leucocyte chemotaxis studies have described cell polarization 
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as a biological process that results from a bipolar asymmetric shape mediated by the 
recruitment of surface receptors, signaling complexes, and cellular organelles to discrete 
areas of the plasma membrane, thus leading to cytoskeleton rearrangement.
333
 Moreover, 
cancer cells also have the capacity to form filopodia and endorse cytoskeletal 
rearrangements in order to promote cell motility.
334,335
 Immunostaining was performed in 
Hs766T cells to further clarify the cellular localization of CXCR4 and evaluate miR-139-
5p contribution to the cellular motility through the observations of morphological 
features. 
 
 
Figure 22 – Immunocytochemistry analysis of CXCR4 in Hs766T cells with and without miR-139-5p 
ectopic expression.  Cells were incubated for 72h before fixation in 4% PFA and permeabilized with 0.2% 
Triton X- 100. Immunostaining was performed with a primary monoclonal antibody against human 
CXCR4, followed by labeling with an Alexa-fluor 594-conjugated anti-rabbit Ig antibody. The cells were 
then stained with Hoechst and analyzed by confocal microscopy. Green fluorescence corresponds to eGFP 
reporter gene ectopic expression. Scale bars indicate 20 µm. (A) Hs766T control cells transduced with a 
lenviral vector coding only for eGFP reporter gene and (B) with a lenviral vector coding for eGFP reporter 
gene and miR-139-5p.Confocal images are representative of three independent experiments. 
As illustrated in Figure 22, in control experiments (cells transduced only with eGFP), 
a greater number of cells displaying a polarized and elongated morphology with a 
prominent filopodia formation was observed, which was further attested by an apical 
intense red fluorescence (white arrows), corresponding to the direction of the cell motility 
(Figure 22 A). In contrast, in Hs766T cells co-expressing miR-139-5p and eGFP, as a 
reporter gene, fewer cells exhibit a marked CXCR4 surface expression (Figure 22 B). In 
fact, only the cells that were not successfully transduced with the developed lentiviral 
system for miR-139-5p expression (represented by the lack of eGFP green fluorescence) 
A. 
B. 
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show a CXCR4 polarized immunostaining (white arrows). These findings indicate that 
miR-139-5p ectopic expression acts as an inhibitor of CXCR4-mediated cell-motility. 
 
3.7. MiR-139-5p impairs CXCR4-dependent and non-dependent 
migration in Hs766T cells.  
Wehler T. et al evaluated CXCR4 expression in 103 patients with pancreatic cancer 
and established a correlation with progression of human pancreatic cancer. These authors 
reported variable intensities of CXCR4 expression among patient samples, as well as in 
vitro cell lines, but robust CXCR4 expression was strongly associated with advanced 
stages of the disease and a trend to metastasis formation.
312
 Correlation of CXCR4 
expression with cancer dissemination and metastasis formation has also been reported in 
other studies.
209,336–338
 Furthermore, SDF1-α, also known as CXCL12, the specific ligand 
for CXCR4, was found to play a pivotal role in pancreatic cancer progression,
339
 being 
reported to stimulate cell proliferation in CXCR4-positive pancreatic cancer cell lines. 
Additionally, the SDF1-α/CXCR4 axis was shown to be the responsible for inducing cell 
motility, invasion, survival and proliferation in Hs766T cells.
210
 Therefore, we 
investigated the role of miR-139-5p in SDF1-α/CXCR4-mediated migration in this cell 
line. For this purpose, serum starved Hs766T cells were submitted to matrigel invasion 
experimental conditions in the presence of fetal bovine serum (20%), to stimulate 
CXCR4-non-dependent migration, and SDF1-α (300 ng/ml)to evaluate chemotaxis-
induced migration.  
 
 
 
1) 
2) 
3) 
Control miR-139-5p A. 
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Figure 23 – Migration and chemotaxis of transduced Hs766T cells. Panel A: Representative 3D images 
of the number of migrating cells as displayed in Matrigel-coated inserts. Cells were serum starved for 6 
hours prior being seeded into Matrigel-coated inserts and incubated for 24 h (A1) on the absence of FBS, 
(A2) 20% FBS or (A3) 300 ng/ml of recombinant SDF1-α.Cells were then washed with modified phosphate 
buffered saline solution, fixed with 4% of PFA, and nucleus was stained with DAPI. Migration capacity of 
the cells was assessed by confocal microscopy. Panel B: Quantification of migrating cells in all 
experimental conditions from a representative experiment. *p<0.05 correspond to values that differ 
significantly from those obtained with control cells, n=2. 
 
As shown in Figure 23, upon stimulation with 20% of serum (CXCR4 non-dependent 
migration), cells expressing low levels of miR-139-5p (control) tend to migrate in a 
greater number (25% of migrating cells), than cells ectopically expressing miR-139-5p 
(7% of migrating cells).  When control cells were stimulated with the CXCR4 specific 
ligand, SDF1-α, they showed to be more prone to respond to SDF1-α stimulus (17.7% of 
migrating cells), than miR-139-5p expressing cells (3.5% of migrating cells). Indeed, the 
migration values observed for Hs766T miR-139-5p expressing cells when stimulated with 
SDF1-α, were similar to those obtained for cells exposed exclusively to serum-free 
medium (3.6% migrating cells) or to control cells exposed to the same conditions (3.0% 
of migrating cell). Therefore, we can conclude that miR-139-5p expression significantly 
affects CXCR4-dependent and non-dependent migration in pancreatic cancer cells.  
Regarding the CXCR4 non-dependent migration, it was reported that miR-139-5p 
presents a functional role in cancer cell motility and invasion, inhibiting these cellular 
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events through the disruption of the TGF-β, Wnt7/TCF-4, ROCK2 and MAPK/PI3K 
signaling cascades, both in breast cancer and hepatocellular carcinoma.
207,340,341
 These 
data point out the possible role of miR-139-5p in a more widespread control towards the 
maintenance of normal cellular phenotype. 
 
3.8. MiR-139-5p sensitizes pancreatic cancer cells to the action of 
chemotherapeutic agents.  
Despite the many efforts toward the discovery of new or improved antitumor agents 
for the treatment of pancreatic cancer, few cases of success have been reported, and 
gemcitabine is still the golden standard treatment for the vast majority of unresectable 
pancreatic tumors.
41
 
As we have previously shown,
231
 sunitinib has proven to exert a synergistic effect 
when in combination with a non-viral strategy to inhibit miR-21 expression levels in 
pancreatic cancer cells. In addition, docetaxel is also used to treat pancreatic cancer.
44
 
Therefore, we evaluated the potential of a combined treatment involving the use of small 
amounts of these chemotherapeutic drugs (sunitinib, docetaxel or gemcitabine), in 
association with the overexpression of the tumor suppressor miR-139-5p in Hs766T cells. 
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Figure 24 - Viability assessment of control and miR-139-5p transduced Hs766T cells. Twenty-four 
hours after seeding, control and miR-139-5p transduced Hs766T cells were treated for 24 h with and 
without several concentrations of chemotherapeutic drugs. Cell viability was evaluated by the Alamar Blue 
assay (as described in the Materials and Methods section). (A) Cells treated with and without1 µM and 5 
µM of gemcitabine, n=3. (B) Cells treated with and without 5 and 7.5 µM of sunitinib. 
***p<0.001correspond to values that differ significantly from those obtained with control cells, n=4. (C) 
Cells treated with and without 1 µM of docetaxel. ***p<0.001correspond to values that differ significantly 
from those obtained with control cells, n=4.  
 
Hs766T pancreatic tumoral cells transduced either with the control vector or with 
the vector coding for miR-139-5p were treated with three different chemotherapeutic 
drugs, gemcitabine, sunitinib and docetaxel, in order to evaluate the influence of miR-
139-5p overexpression on the sensitization of tumor cells to the action of these 
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chemotherapeutic agents.  As illustrated in Figure 24, overexpression of miR-139-5p was 
able to reduce cell viability approximately 10%. When miR-139-5p overexpression was 
combined with gemcitabine, no further antitumor effect on Hs766T cells was observed at 
the tested concentrations. On the other hand, treatment with sunitinib at 5 µM and 7.5 µM 
resulted in a decrease in cell viability by 23% and 31%, respectively. However, when 
cells overexpressing miR-139-5p were treated with the same drug concentration, a 
stronger reduction in cell viability was observed, approximately 39% and 46% for 5 µM 
and 7.5 µM, respectively, being achieved a synergistic antitumor effect. Experimental 
conditions with docetaxel revealed an even greater antitumor synergistic effect, as cells 
overexpressing miR-139-5p, treated with 1 µM docetaxel, presented a significant 
reduction in viability, nearly 55%, when compared with drug treatment alone in control 
cells (37%), as illustrated in Figure 24 C.  
Hence, the reestablishment of normal levels of miR-139-5p in PDAC cells along with 
treatment with small doses of sunitinib or docetaxel may hold great promise for future 
therapeutic application in this highly tumorigenic cancer.  
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4. Conclusion 
 
Overall, our results clearly demonstrate that miR-139-5p has a pivotal role in 
mediating CXCR4 post-transcriptional regulation in PDAC, as both total and cell surface 
CXCR4 levels were successfully reduced upon up-regulation of miR-139-5p expression 
levels. Moreover, miR-139-5p was able to regulate the capability of Hs766T and 354 
pancreatic tumoral cells to form tumorspheres, as concluded from the fewer and smaller 
spheres found after miR-139-5p overexpression, resulting in a diminished clonogenic 
potential. Additionally, PDAC cells expressing miR-139-5p do not exhibit perceptible 
morphological features of migrating cells, which was reinforced by the results obtained 
for the ability of these cells to invade adjacent areas, as fewer cells migrated in a 
dependent and non-dependent CXCR4 manner. Our findings also showed evidences of a 
therapeutic potential of miR-139-5p, as the restoration of the levels of this microRNA in 
combination with sunitinib or docetaxel induced a synergistic antitumor effect in PDAC 
cells. 
Overall, our findings suggest that a new antitumor therapeutic strategy encompassing 
the modulation of miR-139-5p levels and the concomitant treatment with small doses of 
chemotherapeutic agents could hold great promise for metastasis treatments in pancreatic 
cancer, also reducing the aggressive side effect of the current chemotherapy. In 
conclusion, miR-139-5p was demonstrated to be a potential regulator of CXCR4-
mediated metastasis and a potential tumor suppressor agent for the treatment of some 
subtypes of metastatic PDCA.  
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Chapter 5 
 
 
 
Concluding remarks and future 
perspectives 
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1. Concluding remarks and future perspectives 
 
Although microRNAs are responsible for the fine-tuning of molecular mechanisms 
supporting oncogenic features of tumor cells, their impact goes way beyond the simple 
post-transcriptional regulation of a single gene expression. A synchronized network of 
microRNAs is a powerful tool in the maintenance of a normal cellular phenotype; 
nevertheless disruption of this fragile balance can lead to a disturbing outcome, as it is 
cancer. Currently, gene therapy brings new hope into cancer therapeutics, as many 
innovative and promising gene delivery strategies have been design towards this goal, 
thus renewing the optimism lost in previous unsuccessful attempts. Cancer is a deadly and 
devastating disease in every aspect for patients who suffer from this malignancy. 
 Pancreatic cancer, particularly pancreatic adenocarcinoma is one of the most 
aggressive cancers, offering one of the lowest survival rate and quality of life for patients 
submitted to chemotherapeutic regiments that too often are inefficient. Therefore, in this 
work we sought to comprehend and highlight the extent of microRNAs implications in 
pancreatic tumorigenesis and how they can be addressed as potential therapeutic targets 
and incorporated in antitumoral gene therapy strategies.   
Modulation of microRNA levels comprehends two distinct aspects, depending 
whether they are overexpressed, acting as oncogenes, or downregulated, thus exhibiting a 
tumor suppressor role. Considering up-regulated microRNAs, the obvious strategy is to 
reduce their expression levels making use of antisense molecules responsible for 
inhibiting tumorigenic microRNAs, thus silencing their effect. To this purpose we 
developed a lipid-based nanosystem, HSA-EPOPC:Chol/AMOs (+/-) (4/1), which was 
capable of efficiently deliver anti-microRNA oligonucleotides (AMOs) into tumor cells 
that mediated miR-21, miR-221, miR-222 and miR-10b silencing, prompting significantly 
low expression levels. Although a strong microRNAs inhibition was accomplished, the 
biological activity resulting from this event was not consistent for all tested microRNAs. 
For example, abrogation of miR-10b expression levels, one of the most strongly inhibited 
microRNAs, could not exert any noticeable effect upon the target proteins assessed in our 
study, or a visible cytotoxic effect when in combination with drugs. Owing to this fact, 
we could consider addressing other predicted miR-10b targets, but another important 
issue is the extent in which each microRNA can be thoroughly inhibited, as it strongly 
depends on how much up-regulated this microRNA is. In our studies, we used the same 
amount of AMOs, for all microRNAs shown to be overexpressed, aiming at achieving 
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microRNA silencing, strictly as a proof-of-concept. Nevertheless, further investigation 
needs to be performed in order to reach the required optimal dose of AMOs for each 
different microRNA, aiming at achieving the intended biological effect. Importantly, we 
have demonstrated that our lipid-based nanosytem, HSA-EPOPC:Chol/AMOs (+/-) (4/1), 
stands as a promising tool to mediate intracellular delivery of therapeutic oligonucleotides 
in cancer targeted-therapies, displaying high efficiency in microRNA modulation. The 
therapeutic value of microRNA silencing alone might not result in a sufficient antitumor 
impact in cancer cells, nevertheless, as we demonstrated, they can substantially sensitize 
tumor cells to the action of chemotherapeutic drugs. This was one of the most important 
achievements of our work, since we strongly believe that the developed antitumor 
strategy, consisting of microRNA inhibition in combination with treatment with small 
doses of sunitinib, holds great potential as a therapeutic strategy against PDAC, mainly 
due to the significant synergistic antitumor effect and possible fewer side-effects.    
Regarding microRNAs that are progressively repressed in a tumor phenotype 
context, one of the possible approaches is to consider an ectopic induction of the 
expression of these microRNAs. Many microRNA profiling studies indicated miR-139-5p 
is a strongly downregulated microRNA in PDAC, and in silico prediction pointed 
CXCR4 as a potential target. This chemokine receptor has been described as steadily 
related to metastatic potential in pancreatic cancer cells and as a CSC marker. Currently, 
research and clinical treatment in the cancer field are progressively focused in managing 
this disease as a chronic condition rather than searching for a full cure that may reveal to 
be a utopic issue in a short-term context. Considering that pancreatic adenocarcinoma 
displays early and hostile metastization events, assessing the mechanisms backing this 
aggressive feature may hold great hope for successful achievement of this objective.  
The results obtained in this work elucidate the molecular relevance of miR-139-5p-
CXCR4 axis in the metastasis process in PDAC. This microRNA showed to play a crucial 
role in inhibiting CXCR4 expression in pancreatic tumor cells, adding to the negative 
regulation of invasion and clonogenic properties of these cells. Indeed, PDAC cells 
ectopically expressing miR-139-5p demonstrated a significant decrease in CXCR4 levels, 
thus validating this chemokine receptor as a direct target of this microRNA in pancreatic 
cancer. These findings were followed by a diminished capacity of tumor cells to invade 
adjacent matrix, and to form fewer and smaller clonogenic pancreatic tumorspheres, as it 
was verified in vitro studies. Moreover, migration inhibition properties of miR-139-5p are 
very clear when cells were submitted to a gradient of enriched serum medium, as miR-
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139-5p expressing cells were able to invade adjacent matrix in a significantly lower 
number than control cells.  Additionally, when miR-139-5p expressing cells were 
exposed to SDF1- α gradient, the specific ligand of CXCR4, an even more significant 
inhibition effect was attained, as only basal migration values were registered for these 
cells. This data suggest that this microRNA can exert a remarkable effect in PDAC 
metastatic cells not only in a CXCR4 dependent manner, but also by possibly mediating 
this effect through other molecular effectors that were not addressed in our work. 
Therefore, it is of vital importance to devote thoroughly to investigation of other signaling 
pathways involved in invasiveness, proliferation and stemness in future work, namely the 
TGF-β, Wnt7/TCF-4, MAPK/PI3K, Hedgehog or Notch signaling pathways. In 
accordance with the concept that microRNAs represent a fine-tuning of molecular 
mechanisms, miR-139-5p did not exert a strong cell death effect by itself. Nevertheless, 
when cells expressing this microRNA were subsequently treated with sunitinib or 
docetaxel an evident synergistic antitumor effect was obtain. 
Overall, the in vitro experiments involving microRNA modulation in combination 
with chemotherapeutic drugs brought us further insight into innovative therapeutic 
strategies. It would also be interesting to consider a gene therapy strategy targeting a 
specific microRNA network, aiming at achieving a synergistic effect, through the 
simultaneous silencing and/or ectopic expression of several microRNAs aberrantly 
expressed.   Furthermore, emerging chemotherapeutic treatments for metastatic pancreatic 
cancer, such as FOLFIRINOX, could be a valuable option to incorporate into a concerted 
antitumoral therapeutic strategy with microRNA modulation.  Combination of the 
previously described gene therapy approach with small doses of the drugs that compose 
the FOLFIRINOX regiment, which displays high toxicity amongst patients, could hold 
great promising results, as a high antitumor activity together with a substantial reduction 
in side effects could be achieved, resulting in a benefit for the overall patient health.  
Future work involving in vivo experiments to further validate our previous findings 
would be of utmost importance. Therefore, we consider that is fundamental to evaluate 
our concerted therapeutic strategy in two distinct animal models of pancreatic cancer, 
namely orthotopic and intraspleenic tumor cells injection models.  Validating microRNA 
modulation in combination with drugs could be assessed in an orthotopic animal model of 
PDAC, where mice bearing microRNA ectopically expressing PDAC cells or tumoral 
cells locally transfected with the HSA-EPOPC:Chol/AMOs (+/-) (4/1)nanosystem, would 
be subsequently treated with small doses of sunitinib or docetaxel.  Tumor size and 
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overall mice survival would be strong and reliable indicators of the therapeutic relevance 
of our concerted antitumor strategy for clinical applicability. Regarding metastasis 
molecular mechanisms relying on miR-139-5p, intrasplenic injection of tumor cells 
would better mimetize the metastasis formation, as tumor cells would be systemically 
circulating in the organism. SDF-1α expressing tissues, such as liver or limph nodes 
constitute the preferential target niches for circulating metastatic tumor cells. Thus, 
assessing the formation of micrometastasis in these tissues, derived from cells ectopically 
expressing miR-139-5p or control cells, and overall survival would give us a 
comprehensive perspective of how valuable this microRNA can be to integrate new 
therapeutic strategies for metastatic pancreatic cancer.  
Overall, our study revealed that microRNA modulation in combination with small 
doses of chemotherapeutic agents can be considered an appropriate approach for cancer 
treatment, particularly for pancreatic adenocarcinoma.  Moreover, we perspective that 
future biomedical therapeutics will progressively consist of integrated multidisciplinary 
approaches, reflecting the myriad aspects of oncogenesis, in order to achieve high 
antitumor activity and reduced side effects.  
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